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The purpose of this study was to investigate the effects of oral contraceptives (OCs) on 
emotional reactivity and cognitive ability. Previous research has suggested that OC users 
may experience blunted positive affect (PA) reactivity and that some women also 
experience negative mood side effects from OCs. In the present study, 149 participants 
(58 OC users, 46 nonusers, and 38 men) viewed three different emotional videos paired 
with music intended to evoke either happiness, sadness, or fear. After each emotional 
video, participants completed a facial emotions recognition task, and a GoNogo task of 
inhibition. The hypothesis that women taking OCs would have lower PA reactivity 
compared to nonusers and men was not supported. However, a sex difference in negative 
emotional reactivity (women > men) was found and was strongest in OC users (OC users 
> men) and longer duration OC users. While a small sample size reduces validity of the 
findings, the hypothesis that OC users with current negative mood side effects would 
have faster response times than nonusers and men was not supported. However, a sex 
difference was evident in that men had slower response times to negative faces. Also, 
men had slower response times than OC users, after sad and fear mood inductions. There 
was partial support for the third hypothesis that OC users would have more errors of 
commission than nonusers and men. OC users (and women as a group) made more errors 
of commission during the GoNogo task compared to men, but only after the happy mood 
induction. Also, OC users with current negative mood side effects had fewer errors of 
commission after the sad mood induction compared to OC users with no mood side 
effects. Possible mechanisms are discussed for OC-associated impulsivity and for the 
possible reversal of such an effect in women experiencing OC mood side effects.  
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The Effects of Oral Contraceptives on Emotional Reactivity and Cognition 
Oral contraceptive (OC) use has grown steadily since the 1960s and has now 
become the number one contraception method in Canada (Black et al., 2004). The 
Canadian Contraceptive Consensus conducted in 2002 indicated that 28% of Canadian 
women aged 15 to 44 were using OCs (Fisher & Black, 2007) and 80 to 84% of women 
in North America have taken OCs during their lifetime (Fisher, Boroditsky, & Bridges, 
1999; Mosher, Martinez, Chandra, Abma, & Wilson, 2004). Despite the prevalence of 
OC use, however, very little is known about the particular emotional and cognitive 
consequences of consuming various combinations of synthetic hormones.  
Emotional side effects, though widely researched, have shown equivocal findings 
across studies. Among the most common emotional side effects of OC use are: increased 
negative mood or depression, less affect variability across the menstrual cycle, and less 
negative affect during menstruation (see review in Oinonen & Mazmanian, 2002). An 
individual’s reproductive history, baseline emotional and personality variables, and 
genetic factors have all been suggested as possible explanations for individual differences 
in emotional response to OCs (Oinonen & Mazmanian, 2002).  
There is even less evidence, however, to suggest that women experience any 
cognitive changes as a result of OC use. The lack of research on the cognitive side effects 
of OCs is interesting because it has been established that there are some structural brain 
differences between women on OCs and naturally cycling women (Pletzer, Kronbichler, 
Aichhorn, Bergmann, Ladurner & Kerschbau, 2010; Protopopescu et al., 2008).  
Nevertheless, group differences in particular functional abilities have yet to be 
established. For example, even when brain activation patterns differ between OC-using 
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and free-cycling women during a cognitive task, performance on the task may not differ 
significantly (e.g., Rumberg et al., 2010). Investigating potential emotional and cognitive 
functional differences between OC using and free-cycling women was one of the primary 
goals of the current study.  
Additionally, it is possible that emotional and cognitive side effects, negative or 
positive, go unreported or unnoticed by OC users. For example, it may take a particularly 
introspective individual to notice subtleties in their emotional reactivity or to associate 
any emotional or cognitive changes to OC use, and not some other situational factor. The 
current study, therefore, examined the potential emotional and cognitive differences 
between OC users and non-users in a laboratory environment rather than relying solely on 
self-report measures. This study also investigated possible differences in emotional 
reactivity and cognitive ability between free-cycling women, women taking OCs, and 
men.  
The Menstrual Cycle  
Due to hormonal fluctuations across the menstrual cycle, it is important to take 
menstrual cycle phase into account when scheduling or collecting data from female 
participants. Given associations between menstrual cycle phase and both mood (e.g. see 
review in Farage, Osborn, & MacLean, 2008) and cognition (e.g. see reviews in Kimura, 
1996; Torres, Gomez-Gil, Vidal, Puig, Boget & Salamero, 2006) such controls are 
particularly important in this area of research, The menstrual cycle is typically divided 
into two phases: the follicular phase and the luteal phase. Both the follicular and luteal 
phases can be further subdivided into early, mid, and late periods. In order to understand 
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how hormones can potentially affect emotions and cognitions, it is integral to first 
understand the hormonal fluctuations across the adult female’s menstrual cycle. 
The early follicular phase begins on day one of the cycle and is the first day of 
menstrual bleeding. The early follicular phase is typically defined as days 1 to 5 (e.g., 
Pletzer at al., 2010) while the mid-follicular phase is typically defined as days 6 to 10 and 
the late follicular phase from day 11 to after ovulation (e.g., Parry, 1997; Protopopescu et 
al., 2008). During the early follicular phase, when estradiol and progesterone levels are 
low, the anterior pituitary gland begins to release the follicle-stimulating hormone (FSH) 
which then triggers the growth of ovarian follicles. In the mid follicular phase (days 6 to 
10), the ovarian follicles begin to mature and release increasing amounts of estradiol. 
Estradiol peaks by the late follicular phase (days 11 to 13) as the dominant ovarian 
follicle reaches maturity (Merck Laboratories Inc., 2003). 
 Ovulation occurs in the late follicular phase when serum estradiol concentrations 
are at their peak and when luteinizing hormone (LH) is released from the anterior 
pituitary. The release of LH from the anterior pituitary stimulates the release of the 
secondary oocyte (immature ovum), from the follicle.  The rupturing of the follicle and 
release of the secondary oocyte constitutes ovulation. Ovulation lasts between 16 and 32 
hours and typically occurs 13 to 14 days into the cycle (Merck Laboratories Inc., 2003). 
The time around ovulation is associated with maximal conception likelihood (Wilcox, 
Dunson, & Baird, 2000).   
The luteal phase begins following ovulation. During the early luteal phase (the 
first five following ovulation or LH surge; days 15 to 19 for a regular 28-day cycle), the 
ruptured follicle closes and forms a body known as the corpus luteum, which begins to 
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produce increasing amounts of progesterone. The mid luteal phase begins approximately 
five or six days following the LH surge or roughly days 20 to 24 for a regular 28-day 
cycle. It is characterized by elevated levels of progesterone, and low levels of LH and 
FSH (Baker, Waner, Viera, Taylor, Driver, & Mitchell, 2001). At this point, levels of 
estradiol are intermediate between levels seen at ovulation (high) and levels seen at 
menses (low) (Parry, 1997). During the late luteal phase, (days 10 to 14 following LH 
surge; day 25 and on for a regular 28-day cycle) progesterone levels begin to decline and 
it is the fall in progesterone levels that trigger the re-release of FSH and the beginning of 
a new menstrual cycle (Merck Laboratories Inc., 2003). If fertilization does not occur, the 
corpus luteum degenerates, thereby leading to a cessation of secreted progesterone and 
the sloughing off of the blood-enriched uterine lining, thus beginning menstruation 
(Merck Laboratories Inc., 2003). 
In sum, both the early follicular and late luteal phases represent low hormonal 
periods in the cycle, while the late follicular (including ovulation) and mid luteal phases 
represent high hormonal periods in the cycle. Specifically, the late follicular period (days 
11 to 13) is marked by peak estradiol, LH, and FH levels, while the mid luteal phase 
(days 5 to 9 following the LH surge), is marked by peak progesterone, intermediate 
estradiol, and low LH and FH levels. Indeed, comparing women between particular 
phases in their menstrual cycle is an efficient and non-invasive method of approximating 
hormonal levels and thus examining hormonal effects on behaviour or physical 
characteristics (e.g. Gasbarri, Pompili, d’Onofrio, Cifariello, Tavares, & Tomaz, 2008; 
Oinonen & Mazmanian, 2007).  
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 It is important to recognize, however, that menstrual cycle phases differ between 
free-cyclers and women taking OCs. In particular, OCs typically suppress gonadotropin 
secretion thereby halting the LH surge during the late follicular phase and inhibiting 
follicular maturation and ovulation (van Heusdan, & Fauser, 1999). Moreover, OC users 
do not experience the progesterone-induced thickening of the uterine wall and 
consequently do not experience true menstruation. Instead, women taking OCs 
experience “withdrawal bleeding” during the last week of the cycle as a reaction to 
withdrawal from the hormones in the OC pills (van Heusdan, & Fauser, 1999). Therefore, 
in addition to having exogenous estrogen and progestin in their bloodsream, women on 
OCs, show a very different endogenous hormonal pattern across the cycle than naturally 
cycling women.  
Generally speaking, women on OCs have reduced endogenous sex steroid levels 
and reduced hormonal fluctuations across the cycle than free-cycling women (van 
Heusdan, & Fauser, 1999). For example, Folessa et al. (2002) measured neurosteroid 
levels (estradiol and progesterone) in healthy women before and after taking OCs. They 
found that the elevation in neurosteroid levels that previously occurred in the luteal phase 
was completely abolished after three months of OC treatment. Additionally, they found 
that the neurosteroid levels measured during the follicular phase after the onset of the 
third OC cycle were all lower than the neurosteroid levels measured in the follicular 
phase prior to OC use. This within-subjects design verified that hormonal levels change 
across the cycle as a direct result of OC use. 
While it is important to compare OC-using and free-cycling women, it is of 
additional importance to examine differences within OC-using women. Indeed, there are 
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numerous brands of OCs, many of which have different hormonal combinations from one 
another. In order to adequately investigate and understand the effects of OCs on women’s 
emotional and cognitive functioning, it is integral to be aware of the different types of 
OCs and their constituents.   
Oral Contraceptives 
The OCs most commonly prescribed today can be divided into three different 
categories, each with its own different hormonal combination: new generation (also 
known as antiandrogenic), second generation, and third generation OCs (Batur, Edler, & 
Mayer 2003; Wharton, Hirshman, Merritt, Doyle, Paris, & Gleason, 2008). Most of the 
OCs available in all three categories have the same estrogen compound called ethinyl 
estradiol which comes most frequently in a low-dose of 30 to35 μg, or an ultra low dose 
of 20 to 25 μg (Batur, Edler, & Mayer 2003). It is the progesterone compounds in OCs, 
however, that vary in type and ultimately determine the generation of OC pills (Glasier, 
2006).  
New generation OCs contain the progesterone compound drospirenone (e.g. 
Yaz®, Yasmin®) and tend to be monophasic in that they deliver a single dose of 
hormone throughout the cycle (Baker et al., 2012; Glasier, 2006). Second generation OCs 
contain the progesterone compound levonorgestrel or norethindrone (e.g. Alesse®, Ortho 
7/7/7®) and are also typically monophasic (Baker et al., 2012; Glasier, 2006; Wharton, 
Hirshman, Merritt, Doyle, Paris, & Gleason, 2008). Lastly, third generation OCs contain 
gestodene, desogestrel, and norgestimate (e.g. Tri-Cyclen Lo®), yet third generation OCs 
tend to deliver increasing amounts of hormones throughout the cycle in a triphasic rather 
than monophasic fashion (Baker et al., 2012; Glasier, 2006; Wharton et al., 2008). 
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Consequently, while all OCs typically reduce endogenous hormone levels and increase 
exogenous estrogen and progestin levels, different types of OCs can lead to a different 
hormonal profile. This should be taken into consideration when conducting hormonal 
research. Failure to find consistent emotional or cognitive differences between naturally 
cycling women and women on OCs may be due to the fact that many researchers group 
all women taking OCs into one category without taking OC generation or dosage into 
consideration (e.g. Kirschbaum, Pirke, & Hellhammer, 1995; Postma et al., 1999; 
Rumberg et al. , 2010). In fact, as discussed below, the hormone derivatives in second 
and third generation OCs have some effects on the brain that are opposite to those of the 
hormone derivatives in new generation OCs.  
Both second and third generations OCs contain progestins that are testosterone-
derived. These testosterone-derived progestins bind to the androgen receptors in the brain 
and are responsible for varying levels of androgenic activity (Batur, Edler, & Mayer 
2003). Having a more androgenic brain implies a more “masculinized” brain in that 
androgens are responsible for the development of male-typical characteristics (Batur, 
Edler, & Mayer 2003). Second generation pills are the most androgenic of OCs while 
third generation OCs are also androgenic but less so than second generation OCs. In 
contrast, the drospirenone found in new generation OCs is spironoelactone- rather than 
testosterone-derived and has antimineralocorticoid and antiandrogenic properties 
(Wharton et al., 2008). Therefore, OCs can have a largely different and potentially 
opposite effect on women depending on the generation of OC used. For example, 
Wharton et al. (2008) found that performance on a mental rotation task (MRT) differed 
depending on OC generation. Second generation OCs users outperformed other OC users 
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on the MRT. New generation users, on the other hand, showed the worst performance on 
the MRT task compared to all other OC users and naturally cycling women combined. 
Thus, while looking at OC users as a whole may be valuable due to some common 
hormonal changes within this group, taking OC type into consideration may also be 
important for understanding some hormonal, cognitive, and emotional differences 
between and within OC user and nonuser groups of women.  
Hormones and Brain Structure 
Along with differences in hormonal concentrations, sex-related steroid hormones, 
and OC use have also been associated with differences in brain structures and grey matter 
quantities (see Cosgrove, Mazure, & Staley, 2007; Goldstein et al., 2001; McEwan, 
Allves, Bulloch, & Weiland, 1997 for a review). Pletzer at al. (2010) obtained high-
resolution structural images of the brains of 14 men, 14 women using OCs, and 14 
women not using OCs. Women who were not using OCs were scanned once during the 
early follicular phase (which the authors defined as onset of menstruation to 5 days 
before ovulation) and again during the mid-luteal phase (which the authors defined as 3 
days post ovulation to 5 days before menstruation). The scans revealed that men had 
larger hippocampi, parahippocampal and fusiform gyri, amygdalae, and basal ganglia 
than both OC-using and free-cycling women. Gray matter volumes were also larger in 
men compared to women bilaterally in the hippocampus, parahippocampal and fusiform 
gyri, putamen, pallidum, amygdala, and temporal regions. However, gray matter volumes 
were larger in women compared to men bilaterally in: the prefrontal cortex, the pre- and 
postcentral gyri, the supplementary motor area, and the inferior parietal lobule. These 
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scans provide evidence that there may be hormonally related differences in brain 
structures between men and women.  
In the same study, brain structure differences were found in women as a function 
of cycle phase and OC use. Free-cycling women during the early follicular phase (when 
estrogen and progesterone levels are both low) showed larger gray matter volumes in the 
prefrontal cortex, pre- and postcentral gyri and larger volumes in the right fusiform/ 
parahippocampal gyrus compared to free-cycling women in the mid-luteal phase (when 
estrogen and progesterone levels are both high) (Pletzer et al., 2010). Additionally, 
women using hormonal contraceptives showed significantly larger prefrontal cortices, 
pre- and postcentral gyri, parahippocampal and fusiform gyri and temporal regions, 
compared to women not using OCs. Furthermore, total grey matter volume of women 
using hormonal contraceptives was smaller than in naturally cycling women. Pletzer et al. 
(2010) used a between- rather than a within-subjects design. A within-subjects design 
(before and during OC use) would better provide evidence for a direct effect of OC use 
on changes in grey matter and brain structure. Nevertheless, the scans from the Pletzer et 
al. (2010) study suggest that there are differences in brain structures between women as a 
function of cycle phase and OC use.  
Protopopescu et al. (2008) used brain scans and a within-subjects design to 
compare women during the late follicular phase (days 10 to 12 after onset of 
menstruation) and the late luteal phase (1 to 5 days before menstruation). They found that 
during the late follicular phase (when estrogen is high but progesterone is low) the 
women had increased grey matter volumes in the lingual gyrus and hippocampus and 
decreased grey matter volumes in the superior parietal lobe, pallidum/putamen and 
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anterior cingulate gyrus compared to during the late luteal phase (when both estrogen and 
progesterone are low). These findings provide further evidence of menstrual cyclicity and 
hormonal effects on grey matter structure.  
These two studies provide evidence that sex steroid hormones likely influence 
structural brain differences in women and men as well as within women across the 
menstrual cycle or with use of OCs. The implications of these structural differences, 
however, are unknown and it is of interest to determine if they are associated with 
differences in mood and/or differences in functional ability or performance on emotional 
or cognitive tasks. Future studies should investigate the implications of these structural 
differences by choosing particular tasks that tap into brain areas affected by hormonal 
changes.  
Oral Contraceptives and Affect 
Along with structural brain differences, OCs have also been linked to mood 
changes in users. Mood side effects have been reported by women and recognized by 
researchers since the release of the pill (Sanders, Graham, Bass, & Bancroft, 2001; see 
review in Oinonen & Mazmanian, 2002). Currently, approximately 4 to 10% of women 
on OCs experience negative mood side effects (Gingnell et al., 2013). Many of those 
women opt to discontinue OCs as a consequence of the negative mood effects and begin 
to rely on other, possibly less effective, means of birth control. For example, Sanders et 
al. (2001) found that, in their study of 79 OC-using women, 49% of the participants 
discontinued OCs, and 87% of those who discontinued cited negative emotional side 
effects, worsening of PMS, or decreased sexual thoughts and desire as their main reason 
for discontinuation.   
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Interestingly, Gingnell et al. (2013) found that when women who discontinued 
OCs due to negative mood side effects were put back on OCs using a randomized 
placebo-controlled design, they re-experienced the negative mood side effects while those 
given placebo did not report the negative mood side effects. These results support the 
idea that negative mood side effects are indeed a possible consequence of OCs, that a 
subset of women seem susceptible or sensitive to such effects, and that upon terminating 
OC use, negative mood side effects are diminished. Importantly, this study also provided 
evidence for the validity women’s self-report of negative mood side effects from OC use.  
While research on women who report negative mood side effects from OCs is 
important, it is integral to recognize that many women do not report negative mood side 
effects from OC use. In fact, a review by Kurshan and Epperson (2006) indicated that 
women taking new generation pills (estradiol ethyl and drospirenone combination) 
indicated an improvement of mood symptoms from baseline (Brown et al., 2001; Parsey 
& Pong, 2000; Silem at al., 2003; Freeman et al., 2001). Additionally, a study conducted 
by Rosenthal et al. (2002) indicated that the adolescents in their study anticipated 
negative mood changes upon starting a levonorgestrel based OC (second generation) yet 
despite their expectations, 91% of the participants did not experience a negative mood 
change. Also, a study conducted by Graham and Sherwin (1992) indicated that women 
who had been depressed at baseline prior to OC use reported greater improvement in 
measures of impairment at work, needing sleep, and lack of energy premenstrually after 
taking an estradiol ethyl and norethindrone combination (second generation) OC for three 
cycles. Therefore, while much of the research on the emotional effect from OCs tends to 
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focus on negative side effects, there may in fact be positive emotional side effects as well 
for some women or with some OCs.  
Another recent finding in the link between OC use and affect is not the presence 
of a change in the level of positive or negative affect per se, but instead there is evidence 
suggesting that OCs may cause a blunting of affect (i.e., less mood reactivity). Jarva and 
Oinonen (2007) conducted a study that indicated that women on OCs experience a 
blunting of positive affect variability compared to non-users. A sample of 40 OC users, 
36 nonusers, and 31 men completed the Positive and Negative Affect Schedule (PANAS) 
before and after a series of procedures designed to induce positive affect, jealousy, social 
ostracism, and parental feelings. While no differences were found between groups for the 
level of jealousy, social ostracism, or parental feelings, OC users did display significantly 
less positive affect reactivity than non-users and men across the laboratory session. 
Furthermore, women who had been taking OCs for less than 24-months displayed the 
highest blunting of positive affect reactivity. These results suggest that OCs may cause 
women’s range of positive emotions to be reduced or blunted.  
The idea that women on OCs may experience a blunting of positive affect might 
potentially be explained by the constant low dose of ethinyl estradiol (estrogen) that most 
OCs contain as opposed to the cyclical peaks in estradiol found in free-cycling women. 
Indeed, research suggests that estrogen has been linked to an increase in positive moods 
(Gasbarri, Pompili, d’Onofrio, Cifariello, Tavares, & Tomaz, 2008; Jacobs & D’Esposito, 
201; Miller, Conney, Rasgon, Fairbanks, & Small, 2002). Therefore, if women on OCs 
are not experiencing the high levels of estradiol that free-cycling women are 
experiencing, they may also not experience positive emotions in the same way as free-
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cycling women. Moreover, if women on OCs are indeed experiencing a blunting in 
positive affect reactivity, it may have both negative emotional and social consequences. It 
is important, therefore, for future studies to further investigate the potential blunting of 
positive affect reactivity in women on OCs.  
The Effect of Hormones on Emotional Tasks and Response Inhibition 
Differences in how free-cycling and OC-using women experience affect can have 
not only emotional and social consequences, but cognitive consequences, as well. As 
mentioned above, a study conducted by Gingnell et al. (2013) found that when women 
discontinued OCs due to negative mood side effects and were put back on OCs using a 
randomized placebo-controlled design, they re-experienced the negative mood side 
effects. While this provides strong evidence that OCs did in fact directly contribute to 
negative mood side effects for these women, Gingnell et al. (2013) also found some 
notable cognitive effects. Specifically they found that while viewing angry or fearful 
faces, brain reactivity patterns differed between the women who were put back on the OC 
regimen and the free-cycling women taking a placebo.  
Gingnell et al. (2013) recruited 34 women with previous experience of mood 
deterioration during OC use and randomized the participants to one treatment cycle using 
a levonorgestrel-containing OC or placebo. The women taking the OCs had quicker 
response times to identify the angry and fearful faces, lower reactivity in the left insula 
(typically associated with positive or salient emotional stimuli) (Jabbi et al., 2007; 
Takahashi et al., 2008), and lower reactivity in the inferior frontal gyri (associated with 
verbal language production, empathy, response inhibition, and emotional distraction) 
(Hampshire et al., 2010; Liakakis et al. 2011; Wang et al., 2008). These results indicate 
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that OCs may cause some women to be more reactive to negative stimuli and have lower 
emotional distraction and lower response inhibition while viewing negative stimuli 
compared to naturally cycling women. 
Interestingly, since the inferior frontal gyrus is involved in a number of cognitive 
functions and processes related to social interactions such as: speech processing, verbal 
language production, empathy, and motor execution and response inhibition (Hampshire 
et al., 2010; Liakakis et al. 2011; Wang et al., 2008), it would be interesting to conduct 
additional studies that use tasks that target the inferior frontal gyrus. This would further 
clarify are any additional functional differences between women taking OCs and free-
cycling women. 
It would be of additional interest for future studies to examine whether women on 
OCs with negative mood side effects also differ in their responses to other negative 
emotional stimuli besides fear and anger such as sadness or disgust. Additionally, since 
the Gingnell et al. (2013) study did not collect information on the level of emotional 
distraction between groups, future studies should investigate if women experiencing 
negative mood side effects from OCs are less able to disengage from the negative 
emotion and focus their attention elsewhere. This would provide confirmation that the 
low reactivity in the inferior frontal gyrus of OC users with current negative mood side 
effects noted by Gingnell and colleagues is indeed associated with low emotional 
distraction. Lastly, the Gingnell et al. (2013) study only used levonorgestrel-containing 
(second generation) OCs with the explanation that levonorgestrel has been most linked 
with negative mood side effects. Undoubtedly, other OCs containing different hormone 
combinations could have a different effect on brain regions as well as on mood side 
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effects. Thus, it is of great importance to also look into the differences between women 
taking different brands and hormonal combinations of OCs as well as to examine 
emotional and cognitive effects on OC users as a whole. In sum, future studies should 
investigate the differences between free-cycling women and women using a variety of 
different generations of OCs in their responses to a diverse range of emotional faces, and 
in their level of emotional distraction.  
In contrast to the finding that OC users may show a quicker response to identify 
negative emotional stimuli, Gasbarri, Pompili, d’Onofrio, Cifariello, Tavares, and Tomaz 
(2008) found that naturally cycling women during the late follicular (high estrogen) phase 
had slower response times and made more errors when trying to remember and respond 
to certain negative emotional faces. Participants included 56 naturally cycling females 
who were either menstruating, in the middle to late follicular phase (day 4 to 13), or in 
the luteal phase (days 14 to 32). They completed a Delayed Matching To Sample 
(DMTS) working memory task that presented a sample stimulus of a face expressing 1 of 
6 emotions (happiness, anger, fear, sadness, disgust, surprise) and after a delay of 8 
seconds 4 stimuli appeared of the same actor emitting different expressions. The 
participant was instructed to choose the expression that matched the one they just saw in 
the sample stimulus. They found that women during the mid to late follicular phase had 
higher errors than women in the luteal or menstrual phase when it came to remembering 
and matching faces emoting sadness or disgust. Furthermore, women in the middle to late 
follicular phase took significantly longer than the other groups to respond to sad facial 
expressions. This study further contributed to the evidence that gonadal hormones 
influence accuracy and speed in recognizing facial emotions.  
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The authors suggested that because estrogen is known to improve mood, perhaps 
the high estrogen levels from the middle to late follicular phase caused the women to 
have problems in identifying mood incongruent stimuli (Gasbarri et al., 2008). 
Alternatively, the authors suggest that during the middle to late follicular phase the higher 
levels of estrogen increase a woman’s sensitivity to stimuli that have reproductive 
relevance because the chance of conception is higher (e.g. Krug, Piertrowsky, Fehm, & 
Born, 1994). Therefore, since sadness and disgust are less important from a sexual or 
reproductive point of view, women during the follicular phase may be less likely to 
recognize or correctly identify those emotions (Gasbarri et al., 2008). 
Evidently, there may be some important differences in women’s emotional 
reactivity and ability to identify particular emotions depending on their use of OCs, or 
phase in the menstrual cycle. Moreover, there may be particular subgroups of women that 
experience negative mood side effects from OCs or a blunting of affect reactivity from 
OCs. It would be of particular interest to further investigate how OC use and menstrual 
cycle phase affect emotional reaction to both positive and negative stimuli as well as how 
they would affect women’s ability to recognize various emotions. To date, there has been 
no study that directly compares how both positive and negative mood or affect might 
differentially influence emotional recognition abilities of free-cycling, and OC-using 
women.  
Moreover, since both endogenous and exogenous hormones have been shown to 
influence emotion recognition abilities, there may also be sex differences in the way men 
and women perform on facial emotion recognition tasks. Previous research has indicated 
women outperform men on facial emotion recognition (e.g. see reviews in McClure, 
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2000; Thayer & Johnsen, 2000). Fewer studies, however, have examined sex differences 
in response times to facial expressions. Rizzolatti and Buchtel (1977) found in their study 
that men had faster reaction times to faces when the stimuli were presented to the right 
hemisphere. They found no hemispheric differences for females. However, this study did 
not take into account the emotional expression of the faces and how the men and women 
may respond based on the emotional expression. Future studies, therefore, should look 
into sex differences on performance on facial recognition tasks, including correct 
identification and differences in response times.  
Along with differing responses to facial stimuli, Borgstrom, Kask, Gulinello, 
Odlind, and Sundstrom-Poromaa (2008) found that women on OCs with current negative 
mood side effects also differed in their prepulse inhibition (PPI) responses compared to 
naturally cycling women and OC using women with no mood side effects. Borgstrom et 
al. (2008) conducted a study examining the acoustic startle reflex of 20 women on OCs 
with no reported mood symptoms, 28 women currently on OCs and reporting adverse 
mood side effects, 27 women who has discontinued OCs not due to adverse mood side 
effects, and 32 women who discontinued OCs due to adverse mood side effects. The 
acoustic startle reflex was measured via eyeblink responses to the prepulse inhibition 
(PPI) trials. The prepulse stimuli consisted of 115 dB noise bursts for 40ms followed by 
20ms prepulses that were 72, 74, 78, or 86 dB. Those who have the expected reduction in 
the startle reflex after prepulse exposure are those who are considered to have prepulse 
inhibition. Deficits in PPI manifest in the inability to filter out unnecessary information 
and possible abnormalities in sensorimotor gating (see Braff, Geyer, & Swerdlow, 2001 
for a review).  
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Borgstrom et al. (2008) found that the women with current adverse mood effects 
from OCs exhibited lower levels of PPI at 86 dB compared to current OC users with no 
adverse mood effects. There was no difference in PPI between the two groups of prior 
OC users. These findings also replicated Borgstrom’s previous findings in patients with 
Premenstrual Dysphoric Disorder (PMDD) where PMDD patients displayed lower levels 
of PPI in the late luteal phase (when mood would be most negative) compared to healthy 
controls (Kask, Gulinello, Backstrom, geyer, & Sundstrom-Poropmaa, 2007). The 
findings of lower PPI in OC users with negative mood side effects suggest that these 
women may possibly experience difficulty filtering out unnecessary information. 
Holloway, Beck, and Servatius (2011) also found PPI differences between OC 
users and nonusers even without taking into account mood side effects. Using a classic 
eyeblink conditioned response, they tested 71 participant’s eyeblink responses to a 500-
ms conditional stimulus or a 100ms air-puff unconditional stimulus. They found that PPI 
was lower in both males and OC users than free-cyclers. Also, free-cycling women 
acquired a conditioned eyeblink response faster than males, and OC users developed an 
accelerated conditioned eyeblink response compared to non-users. Nevertheless, the 
authors of this study did not collect information about the mood side effects of their OC 
users. Therefore, it is difficult to determine if the differences in PPI are due to OCs in 
general, or if the women in this particular study had negative mood side effects that were 
not recorded. Nevertheless, it is evident that hormones have an effect on automatic startle 
responses, which could be a reflection of structural and functional brain differences 
between OC users and naturally cycling women.  
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Borgstrom et al. (2008) explained that PPI is subject to regulation by steroid 
hormones and dysregulation of inhibitory neurotransmission. Inhibition and sensorimotor 
gating are regulated by GABA receptors in several brain regions. Disturbances in 
GABAergic systems have been shown to contribute to deficits in PPI. For example, 
pharmacological interventions (such as GABA antagonist picrotoxin) aiming to decrease 
GABAergic inhibition in the hippocampus as well as the medial prefrontal cortex also 
result in PPI deficits (Japha & Koch, 1999). Therefore, it is possible that women taking 
OCs or women experiencing negative side effects from OCs may be experiencing 
GABAergic disturbances. This finding fits with the findings of the Follessa et al. (2002) 
study which investigated the effects of OCs in rats and women. They found that 3 months 
of treatment with an ethinyl estradiol and levonorgestrel OC (second generation OC) 
resulted in decreased levels of progesterone and its GABAA receptor-active metabolite 
allopregnanolone in both rats and women. Moreover, rats treated with OCs displayed 
more anxious behaviours during a maze test. Since the GABAA system is the major 
inhibitory system in the CNS of mammals, reduction of its metabolites can cause 
disturbances in steroid hormone concentrations as well as in functional behavior. Using a 
task that taps into inhibitory processes and examines an individual’s ability to inhibit 
certain responses could determine possible GABAergic disturbances that affect 
functioning in OC users and would be an interesting avenue for future studies.  
Indeed, Bannbers et al. (2012) conducted a study looking at how hormones affect 
response inhibition among 13 healthy postpartum women. The women were tested 
immediately after delivery and 4 to 6 weeks after delivery in order to capture the dramatic 
drop in progesterone and estradiol, and the abundance of ovarian steroid receptors in the 
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brain following delivery. The women performed a non-emotional Go/Nogo task while 
undergoing an fMRI. The Go/Nogo task instructed participants to press a button 
whenever the letters X or Y appeared but to refrain from pressing the button when the 
same letter was presented two times in a row. Scans from the fMRI showed that correct 
inhibition to Nogo trials activated several areas of the brain that are responsible for 
inhibition including the left inferior frontal gyrus, right superior frontal gyrus, right ACC, 
left cingulate gyrus, right posterior cingulate gyrus, and left parahippocampal gyrus. 
Also, fMRIs revealed a decrease in activation in task-related and ovarian steroid-related 
brain areas such as the right inferior frontal gyrus, right ACC, and bilateral precentral 
gyrus in the late post-partum phase. However, no difference in performance during 
response inhibition was detected across the postpartum period or between the postpartum 
women and non-postpartum controls. Despite the lack of group differences in 
performance, this study found important brain activation patterns responsible for 
inhibition in women.  
Albert, Lopez-Martin, and Carretie (2010) also investigated behavioural 
inhibition, however they used an emotional rather than a non-emotional GoNogo task. 
Thirty healthy students (16 females, 14 males) were instructed to press a key with their 
right thumb when they saw the letter “M” (Go task) and not press the key if they saw the 
letter “W” (Nogo task). The letters would appear on top of an image selected from the 
IAPS that was deemed as positive, negative, or neutral in valence. Error rates, response 
times, and ERP data was collected. Error rates were higher for the nogo trials than the go 
trials meaning it was generally harder for participants to inhibit a response than to 
respond, regardless of the emotional context of the pictures. In contrast, response times 
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on the Go trials differed based on the emotional context. Response times were shorter in 
the positive context for the Go trials than in the negative and neutral contexts.  
ERPs showed that, during the nogo trials, P3 amplitude was larger and anterior 
cingulate cortex activation was stronger in the positive context than in the negative 
context (Albert, Lopez-Martin, & Carretie, 2010). P3 is a component of the frontocentral 
area of the brain that is related to the inhibitory process. Therefore, the positive emotional 
contexts require the mobilization of inhibitory resources more than negative emotional 
contexts in healthy individuals. Furthermore, the authors found that it was valence and 
not arousal that was associated with the Nogo-P3 amplitude. Based on P3 and cingulate 
cortex activation, they concluded that withholding a prepared response within a positive 
context is more difficult and consumes greater inhibitory resources than within a negative 
context, regardless of the arousal level of the context.  
Nevertheless, Albert, Lopez-Martin, and Carretie (2010) did not take hormonal 
influences into consideration and did not explicitly include women on OCs with negative 
mood side effects in their study. While it can generally be expected that most individuals 
can more easily inhibit their responses to negative stimuli (Albert, Lopez-Martin, & 
Carretie, 2010), there may be a different pattern for women on OCs with negative mood 
side effects. In the Gignell et al. (2013) study mentioned above, women on OCs who had 
previous negative mood side effects who were viewing angry and fearful faces responded 
much faster to the faces and showed decreased activation in the inferior frontal gyrus 
(indicating low emotional distraction) as compared to women not on OCs. Interestingly, 
the pattern observed among women who are correctly inhibiting a response as shown in 
the Bannbers et al. (2012) study is that women had increased activity in the inferior 
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frontal gyrus while correctly inhibiting a response. Perhaps women taking OCs with 
negative mood side effects are a specific subgroup of individuals that have lower 
emotional distraction after viewing emotionally negative stimuli and therefore have 
differing inhibitive responses compared to women with no negative mood side effects. It 
would be of interest for future studies to investigate whether emotional inhibitory 
processes generally differ between OC users and nonusers or if emotional inhibitory 
processes are particularly affected in women with negative mood side effects (either 
generally or when taking OCs). 
In sum, natural hormonal fluctuations and OC use have been shown to influence 
women’s performance on emotional and inhibitory tasks. Women on OCs with negative 
side effects have an accelerated ability to detect negative emotional faces (Gignell et al., 
2013), while naturally cycling women in the high estrogen phase (late follicular) have a 
decreased ability to detect negative emotional faces (Gasbarri et al., 2008). Additionally, 
regardless of mood side effects, women on OCs have generally shown a decreased ability 
to inhibit behaviour as seen in PPI studies (Borgstrom et al 2008; Holloway, Beck, & 
Servatius, 2011), which may be explained by hormonally induced GABAergic 
disturbances (Borgstrom et al., 2008; Follesa et al., 2002). Future studies should further 
investigate the facial-expression detecting performances of women on OCs and free-
cycling women across the menstrual cycle. Moreover, future studies should also 
investigate inhibitory responses in an emotional context in order to tap into possible 
hormonally-related differences in emotional inhibition (Albert, Lopez-Martin, & Carretie, 
2010; Bannbers et al. 2012).  
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Cortisol and Affect 
Another possible explanation for the emotional differences between free-cyclers 
and women using OCs is the possible moderating effects of cortisol. A study by 
Kirschbaum, Pirke and Hellhammer (1995) found no differences in baseline cortisol 
levels between OC users and non-users, but instead found significantly attenuated cortisol 
responses in OC users during the Trier Social Stress Test (TSST) compared to non-users 
and men. The TSST requires participants to perform a 5-minute public speaking task and 
a 5-minute mental arithmetic in front of an audience. In response to the stressor, women 
on OCs showed peak cortisol levels only slightly elevated above baseline, less than half 
of what was found in non-OC users. The authors suggest that this could provide 
preliminary evidence for an altered hypothalamus-pituitary-adrenal (HPA) Axis due to 
OC use. Yet despite the differences in cortisol responses, they found no significant 
differences in perceived stress between subject groups as measure by a Visual Analogue 
Scale (VAS).  
Interestingly, Het and Wolf (2007) found that when women on OCs were treated 
with exogenous cortisol, the cortisol did indeed have buffering effects on mood in 
response to the TSST. Forty-four women on monophasic OCs (containing a progesterone 
derivative and between 0.02 to 0.035 ethinylestradiol) were treated with 30mg cortisol or 
matching placebo before participating in the TSST. They found the women treated with 
placebo had a blunted free-cortisol response to the TSST as previously established by 
Kirschbaum and colleagues (1995). Moreover, the women treated with cortisol reported 
significantly less negative mood than the women treated with placebo. Het and Wolf 
(2007) offer several explanations as to why cortisol may inhibit a stress response. 
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Cortisol treatment may modulate the emotional processing pathway including the 
network involving the prefrontal cortex, amygdala, insula, basal ganglia and anterior 
cingulate. Alternatively, cortisol may exert a negative feedback response on the 
hypothalamic neurons and cause cortisol-treated individuals to have a reduced central 
corticotropin-releasing hormone (CRH) secretion in response to a stressor and thus, 
reduce negative affect.  
These studies show that while the blunted free cortisol response affects some 
important brain mechanisms, it does not always influence affective response to a 
psychosocial stressor. Also, Kirschbaum, Pirke and Hellhammer (1995) studied naturally 
occurring levels of cortisol while Het and Wolf (2007) administered synthetic cortisol. 
Therefore, any differences in the reported mood effects subsequent to the stressful event 
may not be comparable between the two studies. It would be of interest to further 
investigate the emotional reactions of OC users and non users experiencing a variety of 
different emotions, stressful or otherwise, to determine if there are differences in reported 
affect. For example, if there is an altered HPA axis reactivity, this may be evident in a 
blunting of other stressful emotions such as fear, rather than social stress.  
Interestingly, despite the above finding that cortisol may have a protective effect 
in terms of experiencing negative affect, Merz et al. (2012) found that cortisol actually 
enhanced implicit fear learning in women on OCs. Participants were given 30 mg of 
cortisol or matching placebo and shown three different shapes on a screen in random 
order with one shape consistently being paired with a mild electric shock. The 
participants were not told about when to expect the shock. Fear conditioned responses 
were detected via brain scans and skin conductance responses. Brain scans revealed an 
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increase in neuronal differentiation in women using OCs and reduced fear learning in the 
anterior parahippocampal gyrus and the hippocampus in men and naturally cycling 
women. Thus, Merz et al. (2012) stated that cortisol enhanced fear conditioning for OC 
users yet decreased fear conditioning in men and women both in the luteal and follicular 
phase. They concluded that OC usage modifies cortisol effects on emotional learning.  
In 2013, Merz, Stark, Vaitl, Tabbert, and Wolf conducted another study on 
cortisol and fear conditioning. However, they did not administer cortisol and instead 
sampled endogenous cortisol levels from the participants’ saliva. The participants were 
again shown three different shapes but this time were told explicitly when to expect a 
mild electric shock. Through fMRI, a higher conditioned-unconditioned stimulus 
differentiation was revealed in the amygdala of women during their follicular phase 
compared to men and OC users. In other words, women during their follicular phase 
demonstrated the strongest neuronal evidence of the conditioned response as compared to 
men and OC users. This result is congruent with previous research that has suggested that 
women on OCs have an attenuated cortisol response and that cortisol enhances fear 
conditioning. If cortisol enhances fear conditioning (i.e., Merz et al., 2012) and women 
on OCs have an attenuated cortisol response (i.e., Kirschbaum, Pirke & Hellhammer, 
1995; Het & Wolf, 2007) then it would be expected that women on OCs would have 
weaker cortisol response and thus a weaker conditioned-unconditioned stimulus 
differentiation compared to naturally cycling women. This might also suggest that 
women taking OCs would be less able to implicitly or automatically differentiate relevant 
fearful stimuli from irrelevant stimuli and may thus overreact to irrelevant stimuli (i.e., a 
failure of inhibition).  
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Nevertheless, neither of the Merz et al. (2012) or Merz et al. (2013) studies 
collected mood or affect information from their participants so it remains unknown as to 
whether these cortical structural and neuronal differentiations would translate into actual 
enhanced or decreased feelings of fear. It would be of interest for future studies to further 
investigate whether or not there are hormonal and OC-related influences on reactivity to 
fear stimuli.  
The Effects of Hormones on Cognition 
Along with hormones affecting brain regions related to emotion and inhibition, 
hormones also largely affect brain areas related to cognition and performance on 
cognitive tasks (see reviews in Kimura, 1996;Torres, Gomez-Gil, Vidal, Puig, Boget & 
Salamero, 2006). In reviews on sex hormones and cognitive tasks, women tend to 
outperform men in tasks of verbal memory, verbal fluency, item memory, and the 
specific visuospatial task of object location memory (Kimura, 1996; Torres et al., 2006). 
Also, men generally tend to outperform women on mental rotation tasks (Collins & 
Kimura, 1997), targeting tasks, and generally all visuospatial tasks with the exception of 
object location memory (Kimura, 1996). Within women, performance on spatial tasks is 
improved during the early follicular phase (menstruation) compared to during the late 
follicular or midluteal phases (Collins & Kimura, 1997; Torres et al., 2006). In fact, 
spatial working memory is related to the hippocampal region in humans and hippocampal 
volume in women has shown to change across the menstrual cycle (Pleil & Williams, 
2010). This hormonally related change in the hippocampus has led to performance 
variations on certain hippocampal-related cognitive tasks (Pleil & Williams, 2010). 
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A study conducted by Postma, Winkel, Tuiten, and Van Honk (1999) found sex 
and hormonal differences on a visuospatial task in their sample of 23 males and 34 
females. The participants viewed a screen that contained 10 of the same objects for 30 
seconds. The objects then disappeared and reappeared again in different locations and the 
participants were asked to move the objects back into the original positions. Males 
showed a selective advantage for this metric position reconstruction task compared to 
women. From these results, the authors conducted another study to investigate the 
differences within women.  
In their second study, Postma et al. (1999) examined spatial abilities in women as 
a function of menstrual cycle phase using a between-subjects design (22 OC users, 11 
naturally cycling women). Combining both the free-cycling and OC-using women, those 
in the non-menstrual phase performed better on the position reconstruction task than 
those during the menstrual phase. Unfortunately, since naturally cycling women and OC 
users were analyzed together, interpretation of the differences in spatial ability should be 
made with caution. The authors found that OC use did not yield any significant main 
effects, however the sample of OC users (22) and naturally cycling women (11) was 
small and may not have been powerful enough to detect an effect. A within-subjects 
design would have been more sensitive in this study. Furthermore, women were grouped 
as either menstruating or non-menstruating and there was no differentiation between 
luteal and follicular phases. Future research would need to group naturally cycling 
women based on their phase in the menstrual cycle as cycle phase has been shown to 
influence spatial abilities (Collins & Kimura, 1997; Torres et al., 2006) and brain region 
activation patterns during spatial tasks (Pleil & Williams, 2010). Furthermore, when 
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studying women on OCs, the particular hormonal combination of each woman’s OC 
should be taken into consideration as different OCs types have also been shown to 
differentially influence performance on spatial tasks (e.g., Wharton et al., 2008).  
Indeed, a study conducted by Wharton et al. (2008) indicated that certain types of 
OCs affect visuospatial skills in different ways. Wharton and colleagues conducted a 
between-subjects design and recorded the performance of 155 females on a Mental 
Rotation Task and a Recognition Memory Task. Women on anti-androgenic pills (New 
generation pills such as Yasmin®) showed the worst performance on the Mental Rotation 
Task compared to nonusers. Second generation users, on the other hand, had a tendency 
to outperform nonusers on the Mental Rotation Task, however this difference was not 
significant. Their results generally showed a correlation between androgenic activity in 
OCs and visuospatial performance with higher androgenic activity being associated with 
better performance on the MRT. This result is consistent with previous studies indicating 
that androgenic or “male hormones” are related to better performance on visuospatial 
tasks (Collins & Kimura, 1997; Kimura, 1996). 
 Interestingly, Wharton et al. (2008) did not find any differences on the 
Recognition Memory Task, confirming that spatial tasks such as the MRT are more 
affected by androgenicity than verbal recognition tasks. Additionally, no significant 
difference in performance was found between menstrual cycle phases for free-cyclers 
during different phases of their cycle. This is inconsistent with previous findings 
indicating performance difference across the menstrual cycle (Collins & Kimura, 1997; 
Torres et al., 2006). Nevertheless, the means followed the expected direction of higher 
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performance on the MRT during the menstrual phase followed by the follicular and luteal 
phase, respectively.  
Evidently, while it is important to investigate general differences between 
naturally cycling women and women on OCs, studies such as that by Wharton et al. 
(2008) demonstrate the importance of taking into consideration the differences in 
hormonal combinations within OC users. It is possible that inconsistencies in findings or 
lack of differences in visuospatial performance between men and women and across the 
menstrual cycle may be a result of researchers grouping all OC users together or grouping 
all women together without taking OC use into account.  
Along with influencing spatial navigation, hormones also influence performance 
in other important cognitive areas. Miller, Conney, Rasgon, Fairbanks, and Small (2002) 
examined the verbal fluency and working memory of 31 postmenopausal women using 
Estrogen replacement Therapy (ERT) (19 using an estrogen-progesterone combination, 
12 using estrogen only), 16 nonusers, and 49 men. They found that the post-menopausal 
women using ERT had less-severe symptoms of depression and anger and performed 
better on a verbal fluency, and a working memory and attention task than non-ERT users. 
Furthermore, ERT users performed better on semantic fluency (generating words in a 
category) than men. On the other hand, men had lower levels of anger and better working 
memory than women who do not use ERT. There were no significant correlations 
between the cognitive factors and the mood variables.  
Interestingly, the authors noted that ERT was associated with several variables 
that are modulated by the orbitofrontal areas such as mood, verbal fluency, and working 
memory. This is consistent with the fact that estrogen receptors are found in higher 
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concentrations in the orbitofrontal areas such as the basal forebrain and locus coeruleus 
(responsible for the mood-related origin of cholinergic pathways and norepinephrine 
production, respectively), the frontal lobe (modulates the verbal encoding and retrieval 
system), and the hippocampus (modulates learning and semantic memory). Therefore 
when estrogen is high in these areas of the brain, performance is likely to improve in 
tasks tapping into these functions or abilities.  
When considering the potential effects of OCs on mood or cognition, however, it 
is particularly helpful to look at the possible effects of estrogen on premenopausal 
women. Vranic and Hromakto (2008) studied the working memory of 96 women by 
having them complete a working memory task that involved matching the faces of adult 
men and infants. Twenty-seven women were on tri-phasic OCs and 69 were naturally 
cycling. They found that regardless of whether women were free-cycling or using OCs, 
when women were in their high estrogen phases (both midluteal and late follicular) they 
were more efficient in solving the memory task with adult male faces than were women 
in the low estrogen phase of their cycle (early follicular). There was no difference in task 
performance with infant faces indicating that there is a differential influence of estrogen 
on working memory when different stimuli are used. A potential explanation for this is 
that women are more fertile in their high estrogen phase as it typically occurs close to 
ovulation. Therefore, adult male faces may be more salient to women in this more fertile 
high estrogen phase. However, this explanation is only valid for women during their late 
follicular phase as the late follicular phase is when women are most fertile. Another 
possible explanation is that during high estrogen phases, the encoding of male faces is 
deeper than during low estrogen phases (Vranic & Hromakto, 2008). Nevertheless, more 
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research would be needed to directly identify whether or not adult male faces are more 
deeply encoded during high estrogen periods than other types of faces such as adult 
female faces, for example.  
Along with estrogen, progesterone is also associated with some important areas of 
cognition. Schultheiss, Patalakh, and Rosch (2012) explain that progesterone influences 
cognition, emotion, and behaviour by binding to the GABA receptors which, as 
previously discussed, have an inhibitory effect on neural signal transmission. Therefore 
progesterone can have wide-ranging effects on alertness, emotionality, and learning. 
Furthermore, it had been found that progesterone influences lateralization. Women in the 
lower progesterone (early follicular) phase show lateralization on tasks for which 
lateralization is typically found. For example, women in the early follicular phase show 
high activation in the left-brain during a verbal task. Women during their high 
progesterone (mid luteal) phase, however, show less lateralization on tasks for which 
lateralization is typically found. For example, women with high progesterone will show 
brain activation in both the left- and right-brain during a verbal task. (Hausmann, 
Slabbekoorn, Van Goozen, Cohen-Kettenis & Gunturkun, 2000).  
In their study, Schultheiss, Patalakh, and Rosch (2012) recruited 28 OC users, 14 
nonusers, and 50 men who provided saliva samples for cortisol and progesterone levels 
and completed a number of cognitive tasks including the Lateralized Network Attention 
Task. Assessment of alerting was tested by presenting a cue that precedes the target 
stimulus of an arrow point either up or down. Faster responses on cued rather than 
uncued trials indicate efficient alerting. Assessment of orienting was tested using the 
same concept as alerting however the cues would appear in different locations across the 
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screen. Correctly identifying cues that were in the same location as the target stimuli was 
indicative of efficient orienting. Conflict resolution performance was indicated by how 
long the participant responded when a target arrow was present within an incongruent 
context (i.e. presented with another arrow pointing in a different direction than the target 
arrow). Slower responses on incongruent trials than on congruent trials was an indicator 
of less efficient conflict resolution.  
Schultheiss and colleagues (2012) found that high progesterone levels, regardless 
of OC use or non-use, were linked to lower inter-hemispheric correlations for alerting and 
orienting (functions dependent on the posterior and subcortical brain networks) but were 
linked to a higher correlation of conflict-resolution performance (functions dependent on 
prefrontal brain functions such as the anterior cingulate). Higher progesterone was also 
linked to slower interhemispheric transfer times. This study shows the complicated 
interaction between hormones and cognition. Evidently, depending on the task, 
progesterone may influence performance in different ways. It could be expected that 
attention tasks that rely on subcortical structures would show worse performance during 
high progesterone periods, while tasks tapping into prefrontal brain regions like judgment 
and working memory may show improved performance during high progesterone 
periods.  
Nevertheless, differences in brain activation do not always lead to differences in 
performance on a task. A study by Rumberg et al. (2010) sought to investigate the cycle-
and gender-dependent cerebral activation effects in 12 males, 12 females using OCs, and 
12 females not using OCs during a verbal generation task. For male subjects, the regions 
that were most activated were the left inferior frontal, the left medial temporal, and the 
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left prefrontal cortex.  For female subjects regardless of cycle phase or OC use, the areas 
that were the most activated were left inferior frontal, the left medial temporal, and the 
bilateral occipital cortex. Women scanned during their menses and during their luteal 
phase did not show brain differences during the verbal generation task. However, women 
using OCs showed higher levels of activation in the right superior temporal cortex during 
verb generation compared to free-cycling women in the menstrual phase. Higher levels of 
activation for OCs users were also found in the right inferior frontal cortex compared to 
women in the mid-luteal phase. Overall, the study by Rumberg and colleagues showed 
significant sex differences in cerebral activation when women were in their mid-luteal 
phase however no groups showed significant difference in their performance on the tasks. 
Similarly, Kucian, Loenneker, Dietrich, Martin, and Von Aster (2005) had a small 
sample of men and women complete a calculation task, a magnitude task, or a mental 
rotation task while scanning their brains with an fMRI. During the mental rotation task, 
women showed a significant bilateral activation during mental rotation in the inferior 
parietal lobe, the visual areas, fusiform gyrus and the inferior frontal gyrus. Men, on the 
other hand, showed activation in a similar but more diffuse network than women during 
mental rotation. Generally, women utilized additional brain regions during approximation 
calculation, exact calculation, and mental rotation tasks compared to men. No gender 
differences were found, however, in terms of accuracy or performance on any of the 
cognitive tasks. Additionally, Bell, Willson, Wilman, Dave, and Silverstone (2006) found 
brain activation differences among their sample of 23 males and 10 females completing 
four separate digit memory, spatial attention, word generation, and motor tasks. Yet, there 
were no significant sex differences in performance on any of the tasks. Evidently, brain 
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activation patterns are not always indicative of actual functional differences. More 
research needs to be done to further clarify precise hormonal influences on performance 
on cognitive tasks.  
Mood Induction and Cognition 
When looking at hormonal influences on cognition many studies do not take into 
account mood or affect variables. Understanding how hormones influence the experience 
of certain emotions, and how those emotions in turn influence cognition was an integral 
component of this current study. Consequently, it is important to first understand 
different methods of mood induction and how mood influences performance on cognitive 
tasks (See Gilet, 2008; Västfjäll, 2002 for a review).  
Generally, it has been found that positive mood leads to improved performance on 
a variety of tasks. For example, Lesiuk (2010) examined 24 computer information 
systems developers who participated in a 3-week study where they listened to their own 
music whenever they wanted for the first and last week, and no music during the second 
week. Cognitive performance scores were measured by self-report Quality of Work 
questionnaires. Mood and cognitive performance were significantly improved during the 
music listening weeks versus the non-music listening week. 
Brand and Opwis (2007) found that a positive mood increases cognitive 
performance. Males and females were instructed to write about a positive or negative 
event for 15 minutes. They were then asked to solve several problem-solving tasks in 
pairs and alone. They found that positive mood facilitated individual transfer 
performance of a previously learned task acquired in dyads or alone. 
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Indeed, the dopamine released from positive mood induction could be responsible 
for helping several cognitive functions. Fried et al. (2001) explains that dopamine 
potentiates the firing or delay-active neurons thought to be critical for working memory. 
Moreover, in the amygdala, dopamine projections from the midbrain are thought to 
modulate the associative learning processes, particularly those involving behavioural 
responses to rewarding or aversive stimuli. The amygdala and the prefrontal cortex are 
interconnected and activity in one can affect activity in the other.  
Fried et al. (2001) used intercerebral micro dialysis to directly sample 
extracellular dopamine in the amygdala of seven patients undergoing evaluation for 
epileptic surgery. They found that dopamine release in the amygdala was related to 
learning performance. In their study, participants completed a working memory task 
accompanied by a controlled reading task, followed by a rest period and then a word 
paired-associates learning task. The data appeared to reveal two groups of people. In one 
group, the rise in dopamine was transient and was coincident with the early phase of the 
task when most of the learning occurred. These subjects learned 95% or more of the 
paired associates and had 75% correct by the end of this trial. In the second group, 
however, the rise in dopamine was protracted and these subjects never learned more than 
60% of the pairs and knew 40% or less by the third trial. Therefore, increase in dopamine 
release in the amygdala is related to learning performance. 
On the other hand, negative mood induction may have a more complex effect on 
cognition. Chepenik, Cornew, and Farah (2007) found that sad mood affected 
performance on only certain types of cognitive tasks. Participants (14 men and 19 
women) were induced with a sad or neutral mood and were required to subsequently 
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perform a series of cognitive tasks. All participants were tested under both a neutral and 
sad mood condition one week apart. To induce sad mood, the experimenters read a script 
to the participants that involved imagining the death of a loved one while mood 
congruent music played. To induce neutral mood, the experimenters read a script to the 
participants that involved them imagining they were going to the grocery store while 
mood congruent music was played. The participants then completed working memory 
tasks (object 2-back and digit span); cognitive control tasks (Stroop Color-Word 
Interference, Go/Nogo); and attention, perception, and memory for affectively valenced 
materials tasks (Attention Probe, Free Recall and Recognition Memory, and Facial 
Emotion recognition). They found that sad mood caused a significant bias in recognition 
memory towards negatively valenced words relative to the neutral mood condition, 
however, overall word recognition was not affected by mood. Additionally, sad mood 
caused more inaccuracies in facial emotion recognition than neutral mood, however, sad 
mood did not cause a bias towards mislabeling non-sad faces as sad. There was no 
difference in performance between sad and neutral mood for the other cognitive tasks. 
Evidently, sad mood does not influence performance on cognitive tasks across the board 
but rather influences performance on memory of emotionally relevant words and facial 
recognition tasks.  
Interestingly, Spering, Wagener, and Funke (2005) found that induced emotions 
did not affect overall performance on their cognitive task, however, induced positive or 
negative emotions did influence the types of strategies used by individuals. Participants 
were given false positive or false negative feedback about their performance twice 
throughout a complex cognitive task (computer-simulated town). The computer-
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simulated task required participants to manage a forest enterprise (plant, grow, cut down 
tress, and maintain tree and soil quality) over 50 months at a profit. Those who were 
induced with negative emotion tended to adopt a more detail-oriented and information 
search approach than those who were in the positive induction group. 
Some individuals, however, are more likely to attempt to suppress their emotions 
during a negative emotional event. Pu, Schmeichel, and Damaree (2009) found that 
participants who were suppressing their emotions during a negative emotional video 
performed worse on verbal and spatial working memory tasks than those who did not 
suppress emotions and than those in the neutral film condition. Facial expressions of 136 
participants were recorded while watching either an emotionally negative or neutral film 
clip and emotional responses were assessed afterwards. Visual and spatial working 
memory tasks were performed both before and after film clips. Participants with higher 
resting Respiratory Sinus Arrhythmia (RSA) showed less emotional facial expressions 
but reported the same amount of negative emotion as those with lower resting RSA. 
However higher resting RSA individuals had smaller pre-film to post-film improvements 
in spatial working memory performance in the negative film condition. This expressive 
suppression, therefore, temporarily undermined the operation of working memory. For 
the neutral film condition, resting RSA did not relate to expressive or subjective 
responses or differences in working memory performance. 
Two common explanations for the decrease in cognitive performance subsequent 
to negative mood induction are the capacity position (Pu, Schmeichel, & Damaree, 2009) 
and the strategy position (Spering, Wagner, & Funke, 2005). The capacity position 
suggests that negative mood induction decreases processing capacity, thus causing 
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individuals to perform worse on cognitive tasks. The strategy position, on the other hand, 
suggests that negative mood induction results in systematic, analytical, and detail-
oriented strategies. In the Pu et al. study discussed above, emotion suppression after a 
negative mood induction may have utilized valuable cognitive resources that undermined 
the participant’s ability to perform on the verbal and spatial tasks. Thus the Pu et al. 
findings provide support for the capacity position. The Spering et al. study, on the other 
hand, demonstrated that negative mood did not influence performance on the tasks, but 
instead influenced the strategic approach to the task. Thus, Spering et al. showed clear 
support for the strategy position rather than the capacity position.  
Another element of affect worth exploring in relation to cognitive performance is 
whether the emotion evokes an approach or avoidance motivation within the individual. 
Papousek, Schulter, and Lang (2009) had 70 female participants watch videos of an 
actress going through particular emotional states (anger, sadness, joy) and they were 
asked to identify with the actress and indicate how the short clips made them feel and 
their tendency to want to approach or avoid the person in the video. The participants then 
completed a verbal and figural fluency task. They found that both approach motivation 
and low intensity of emotional arousal were associated with relatively better left (Verbal 
fluency) than right (Figural fluency) hemisphere performance. Withdrawal motivation 
and high intensity of arousal were associated with relatively better right (Figural fluency) 
than left (Verbal fluency) hemisphere performance. These results may possibly relate to 
the Albert, Lopez-Martin, and Carretie (2010) findings from their study on the emotional 
Go/Nogo task. Since it is harder to inhibit a response during the positive emotional 
context on the emotional Go/Nogo task, it could be that positive emotions generally elicit 
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an approach reaction while negative emotions elicit a withdraw reaction. Nevertheless, 
the Papousek, Schulter, and Lang (2009) study did not necessarily find approach-
withdraw reactions consistent across emotions. For example when angered, some 
individuals may feel a withdraw response and prefer to avoid the source of anger, while 
others may feel an approach response and prefer to approach or confront the source of 
anger. Thus, approach-withdraw information would be valuable to consider when using 
emotion induction in a future study as it may influence performance on cognitive tasks 
irrespective of the type of emotion.  
Bartolic, Basso, Schefft, Glauser, and Titanic-Schefft (1999) also looked at how 
mood induction influences performance on left and right hemisphere tasks. Either a 
positive or negative Velten Mood Induction procedure was performed on 60 women who 
subsequently performed either a verbal or figural fluency task. Euphoria resulted in better 
verbal than figural fluency (i.e. better left than right hemisphere performance) while 
dysphoria resulted in better figural than verbal fluency (i.e. better right than left 
hemisphere performance). Evidently, both positive emotion, and approach response are 
related to better performance in tasks that engage the left hemisphere while negative 
emotion and withdrawal response are related to better performance in tasks that engage 
the right hemisphere. Nevertheless, Bartolic et al. (1999) did not collect menstrual cycle 
phase data. Since the presence of progesterone may influence laterality of tasks, it would 
be important for future studies to collect hormonal data in order to better determine the 
variables influencing performance on cognitive tasks 
Basso, Schefft and Hoffman (1994) found that an individual’s affect intensity also 
affected cognitive performance. Female participants were given false negative or positive 
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feedback on IQ performance and given questionnaires to measure their affect intensity 
and mood prior to performing a verbal learning task. Interestingly, after a positive mood 
induction, individuals with low affect intensity outperformed individuals with high affect 
intensity on a verbal learning task. On the other hand, after a negative mood induction, 
individuals with high affect intensity outperformed individuals with low affect intensity 
on a verbal learning task. The authors explain that individuals with high affect intensity 
generally tend to be more drawn towards positive affect-related stimuli relative to low-
affect intense individuals. Furthermore, task performance is disrupted when attention 
resources are taken away from the task and directed toward emotionally related stimuli. 
Therefore, when high affect intense individuals experience positive emotion, the 
experience of the positive emotion draws more attentional resources and thus results in 
poorer performance on learning tasks.  
However, Basso, Schefft and Hoffman (1994) investigated women with no known 
negative mood problems and did not collect information on hormones or use of oral 
contraception. Therefore, women on OCs with negative mood side effects, for example, 
may have a different response than other women with no mood side effects. Indeed, 
individuals with high affect intensity and negative mood side effects may potentially be 
more drawn towards negative stimuli rather than positive. However, as demonstrated by 
Cheperik, Cornew, and Farah (2007), and Spering, Wagner and Funke (2005) negative 
emotion may have a more complex effect on cognitive performance and does not 
necessarily hinder cognitive performance across the board. Future studies investigating 
hormones, emotions, and cognition should take into account possible hormonally-related 
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mood side effects, various reactions to different types of negative emotions, as well as 
affect intensity. 
Current Study 
As reviewed above, both exogenous and endogenous hormones affect the 
structure and function of the brain in many important ways. Despite consistent 
differences in brain activity, however, studies on emotional and cognitive function 
differences between women on OCs, naturally cycling women, and men have been 
inconsistent. This current study aimed to investigate any differences in the emotional 
variability, reactivity, and cognitive performance of women on OCs, naturally cycling 
women, and men. This was the first study to our knowledge that compared the cognitive 
performance of free-cycling women and women on OCs after mood induction. In this 
study, participants underwent three different mood inductions (happy, sad, and fear) via 
an emotional video paired with mood congruent music. After each and every mood 
induction, participants performed two cognitive tasks aimed to tap into facial recognition, 
inhibition, and attentional abilities. Despite a lack of consensus in the literature about 
hormonal influences on emotion and cognition, however, several hypotheses were made 
about the potential outcomes for this study.  
The first hypothesis (Hypothesis 1) was that there will be reduced positive affect 
reactivity across the lab session among OC users compared to naturally cycling women. 
This hypothesis was an attempt to replicate the Jarva and Oinonen (2007) findings of 
blunted positive affect variability among women taking OCs. The Jarva and Oinonen 
(2007) study used the term ‘variability’ to capture the variability of emotional reactivity 
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of the participants across the laboratory session. For the purposes of this study, however, 
the term ‘reactivity’ is used as a more accurate way to describe the same phenomenon.  
The second hypothesis (Hypothesis 2) was that women on OCs with current 
negative mood side effects will have quicker reaction times to negative faces, especially 
during negative emotion inductions, and make overall more errors in facial emotional 
recognition compared to women on OCs with no current negative mood side effects, free-
cycling women, and men. This hypothesis was based on one study which indicated that 
women on OCs with current negative mood side effects have quicker reaction times to 
angry and fearful faces as well as lower activity in the inferior frontal gyri and left insula 
while viewing angry and fearful faces (Gingnell et al., 2013). Lower activity in the 
inferior frontal gyri suggests lower emotional distraction likely because the women on 
OCs with current negative mood side effects were viewing negative (thus, mood-
congruent) faces. Therefore, it was predicted that after the negative mood inductions, the 
salience of the mood-congruent stimuli would be higher for OC users with current 
negative mood side effects and the OC users with current negative mood side effects 
would respond even quicker the negative faces compared to the other groups.  
Lower activity in the inferior frontal gyri, however, also may be indicative of 
lower response inhibition and potentially blunted processes related to social interaction, 
such as empathy (Hampshire et al., 2010; Liakakis et al. 2011; Wang et al., 2008). 
Therefore, OC users with current negative mood side effects may respond in a less 
inhibited manner to the emotional facial stimuli, have a lower ability to recognize facial 
emotions and thus, make overall more errors during the facial emotion recognition task 
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compared to the other groups. This is expected to occur across the laboratory session 
regardless of mood induction. 
The third hypothesis (Hypothesis 3) was that women on OCs will make more 
errors of commission on the GoNogo task than free-cycling women and men, especially 
during the positive mood induction. This hypothesis was based on previous literature that 
indicated that quicker response times occur during the positive context of the emotional 
GoNogo task (Albert, Lopez-Martin, & Carretie, 2010). The same study also reported 
that, generally, individuals make more errors of commission rather than errors of 
omission regardless of the emotional context. Since women on OCs have been shown to 
have lower pre-pulse inhibition (Borgstrom et al., 2008; Holloway, Beck, & Servatius, 
2011) and possible GABAergic disturbances (Borgstrom et al., 2008; Follesa et al., 2002; 
Schultheiss, Patalakh, & Rosch, 2012), it was predicted that they would show more 
pronounced difficulty inhibiting their responses. Moreover, since the Albert, Lopez-
Martin, and Carretie (2010) study demonstrated that individuals have a more difficult 
time inhibiting their responses during positive emotional context, these effects were 
expected to be further pronounced after the positive mood induction. 
The fourth and final hypothesis (Hypothesis 4) was exploratory in nature. It was 
expected that OC users would differ in their overall performance on the cognitive and 
perceptual tasks as a function of the mood primes compared to free-cycling women and 
men. This hypothesis was nondirectional in nature. Positive mood induction has been 
shown to improve performance on cognitive tasks (Brand & Opwis, 2007; Fried et al., 
2001; & Lesiuk, 2010). However if women on OCs have a blunting of positive affect 
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variability (Jarva & Oinonen, 2007), positive mood induction may not necessarily 
improve performance relative to the other mood inductions for this group.  
Method 
Participants 
Screening phase. A total of 377 participants (mean age = 22.02 SD = 5.78; 138 
OC users, 73 nonusers, 76 men) completed an online screening questionnaire and 
provided enough data to be used for the analyses in this phase (for frequencies and 
percentages of demographic variables see Table 1).  
Participants were recruited from Psychology and other university classes at a 
Canadian university as well as from the local community. University students were 16 
years and members of the general public were 18 years or older.  University students 
were recruited directly through classroom visits, or indirectly through email, and posters. 
From the larger community, participants were recruited through the use of posters. 
Additionally, emails were sent out to individuals in the Health Hormones and Behaviour 
(HHAB) lab’s database who have previously indicated an interest in being contacted for 
future studies. Lakehead University’s Research Ethics Board (REB) approved the project 
and all recruitment materials (Appendix I to L). All participants were told that they were 
being recruited for a project investigating the effects of sex and hormones on emotion. 
Students received a one-half bonus point towards their Introductory Psychology mark for 
their participation in the screening phase of the study. No exclusionary criteria were used 








Frequencies (Percentages) of Demographic Information for Participants in the Screening 
and Laboratory Phases of the Study  
________________________________________________________________________ 
Variable   Screening Phase   Laboratory Phase 
(n = 377)   (n= 147) 
________________________________________________________________________ 
Sex 
Male     76 (20.2)   38 (25.9) 
Female    301 (79.8)   109 (74.1) 
 
    
Ethnicity 
 
Caucasian or    314 (83.28)   125 (85.03) 
European        
African-Canadian/   16 (4.2)   6 (4.1) 
America/Black 
First Nation/    17 (4.5)   5 (3.4) 
Aboriginal/  
American Indian 




   
Less than High school  2 (0.6)   0 (0.0) 
Completed High   50 (13.3)   22 (15.0) 
School 
Some College or 
University   266 (70.56)   97 (65.99)    
Completed College   41 (10.88)   17 (11.56) 
or University 
Some Graduate Studies  2 (0.5)   2 (1.4) 
Completed a Graduate  16 (4.2)   9 (6.1) 
Degree 
________________________________________________________________________ 
Note. For laboratory phase, there were missing data for 2 participants.  
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Experimental Phase. From the participants in the screening phase, 149 
volunteers (mean age = 21.82, SD = 4.22) participated in the experimental phase of the 
study (58 OC users, 46 nonusers, and 38 men). The 58 OC users included 15 (25.9%) 
with current OC negative mood side effects and 43 (73.1%) without current negative 
mood side effects (see Table 2 for frequencies and percentages of OC brand usage). The 
46 nonusers or naturally cycling women included 20 (18.7%) previous OC users and 26 
(24.3%) never-users. Inclusion criteria for the OC user group included a minimum of 2 
months of OC use. All naturally cycling women were selected based on the criterion of 
no OC use for the past 2 months (see Table 3 for means and standard deviations of length 
of OC use for current OC users and length of nonuse for previous OC users). Women on 
OCs with current negative mood side effects were determined based on their answers to 
questions in the screening questionnaire regarding their belief that OCs are currently 
causing them negative emotional symptoms. Women that indicated experiencing one or 
more current negative mood side effect(s) from OCs were categorized into the OC users 
with current negative mood side effects group.  
There were eight exclusion criteria used to select participants for the laboratory 
portion of the study. In order to ensure that women of reproductive age were sampled, 
peri-menopausal and post-menopausal women were excluded from participation (n = 11). 
Participants taking psychotropic medication(s) or anti-depressants at the time of 
screening (n = 40), participants 45 years or older (n = 9), participants who have been on 
OCs for less than 2 months (n =8), participants who have been off OCs for less than 2 
  




Frequencies (Percentages) of Oral Contraceptive (OC) Brand Usage for Current OC 
Users in the Screening and Laboratory Samples 
________________________________________________________________________ 
Variable    Screening Phase   Laboratory Phase  
    (n = 138)      (n = 57) 
 
OC Formulation       (n = 56) 
Alesse   50 (36.2)    21 (37.5) 
Alysena   6 (4.4)     3 (5.4) 
Apri   5 (3.7)             3 (5.4) 
            Aviane                        1 (0.7)                                                  1 (1.8)   
Brevicon 0.5/35  1 (0.7)     1 (1.8) 
Cyclen   1 (.07)     0 (0.0) 
Cyestra   3 (2.2)     1 (1.8) 
Diane 35  1 (0.7)     0 (0.0) 
Loestrin 1.5/30  4 (2.9)     0 (0.0) 
Marvelon  11 (8.1)    8 (14.3) 
Micronor   1 (0.7)     0 (0.0) 
Min-Ovral   7 (5.1)     3 (5.4) 
Portia   3 (2.2)     2 (3.6) 
Seasonique   1 (0.7)     1 (1.8) 
Seasonale   4 (2.9)     0 (0.0) 
Synphasic   1 (0.7)     0 (0.0) 
Tri-Cyclen  4 (2.9)     1 (1.8) 
Tri-cyclen Lo  25 (18.4)           8 (14.3) 
Tricera Lo    2 (1.5)     1 (1.8) 
Yasmin   1 (0.7)     0 (0.0) 
Yaz    3 (2.2)     1 (1.8) 
Zarah    1 (0.7)     1 (1.8) 
    
Number of Brands used      (n =57) 
1 Brand   78 (57.8)     35 (61.4) 
2 Brands  33 (24.4)     11 (19.3) 
3 Brands  13 (9.6)     6 (10.5) 
4 Brands  6 (4.4)     3 (5.3) 
5 Brands  4 (3.0)     1 (1.8) 
9 Brands  1 (0.7)     1 (1.8) 
________________________________________________________________________ 
Note. For current OC formulation in laboratory phase data for two participants is missing 
and for number of brands use in the laboratory phase, data from one participant is 
missing.  




Means (Standard Deviations) for Length of Oral Contraceptive (OC) use for Current OC 
Users and Means (Standard Deviations) for Length Since Last Use of OCs for Nonusers 
in the Screening and Laboratory Phases 
________________________________________________________________________ 
Variable    Screening Phase  Laboratory Phase 
(n = 137)    (n = 57) 
________________________________________________________________________ 
Total OC use months    51.58 (38.43)    48.82 (32.21) 
Mode     48.0     48.0 
Median     48.0      44.0 
 
Current OC months    37.73 (27.81)   35.44 (23.69) 
Mode     48     31.0 
Median     36     15.0 
Nonusers     (n = 69)   (n = 17) 
 
Last took OCs months   57.97 (82.74)    35.18 (41.0) 
Mode     36.0     2.0 
Median     36.0     36.0 
Note. In screening phase, OC users missing data for 1 participant. 
For screening phase, nonusers missing data for 4 participants.  For laboratory phase 
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months (n =7), those who have taken plan B in the past 2 months before screening (n = 
23), those who are currently taking another hormonal contraception (n = 24) and 
participants who had irregular menstrual cycles (n = 56) were also excluded from 
participation. For participation in the experimental laboratory phase of the study, eligible 
psychology students received one and a half bonus points toward their applicable 
Psychology grade. For those participants that were not eligible to receive bonus marks, 
they received $2 for their participation in the laboratory session.   
Screening Phase Measures 
Screening questionnaire (SQ). The screening questionnaire (see appendix A) 
provided information regarding the menstrual cycle, OC use and history, demographics, 
psychiatric diagnoses, reproductive history, medical and health history, and PMS 
symptom history. The OC use and history section included questions about length of OC 
use and specific questions regarding the experience of certain OC side effects including 
any positive or negative physical symptoms or mood changes. Most of these items have 
been developed and used within our lab in past studies (e.g., Oinonen, 2009) and have 
demonstrated reliability and validity. Additional measures included within the SQ are 
described below. Many of these measures were included as possible covariates or for 
exploratory purposes and are not examined in the current theses but may be used in the 
larger project.  
The Reactivity Subscale of the Mood Survey. This scale developed by 
Underwood and Froming (1980) consists of 6 statements regarding the participant’s 
perceived mood reactivity and changeability (see Question 10). The participant is asked 
to indicate on a scale from 1 (Strongly disagree) to 6 (Strongly agree) how much they 
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agree with the statements. Two additional questions have the participant rate the 
following on a scale from 1 (hardly ever) to 99 (extremely): “how frequently do your 
moods change?” and “how intensely do you react to mood experiences?” Test-retest 
reliability for the reactivity subscale has been found to be high for both three (.85) and 
seven (.83) week periods (Underwood & Froming, 1980). The Mood Survey has good 
concurrent validity and preliminary construct validity (Underwood & Froming, 1980). In 
the present study, the instructions were amended to ask participants to consider their 
mood and behavior “over the past two months”. This was done to ensure that responses 
provided represented a time frame where participants were generally consistently users or 
nonusers of OCs.  
Affect Intensity Measure (AIM). The affect intensity measure was developed by 
Larson in 1984 and used in the Basso, Schefft, and Hoffman (1994) study which 
investigated the influence of affect intensity on cognitive performance subsequent to 
mood induction (Question 11). For efficiency, the current study used the short-form 
version of this scale which involves 20 questions regarding an individual’s self-report on 
their emotional reaction and intensity to various events. Answers are rated on a 6-point 
scale from 1 (Never) to 6 (Almost Always). A significant mean difference in scores was 
found for males and females with females obtaining higher overall mean scores than 
males (Goldsmith & Walters, 1989). Bagozzi and Moore (2011) determined the AIM’s 
external and internal construct validity using factor analysis and replicated the finding 
that women tend to have an overall higher mean score than men.  In the present study, the 
instructions were amended to ask participants to consider their reactions “over the past 
two months”. 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
60 
Hamilton Rating Scale for Depression (HRSD). The HRSD (Hamilton, 1960) is 
a widely used tool to assess current symptoms of depression in both clinical and research 
settings (Question 12). The core scale consists of 21 items, scored from 0 (Not at all) to 4 
(Marked or severely). For this study, the 17-item HRSD was employed because it is the 
standard for use of the scale in clinical trials (Cusin, Yang, Yeung, & Fava, 2009). For 
ethical reasons, item 11 “wishing for death or suicidal” was removed. 
Handedness assessment. This measure was included as a measure of handedness 
and lateral dominance of the participants. It was adopted from Briggs and Nebes (1975). 
This 7-item self-report measure requires participants to indicate their hand preference for 
various activities (Question 13). Their hand preference is indicated on a 5-point likert-
type scale from 1 indicating “always right” to 5 “always left” with the middle option 3 
indicating a preference for “both”. Scoring on each item can range from -2 to +2 with 
negative scores indicating left preferences and positive scores indicating right 
preferences. Total scores can range from -14 to +14.  
Negative Impression (NIM)/Positive Impression scales (PIM). These scales are 
used as part of a validity measure for the Personality Assessment Inventory (PAI) 
developed by Morey (1991). The NIM scale items are intended to detect respondents 
whom are likely to present themselves in an exaggeratedly negative way while the PIM 
scale items are intended to detect respondents whom are likely to present themselves in 
an exaggeratedly positive way (Morey, 2007).  
Both the NIM and PIM scales are each made up of 9 items that consist of 
sentences endorsed most frequently by those attempting to fake a mental disorder, yet 
rarely endorsed by individuals who actually have a mental disorder and sentences 
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endorsed most frequently by those attempting to make a positive impression, yet rarely 
endorsed by individuals that are filling out the answers honestly (Morey, 2007).   
Both scales have been widely used and have highly established reliability and 
validity. The NIM has been shown to have a Cronbach’s alpha ranging from .63 to 74, 
with a mean inter-item correlation ranging from .17 to .25 and a test-retest reliability 
ranging from .71 to .80. Similarly, the PIM has been shown to have a Cronbach’s alpha 
ranging from .71 to 77, with a mean inter-item correlation ranging from .17 to .26, and a 
test-retest reliability ranging from .75 to .81. (Morey, 2007).  
Several criterion and correlational studies have demonstrated the validity of the 
NIM and PIM scales. Both NIM and PIM scales accurately detected respondents that 
were told to malinger their responses either in a negative or positive manner from those 
who were told to respond honestly with 88.6% identification rate for the NIM and 95.5% 
correct identification rate for the PIM. Furthermore, both scales have been shown to 
correlate highly with other established measures that are intended to measure similar 
constructs. For example, the correlation between the NIM and the Minnesota Multi 
Phasic Personality Inventory F-scale ranges from .70 to .75. (Morey, 2007).  
Big Five Inventory (BFI): Neuroticism scale. The neuroticism scale from the 
Big Five Inventory (Question 15) consists of 9 personal statements that begin with “I am 
someone who” and the respondent is required to indicate the extent to which they agree 
with each statement on a scale of 1 (Strongly disagree) to 5 (Strongly agree) (John, 
Donahue, & Kentle, 1991). Sentences are forward scored, for example, “can be moody”, 
as well as backward scored, for example, “is emotionally stable, not easily upset”. Items 
b, e, and g are reversed scored and items a, c, d, f, and h are forward scored. Scores can 
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range from 8 to 40. To code the reverse score items, the answer for each item is 
subtracted from six. Therefore for reverse score items, a score of 5 becomes 1, 4 becomes 
2, 3 remains 3, 2 becomes 4, and 1 becomes 5.  
Both the reliability and validity of the BFI neuroticism scale have been 
established. The test-retest stability of the BFI neuroticism scale ranges from .71 to .76 
with a self-peer convergent validity correlation ranging from .30 to .45. The neuroticism 
scale also had correlations in the expected direction for similar scales on other established 
measures of personality. For example, the BFI neuroticism scale has a correlation ranging 
from .67 to .72 with the NEO Personality Inventory Revised anxiety and vulnerability 
subscales (Rammstedt & John, 2006).  
The Behavioral Inhibition System (BIS) and Behavioural Activation System 
(BAS) Scales. These measures comprise one 24-item questionnaire (see question 16) 
where respondents are asked to rate each statement on a scale ranging from 1 (very true 
for me) to 4 (very false for me). The BIS questions (items b, h, m, p, s, v, x) represent an 
avoidance or behavioural inhibition motivational-approach. An example of a BIS item 
would be: “Criticism or scolding hurts me quite a bit”. The BAS questions, on the other 
hand, represent appetitive motives or the tendency to move toward something. The BAS 
questions are subdivided into 3 different subscales: Funseeking, Drive, and Reward 
Responsiveness subscales. BAS fun seeking items are e, j, o, t; BAS Drive items are c, i, 
l, u; and the BAS reward responsiveness items are d, g, n, r, w. An example of a BAS fun 
seeking item would be: “I'm always willing to try something new if I think it will be fun” 
while an example of a BAS drive item would be: “I go out of my way to get things I 
want” and an example of a BAS reward responsiveness item would be: “When I'm doing 
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well at something I love to keep at it”. The remainder of the items (a, f, k, q) are filler 
items that are not scored or calculated into the final score.  
Carver and White (1994) created these scales on the theoretical basis that there are 
two general motivational systems that underlie behaviour: An approach system, and an 
avoidance system. The three BAS subscales emerged empirically through validity testing 
and factor analyses. The BIS scale is highly correlated with measures of related 
constructs such as neuroticism (Elliot & Thrash, 2002). Both the internal consistency and 
test-retest reliability of the BIS/BAS scales range from .66 to .76 (Sutton & Davidson, 
1997). Additionally, the BIS scale was relatively independent of the BAS subscales with 
correlations of -.12 with the Drive subscale, .28 with the Reward Responsiveness 
subscale, and -.08 with the Fun Seeking subscale (Carver & White, 1994).  
Stress Questionnaire. This questionnaire was developed by Oinonen and Teatero 
(See question 17) as part of a dissertation (Oinonen & Teatero, unpublished manuscript). 
The measure consists of four questions that require the participant to indicate on a scale 
of 1 (much less) to 7 (Much more) the extent to which they experience positive or 
negative stressful experiences during a certain time period compared to same-sex same-
aged individuals. For example, participants are asked to indicate, compared to other 
people your age, to what extent did you “experience stressful negative life events in the 
past year”? The original questionnaire contained two questions about stressful negative 
or positive life events from birth to age 10. For the purposes of this study, however, those 
questions were replaced with questions about stressful negative or positive life events in 
the past two months.  
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Lakehead Inventory of Premenstrual Symptoms (LIPS). This is a 33-item 
scale developed by Richards and Oinonen (2009) designed to assess the degree to which 
participants meet the American Psychological Association’s preliminary Diagnostic and 
Statistical Manual-IV criteria for Pre-Menstrual Dysphoric Disorder (Question 20). The 
scale can also be used as a subclinical measure of premenstrual symptom severity. For 
each of the eleven criteria listed in the DSM-IV, participants are asked three questions 
assessing: (1) the frequency with which each set of symptoms is experienced, (2) the 
degree to which each symptom impairs work, school, or interpersonal 
performance/functioning, and (3) the severity with which each symptom is experienced. 
All questions are rated using seven-point likert scales anchored by 0 (Not at all) on one 
end, and 6 (Extremely) for the latter two categories of questions and 6 (Frequently) for 
the first category. All questions ask women to estimate whether the described symptoms 
have occurred during the week prior to their menstrual period over the past 12 months.  
Scores can range from 0 to 198 with higher scores indicating a larger degree of 
symptom severity and a greater degree of impairment. Internal consistency for this 
measure has been examined and a Cronbach’s alpha of .89 was found for a sample of 177 
women (Richards, Oinonen, and Wesner, unpublished manuscript). This scale also 
reliably differentiates between women low and high on PMS symptoms. 
Physical Symptoms from OCs Questionnaire. The physical Symptoms from 
OCs Questionnaire is a 26-item questionnaire that required participants to indicate 
whether or not they have experienced a certain physical symptoms as a result of oral 
contraceptive use. The list of potential physical symptoms from OCs was taken from 
questionnaires that have been developed and used within the Health Hormones and 
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Behaviour lab in past studies (e.g., Oinonen, 2009). Symptoms include both negative and 
positive physical symptoms such as: nausea, headaches, more menstrual cramps, clearer 
complexion, and fewer menstrual cramps. If the respondent indicated they had 
experienced a particular physical symptom from OC use, the respondent was then be 
required to indicate which brand of OC they experienced the symptom on, and what 
action they took as a result of this symptom (see Question 22 a.i). The potential actions 
taken as a result of the symptom appeared in a drop down list with the following options: 
“Discontinued OC use because of this symptom, Switched OC brand because of this 
symptom”, “Experienced symptom but did not change OC use”, “No action taken and 
symptoms resolved”, and “No action taken and symptoms continue now”.  
Emotional symptoms from OCs Questionnaire. The Emotional Symptoms 
from OCs Questionnaire is a 26-item questionnaire that required participants to indicate 
whether or not they have experienced a certain emotional symptoms as a result of oral 
contraceptive use. The list of potential emotional symptoms from OCs were taken from 
questionnaires that have been developed and used within the Health Hormones and 
Behaviour lab in past studies. Symptoms include both negative and positive emotional 
symptoms such as: Lower self-esteem, more pessimistic, negative mood change, more 
optimistic, higher self esteem, and less sensitive to criticism. If the respondent indicated 
they have experienced a particular emotional symptom from OC use, the respondent 
would then be required to indicate which brand of OC they experienced the symptom on, 
and what action they took as a result of this symptom (see Question 22 a.ii). The potential 
actions taken as a result of the symptom appeared in a drop down list with the following 
options: “Discontinued OC use because of this symptom, Switched OC brand because of 
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this symptom”, “Experienced symptom but did not change OC use”, “No action taken 
and symptoms resolved”, and “No action taken and symptoms continue now”. These 
emotional symptoms from OCs Questionnaire were used to determine women on OCs 
with current negative mood side effects.  
Laboratory Phase Measures and Materials 
Laboratory Questionnaire. Subsequent to completing the other laboratory 
procedures (see below), participants were asked to complete a brief laboratory 
questionnaire (see Appendix B) designed to collect final demographic, mental state, and 
OC use and menstrual cycle information. Participants were asked to indicate whether they 
have taken any pain medication, consumed any caffeine, and how much sleep they had 
the previous evening. Also, using a scale from 1 (Strongly Agree) to 5 (Strongly 
Disagree), participants were asked to rate their enjoyment of and their effort on the 
laboratory tasks (see question 9). Further, women were asked to confirm their current 
phase in their menstrual cycle by indicating the first day of their last period and when 
they expect their next period. This laboratory questionnaire was presented after the 
completion of the mood inductions and cognitive tasks so as to not influence the 
participant’s performance. 
The Positive and Negative Affect Schedule (PANAS). The PANAS was 
developed by Watson, Clark, and Tellegen (1988) and consists of two scales: one for 
positive affect (PA) and one for negative affect (NA).  High positive affect reflects a state 
of high energy, full concentration, and pleasurable engagement; whereas low PA is 
characterized by sadness and lethargy.  Alternatively, high NA reflects subjective distress 
and unpleasant mood states such as anger, contempt, and disgust.  Low NA indicates a 
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sense of calm and security. The PA PANAS items include attentive, interested, alert, 
excited, enthusiastic, inspired, proud, determined, strong, and active, while the PANAS 
scale for NA includes the items distressed, upset, guilty, scared, hostile, irritable, 
ashamed, nervous, jittery, and afraid (see Appendix C). The questions require the 
participants to rate each adjective on a five-point response scale ranging from 1 (Very 
slightly or not at all) to 5 (Extremely). For the current study, this scale was used to gather 
information about the participants’ affect both before and after each mood induction. 
Participants were asked to indicate how they felt “at the moment” they were completing 
the surveys.  
The PANAS scales have been shown to be highly internally consistent, largely 
uncorrelated with one another, with alpha reliabilities ranging from .84 to .90 for PA and 
from .84 to .87 for NA (Watson, Clark, & Tellegen, 1988). The PANAS scales are also 
high in convergent and discriminant validity (Watson, Clark, & Tellegen, 1988).  
Physical Experiences of Emotions Questionnaire (PEEQ). This questionnaire 
was developed by the researchers for this study with the intention of tapping into physical 
experiences of emotion. The questionnaire consists of 32 items that ask the participant to 
rate on a scale of 1 (Slightly or not at all) to 5 (Extremely) the extent to which they felt a 
certain physical symptom while watching the mood induction slide shows. Items contain 
physical sensations such as “Energized”, “Drained of energy/fatigued”, and “Nausea” 
(See Appendix D, Question 2). Participants completed this measure after each mood 
induction. Validity and reliability of this measure will be calculated and reported on in 
the results section of this paper.  
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Approach/Avoid Questionnaire. This questionnaire was adapted from the 
dimension ratings questionnaire used by Papousek, Schulter, and Lang (2009) to tap into 
the degree to which the mood induction induced feelings of approach or withdrawal in 
the participants. Examples of the approach/avoid questions are: “The film aroused the 
want to escape in me”, “The film aroused the want to take action in me” (see Appendix 
D, Question 3). A motivational direction score is calculated by combining the escape and 
take action ratings. Low values indicate a tendency towards approach and high values 
indicating a tendency towards withdrawal.  Papousek, Schulter, and Lang (2009) used a 
Visual Analogue Scale to record responses, however, for the purposes of consistency and 
for ease of computer administration, the current study employed a 5-point likert scale 
ranging from 1 (Not at all) to 5 (Extremely).  
While no standard reliability or validity studies have been conducted on this 
questionnaire, Papousek and colleagues (2009) did find the responses of their 
questionnaire to correspond significantly, and in the expected direction with the 
emotional films displayed in their study. For example, they found that the sadness and 
anxiety films were associated with significantly more withdrawal motivation than the 
neutral, cheerfulness, and anger films. Also, the cheerfulness film was associated with 
significantly more approach motivation than the neutral film.  
Mood induction stimuli. The mood induction stimuli consisted of three separate 
emotional videos. The videos were a compilation of different emotional videos and 
slideshows of emotional pictures that were chosen based on their ability to elicit 
happiness, sadness and fear. The videos and stimuli were identified using popular search 
engines such as Google and YouTube using general search terms such as “saddest 
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videos”, “happiest videos” and “scariest videos” and more specific search terms such as: 
“people laughing”, “people crying”, and “haunted houses”. The pictures for the slideshow 
were chosen for this study from the International Affective Picture System (IAPS) (Lang 
et al., 2005) based on their scores of arousal and valence. The videos and pictures were 
edited using iMovie on a Macintosh computer. The stimuli for each emotion induction 
transitioned into one another creating a 5-minute video and slideshow compilation for 
each emotion induction. Data supporting the validity of the emotion induction stimuli are 
reported below in the results.  
Mood induction music. Mood congruent music was also chosen to play during 
each of the three mood induction videos. Music chosen was based on Google and 
YouTube searches for sad, happy, and fear-inducing music. Less popular music was 
selected to decrease the likelihood that participants had previously heard the song and had 
existing associations or experience with them. The music was played on loop during the 
emotional videos and continued playing throughout the Facial Emotion Recognition and 
the GoNogo tasks.  
Facial Emotion Recognition Task.  The facial emotion recognition task was 
created specifically for this study was using the Psychopy Software. The faces used for 
the study were obtained from a previously established NimStim Face Stimulus Set 
(available for public at: http://www.macbrain.org/resources.htm). The stimulus set 
included 646 colour images of the faces of actors of different sexes and races displaying 
the following range of emotions: fearful, happy, sad, angry, surprised, calm, neutral, and 
disgusted. Previous research on the identification of the emotional expressions in these 
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photos has established reliability and high agreement among raters (Tottenham, 
Borscheid, Ellersten, Marcus, & Nelson, 2002).  
Three different facial emotion recognition tasks were created for this study. Each 
task had 75 faces strategically selected without replacement from the pool of 646 faces. 
Each task was presented immediately after each emotion induction video. The images of 
the faces appeared on a black background. Each image had two emotions printed on the 
left and right bottom corner of the image. One emotion was the correct emotion that the 
actor was depicting, and one was an incorrect emotion. The participant was asked to press 
‘1’ on the keyboard if the face was expressing the emotion on the left or to press ‘0’ on 
the keyboard if the face was expressing the emotion on the right. The correct answer 
appeared on the left and right side in random order.  
Participants were instructed to respond as quickly as possible to all facial stimuli. 
The images appeared on the screen until the participant responded. This allowed for a 
sensitive measure of response time. Outcome measures included both response times and 
accuracy.  
In order to increase the difficulty of this task, the possible response options for the 
images were strategically selected. Based on a study conducted by Du and Martinez 
(2011) some emotional expressions are more likely to be confused with other emotional 
expressions. In their study, participants viewed faces depicting either happiness, sadness, 
fear, anger, surprise, disgust, or neutral expressions and were asked to pick which of the 7 
emotions the face was depicting. Their results indicated that while most participants were 
accurate in their answers, their incorrect responses showed a consistent pattern of errors 
for certain emotions. Thus, when looking at faces depicting certain emotions, anger 
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would be most likely to be confused with disgust, sadness would be most likely be 
confused with anger, surprise would be most likely to be confused with fear, and disgust 
would be most likely to be confused with either sadness, fear, or anger. Happy, fear, and 
neutral facial expressions did not have significant correlations with any other emotion.  
For this current study, the images of faces depicting anger, sadness, surprise, and 
disgust were paired approximately 35% of the time with the response options of the 
emotion it is most likely to be confused with. Each emotion (calm, neutral, anger, happy, 
sad, fear, surprise, disgust) had approximately 10 images in each of the 3 tasks. 
Therefore, an image depicting an angry facial expression would have the response option 
of disgust 3 or 4 times. Additionally, calm and neutral expressions were the most frequent 
expressions compared to the other emotions. This was done intentionally for the potential 
of investigating whether there may be response biases on neutral and calm faces after 
mood induction.  
Emotional GoNogo task. The emotional GoNogo task for this study was the 
same task as used by Albert, Lopez-Martin, and Carretie (2010) with additional 
background images chosen specifically for this study in order to use the task for three 
different blocks of trials. The background images consisted of one positive, one negative, 
and one neutral image from the IAPS used in the Albert, Lopez-Martin, and Carretie 
(2010) study as well as two additional positive, neutral, and negative pictures from the 
IAPS selected for their arousal and valence. This allowed for three pictures for each 
condition (Positive, Neutral, and Negative) to be used in three blocks. As with the facial 
emotion recognition task described above, three different blocks of this test were created 
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in order to present this task after each of the three mood inductions without presenting the 
exact same stimuli twice. 
 The images described above were used as background contexts for the task. Two 
capital letters, either an “M” or a “W” were displayed for 200ms in yellow ariel font 
outlined in black in order to stand out clearly from the background. The participants were 
not told anything about the context of the background picture. The participants were 
asked to press the space bar as quickly as possible when they see the letter “M” appear 
and to withhold pressing the space button whenever they see the letter “W” appear. The 
instructions were the same regardless of the emotional context of the picture. The 
background pictures were randomized in each block so that some participants started the 
task with a neutral background image, some with a positive background image, and some 
with a negative background image.  
Outcome measures included response times and accuracy. Specifically, within the 
accuracy measure, errors of commission (i.e. responding to an item that required non-
response) and errors of omission (i.e. not responding to an item that required a response) 
were calculated.  
Other cognitive measures. Three additional cognitive tasks were administered at 
the end of each emotion induction (i.e., after the above noted tasks) in order to ensure that 
the mood induced by the mood induction had dissipated (one at the end of each mood 
induction): A Navon Task, a Stroop Task, and a Mental Rotation Task. Each of these 
tasks were presented using the Psychopy Software. The results from these tasks are not 
reported here as they were collected as a part of a larger study.  




Screening phase. Following recruitment, participants were directed to a secure 
website within surveymonkey.com where they were provided with a Letter to Participants 
(see Appendix E) that included a brief synopsis of the study and the details of what their 
participation would entail. The participants were then directed to complete the online 
screening questionnaire, which included the Affect Intensity Scale, the Hamilton Rating 
Scale for Depression (HRSD), and the Lakehead Inventory of Premenstrual Symptoms 
(LIPS). The questionnaires were all completed online in one sitting and took 
approximately 20 to 30 minutes to complete. Upon completion of the screening phase, 
participants were instructed in a debriefing form (see Appendix F) that if they qualified, 
they would be contacted for an appointment to come into the Health Hormones and 
Behaviour laboratory for a session. 
Those selected for participation were contacted by email and invited to participate 
in one laboratory session that would last approximately one hour. The participant’s 
personal details were necessary to schedule the lab session and to link lab data to 
screening questionnaire data. In order to ensure anonymity, however, all identifying data 
was deleted once the screening data was collected and the lab session was complete. 
There is no way to trace back screening and laboratory data to a specific participant.  
Laboratory session dates for women were determined by menstrual cycle phase in 
order to obtain an equal percentage of women in each phase for OC user and nonuser 
groups. All women were recruited to participate during the late follicular phase (day 11 to 
14 or -17 to -14) in order to capture women during periods of high estrogen, or during the 
mid luteal phase (days 20 to 24 or days -5 to -9) in order to capture free-cycling women 
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during times of high endogenous estradiol and progesterone. In order to maintain 
consistency with scheduling and maximize the likelihood of testing OC user and nonuser 
groups at times when they differ most in terms of endogenous and exogenous hormones, 
both women using OCs and free-cycling women were scheduled according to their 
menstrual cycle phase.  
Cycle phase counting. In order to determine cycles phases, the backward 
counting method was employed for this study. The backward counting method controls 
for variability in menstrual cycle length. Since most of the variation in cycle length 
occurs due to variation in the follicular phase, the reverse count is more effective. In the 
backward counting method, the woman’s estimate of day 1 of her upcoming cycle is used 
to predict ovulation. The formula for calculating ovulation using the backward counting 
method is: F = L – 14 where F is the last day of the follicular phase and L is the length of 
the cycle. Day -1 is the day before the first day of menstruation. After female participants 
completed the lab session, they were contacted by email to confirm the start date of their 
next period.  
Laboratory session. Participants came into the laboratory for their scheduled 
appointment time and were directed into a private quiet room with a computer. Upon 
completing Consent Form B (Appendix G), the participants read the instructions for the 
procedures and indicated that they have read and understood what was written. The 
participants then completed the first Laboratory Questionnaire (Appendix B) which 
consisted of the PANAS to indicate the participant’s baseline affect. Following the 
baseline PANAS measure, the participants then viewed the first of three mood induction 
videos paired with the appropriate mood congruent music. The first induction was always 
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the sad mood condition, the second mood induction was always the happy mood 
induction, and the third mood induction was always the fear condition. This order of 
negative-positive-negative allowed the researchers to see more variability from one 
induction to the next and prevented the participant from having to view two negative 
inductions in a row. Immediately after each mood induction, the participants began 
answering the second laboratory questionnaire which consisted of the PANAS, the 
PEEQ, and the Approach/Avoid questionnaire (Appendix D).  
While the mood congruent music continued playing, the participants immediately 
began the cognitive tasks. In order to prolong the mood induction, the mood congruent 
music continually played throughout the completion of questionnaires and the first two 
cognitive tasks. The music eventually faded halfway through the completion of the third 
task in order to ensure mood dissipated before moving on to the next mood induction. 
The cognitive and perceptual tasks were presented as follows: After the sad mood 
induction was the Facial Recognition task, the Emotional GoNogo Task, and the Navon 
task; after the happy mood induction, the participants completed the Facial Recognition 
task, the Emotional GoNogo Task, and the Stroop task; and after the fear emotion 
induction, the participants completed the Facial Recognition task, the Emotional GoNogo 
Task, and the mental rotation task. All participants completed the tasks in the same order. 
Before each task, participants were provided with brief instructions on how to complete 
the task and were required to indicate that they understood the instructions before 
continuing.  
The entire lab session took approximately 45 to 60 minutes. At the very end of the 
session, a short 2-minute comedic video played. The video was made up of clips of 
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animals playing with other animals or engaging in playful behaviour. The purpose of this 
video was to ensure mood from the previous condition had dissipated and to end the 
laboratory session on a positive, rather than negative mood induction. Upon completing 
the session, participants were given a debriefing form (Appendix H) that provided further 
information about the study, as well as information for contacting the researchers or for 
psychological services, if needed. Participants were then awarded 1.5 bonus points 
towards their final grade in their participating undergraduate psychology class, if 
applicable, or with $2 compensation if they were not eligible for bonus marks. 
A follow up email was sent out at all female participants subsequent to their 
participation in the study to confirm the start date of their next period. This confirmation 
allowed for a more accurate method of collecting menstrual cycle information.  
Results 
Mood Induction Manipulation Check 
In order to investigate the validity of the mood inductions, two sets of six paired 
sample t-tests were conducted with PANAS PA and PANAS NA as the comparative 
variables. The first set of six-paired sample t-tests compared post-induction PA scores 
and NA scores with the most recent pre-induction PA and NA scores. Therefore, total PA 
scores after the sad induction were compared to total PA scores from baseline, total PA 
scores after the happy induction were compared to total PA scores after the sad induction, 
and total PA scores after the fear induction were compared to total PA scores after the 
happy induction. The procedure was repeated for total NA scores. The second set of six 
paired sample t-tests compared PA scores after each emotion induction to the PA score at 
baseline. The same procedure was repeated for total NA scores. As indicated in Table 4 
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and illustrated in Figure 1, all PA and NA scores showed significant changes (p <.001) in 
the expected direction following the three mood inductions. That is, the affect changes 
were as follows:  sad mood induction (increase in NA and decrease in PA), happy mood 
induction (decrease in NA and increase in PA), and fear mood induction (increase in NA 
and decrease in PA).  
Questionnaire Validation and Manipulation Check 
The Physical Experiences and Emotions Questionnaire (PEEQ) and the 
Approach/Avoid Questionnaire were both used in this study as an additional measure of 
affect subsequent to the mood inductions. PEEQ scores reflect a total sum of all physical 
sensations experienced subsequent to the mood inductions. Because some physical 
symptoms such as “feeling lightheaded” or having a “tingling sensation” may be 
experience when an individual is both happy and scared, it was not ideal to separate 
physical symptoms into positive and negative categories. Approach/Avoid scores were 
calculated by using the questions “the film aroused the want to escape in me” and “this 
film aroused to want to take action in me”. Separate scores were calculated for each avoid 
(escape) or approach (take action) variable after each emotion induction. Paired sample t-
tests and bivariate correlations were conducted on both of these measures.  
To investigate the validity of the PEEQ (i.e., its ability to capture or assess change 
following mood induction) and to further validate the mood induction paradigms (i.e., the 
ability of the mood induction videos to cause change in physical sensations or 
experiences), two paired sample t-tests were conducted. Results showed that mean total 
PEEQ score after the sad induction (M = 52.99, SD = 13.32) was significantly different 
from the mean total PEEQ score after the happy induction (M = 44.11, SD = 6.73), t(145)  




Mood Induction Manipulation Checks: Descriptive Data and Paired Sample t-Tests Examining 
Change in PANAS PA and NA scores after the Three Mood Inductions (n = 147) 
Affect Scores   Means (SD)   t   df         p 
_____________________________________________________________________________ 
Baseline PA   30.12 (6.13)   19.00  146  <.001 
Sad PA    21.30 (5.76) 
 
Baseline NA   14.27 (4.44)   -14.70  146  <.001 
Sad NA   22.02 (6.61) 
 
Sad PA    21.30 (5.76)   -18.80  145  <.001 
Happy PA   32.09 (7.42) 
 
Sad NA   22.02 (6.61)   19.66  145  <.001 
Happy NA   11.30 (1.84)     
 
Happy PA   32.09 (7.42)   19.13  146  <.001 
Fear PA   20.12 (6.09) 
 
Happy NA   11.30 (1.84)   -20.02  146  <.001 
Fear NA   24.60 (8.09) 
 
Baseline PA   30.12 (6.13)   19.00  146  <.001 
Sad PA    21.30 (5.76) 
 
Baseline NA   14.27 (4.44)   -14.70  146  <.001  
Sad NA   22.02 (6.61) 
 
Baseline PA   30.18 (6.09)   -3.95  145        <.001  
Happy PA   32.09 (7.42) 
 
Baseline NA   14.24 (4.44)   8.85  145  <.001 
Happy NA   11.30 (1.84) 
 
Baseline PA   30.18 (6.09)   17.58  145  <.001 
Fear PA   20.12 (6.09) 
 
Baseline NA   14.24 (4.45)   -14.79  145  <.001 
Fear NA   24.60 (8.09)  
Note. The top of the table examines change in between pre- and post-mood induction affect 
scores while the bottom examines change in affect scores from baseline after each mood 
induction. PANAS = Positive and Negative Affect Schedule. PA = Positive Affect. NA = 
Negative Affect.  






Figure 1. Manipulation Check: Unadjusted Mean Positive Affect (PA) and Negative 
Affect (NA) Scores at Baseline and after all Three Mood Inductions. Both PA and NA 
changed in the expected directions after each induction (all p < .001). Error bars 
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= 9.85, p <.001. Additionally, the mean total PEEQ score after the happy induction was 
significantly different from the mean total PEEQ score after the fear condition (M = 
57.10, SD = 18.37), t(146) = -10.08, p <.001. These results indicated that participants 
endorsed the highest physical symptoms after the fear condition, followed by the sad 
condition, with the lowest physical symptoms endorsed after the happy condition. The 
significantly different PEEQ scores indicate that physical symptoms do indeed differ as a 
function of the type of induced mood, the PEEQ is able to capture change in physical 
symptoms, and the three mood-induction videos are able to cause changes in emotional 
physical symptoms.  
Additional bivariate correlations were conducted to investigate the relationship 
between PEEQ and PANAS PA and NA scores after each emotion induction. After the 
sad induction, PEEQ scores were significantly correlated with PANAS NA scores, r(147) 
= .662, p < .001, but not with PANAS PA scores , r(147) = -.97, p = .242. After the 
happy induction, PEEQ scores were significantly correlated with PANAS PA scores, 
r(147) = .550, p <.001, but not with PANAS NA scores, r(147) = .090, p =.278. After the 
fear induction, PEEQ scores were significantly correlated with PANAS NA scores, 
r(147) = .756, p <.001, but not with PA scores, r(147) = -.142, p = .085. These results 
indicate that participant’s emotional physical sensation scores were correlated with NA 
scores after the sad and fear conditions, and with the PA scores after the happy condition. 
These findings suggest the PEEQ may be a useful addition to the PANAS in studies on 
emotional response to mood primes as the PEEQ may capture emotional physical 
sensations that are somewhat independent of either PA or NA. The PEEQ may assess 
increases in arousal level, regardless of whether the mood prime activates positive or 
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negative affect. For example, endorsing items such as feeling “hot” or  “a tingling 
sensation” may be indicative of arousal from either negative or positive stimuli.  
To investigate the validity of the Approach/Avoid measure, four paired sample t-
tests were conducted. The first two paired sample t-test showed that want to avoid was 
significantly higher in the sad condition (M = 2.34, SD = 1.25) compared to the happy 
condition (M =1.31 SD = 0.720), t(145) = 8.306, p < .001. The want to avoid was also 
significantly lower in the happy condition (M =1.31 SD = .720) compared to the fear 
condition (M =1.67, SD = 1.02), t(146) = -10.95, p < .001. These results are congruent 
with Papousek and colleagues (2009) who indicated that negative stimuli are more likely 
to arouse a feeling of wanting to escape or avoid.  
The second set of paired sample t-tests indicated that the want to approach in the 
happy condition (M = 2.67, SD = 1.19) was significantly higher than in the fear condition 
(M = 1.67, SD = 1.02), t(146) = 8.39, p < .001. However, the want to approach in the sad 
condition (M = 2.81, SD = 1.23) was not significantly different than the want to approach 
in the happy condition (M =2.67, SD = 1.19), t(145) = 1.33, p =.186. Participants were 
more likely to want to approach after the happy condition compared to after the fear 
condition. Papousek et al. (2009) found that their cheerfulness film was associated with 
significantly more approach motivation than the neutral film. The want to approach in the 
happy condition was higher than the want to approach in the sad condition, however there 
was no significant difference. This may be reflective of the nature of the sad stimuli used 
here. In our sad induction, the videos included clips of numerous injustices such as 
children and animals suffering, as well as people in need. Therefore, the sad induction 
may have aroused the viewer into wanting to approach in order to take action or help. 
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Nevertheless, the evidence of different Approach/Avoid measure scores following the 
different types of mood inductions provides some validity evidence for both the 
Approach/Avoid measure and the mood induction paradigms.  
Validation of a Group: OC Users with Current Negative Mood Side Effects 
Women on OCs with current negative mood side effects were determined based 
on their answers to the questions on the Emotional symptoms from OCs Questionnaire 
from the screening questionnaire. Women who indicated experiencing one or more 
current negative mood side effect(s) from OCs was considered to be in the OC users with 
current negative mood side effects group (OC mood group). The mean number of 
negative mood symptoms the women in the OC mood group (n = 15) endorsed was 4.20 
(SD = 3.08; range = 1 to 11). The most frequently endorsed OC-related mood symptoms 
were: more irritable, sadness, more moody, and crying more than usual (see Table 5 for 
frequencies of endorsed mood symptoms).  
In order to provide some evidence for the validity of the classification of our 
group of OC users with current negative mood side effects (OC mood group), Group (OC 
no mood, and nonusers) was used as the independent variable and several measure of 
mood and affect were used as the dependent variables. In the first of two MANCOVAs, 
measures of affect reaction within the laboratory were used as the dependent variables in 
order to determine if women in the OC mood group reacted differently than women in the 
OC no mood group and nonusers. The last MANCOVA used affect measures from the 
screening questionnaire to determine if the OC mood group differed at baseline in overall 
mood and affect characteristics such as intensity  




Frequencies (Percentages) of Current Oral Contraceptive-Related Mood Symptoms 
Endorsed by the sample of Women Currently Experiencing Negative Mood Side Effects 
from Oral Contraceptives (n = 15) 
________________________________________________________________________ 
Negative Mood Symptom  Frequency (Percentage)   
_________________________________________________________________________________________________ 
 
More irritable     9 (60.0) 
Sadness     8 (53.3) 
More Moody     8 (53.3) 
Cried more than usual   8 (53.3) 
Lower self-esteem    6 (40.0) 
Depression     5 (33.3) 
More self-critical    5 (33.3) 
Feelings of inferiority   4 (26.7) 
Negative mood change   4 (26.7) 
More Jealous     2 (13.3) 
More pessimistic    2 (13.3) 
More sensitive to criticism   1 (6.7) 
Less trust in partner    1 (6.7) 
More aggressive    0 (0.0) 
________________________________________________________________________ 
Note. OCs = Oral Contraceptives.  
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level, reactivity, and general depressive symptoms compared to the OC no mood and 
nonuser groups. In all of these analyses, age was used as a covariate (see section titled 
Examination of Group Equivalency below). If women on OCs with current negative 
mood side effects differ on these important measures of affect, it would provide evidence 
for the validity of the OC mood group.  
The first MANCOVA included group (OC mood, OC no mood, and nonusers) as 
the independent variable and NA and PA mean change scores across the laboratory, as 
well as mean NA and PA total scores as the dependent variables (see the top panel of 
Table 6 for the mean scores). There was no overall multivariate group effect, F(8, 192) = 
1.047, p =.402, partial η2 = .042, power = .502 . At the univariate level, there was only a 
weak trend for a group difference on PA total scores, F(2, 98) = 1.704, p = .187, partial η2 
= .034, power = .351. The means for PA total scores reveal that the OC mood group had 
the lowest mean PA score across the laboratory compared to the OC no mood, and 
nonuser groups (see top panel of Table 6 for the univariate ANCOVA follow-up test 
results).  
The second MANCOVA included group (OC mood, OC no mood, and nonusers) 
as the independent variable and PANAS PA and NA levels after each emotion induction 
as the dependent variables (see the bottom panel of Table 6 for the mean scores). There 
was no significant multivariate group effect, F(16, 184) = 0.932, p = .534, partial η2 = 
.075, power = .620. Follow up univariate tests, however, showed a trend for PANAS PA 
after the fear condition, F(2,98) = 2.597, p = .080, partial η2 = .050, power =.507, with the 
OC mood group showing the lowest PA after the fear induction (see bottom panel of 
Table 6 for the univariate ANCOVAs). The results from the first two MANCOVAs
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Table 6 
Means (Standard Deviations) of Scores on the PANAS and Univariate ANCOVA results for Women on OCs with Mood Side Effects (OC Mood; 
n = 15), Women on OCs with No Mood Side Effects (OC No Mood; n = 35), and Nonusers (n = 45) 
_____________________________________________________________________________________________________________________ 
Affect Variable  OC Mood  OC No Mood  Nonusers   df    F      p     Partial η2 Power 
_____________________________________________________________________________________________________________________ 
NA Change  11.16 (5.84)  12.15 (6.00)  10.90 (6.05)   2, 98 0.165    .848       .003 .075  
PA Change  11.88 (5.42)  11.68 (5.69)  10.17 (5.28)   2, 98 0.636    .531       .013 .154 
PA Score  22.86 (4.12)  24.78 (5.01)  25.71 (4.77)  2, 98 1.704    .187       .034 .351  
NA Score  19.05 (3.64)  19.19 (4.53)  17.81 (3.23)   2, 98 0.543    .583       .011 .137 
_____________________________________________________________________________________________________________________ 
NA Baseline  14.93 (4.83)  15.21 (5.45)  13.73 (3.94)  2, 98 0.583     .560        .012  .145 
PA Baseline  26.73 (5.81)  29.14 (6.68)  30.36 (5.63)  2, 98 1.844     .164        .036 .376 
 
NA Sad  22.40 (6.36)  23.79 (7.17)  21.69 (5.98)  2, 98 .538     .586         .011  .137 
PA Sad   17.73 (5.00)  19.86 (5.68)  21.22 (5.54)  2, 98 1.939     .149         .038 .393 
NA Happy  11.93 (2.43)  11.38 (2.02)  11.02 (1.63)   2, 98 1.150     .321         .023  .248 
PA Happy  30.47 (7.73)  31.88 (7.52)  30.96 (7.46)  2, 98 0.247     .782         .005  .088 
 
NA Fear  26.93 (6.76)  26.38 (8.68)  24.78 (7.89)  2, 98 0.123      .844         .003  .068 
PA Feart  16.53 (3.20)  18.19 (5.39)  20.29 (5.48)  2, 98 2.597      .080         .050  .507 
_____________________________________________________________________________________________________________________ 
Note. OC = Oral Contraceptives. NA = Negative Affect from the Positive and Negative Affect Schedule (PANAS). PA = Positive Affect from the 
PANAS. NA change = Negative Affect change across the laboratory session. PA change = Positive Affect change across the laboratory session. 
PA score = Total Positive Affect score. NA Score = Total Negative Affect score. Baseline = scores at baseline. Sad = scores after the sad 
induction. Happy = scores after the happy induction. Fear = scores after the fear induction. Superscript t indicates a trend p < 1 for OC Mood and 
Nonusers to differ.
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indicate that the group of women on OCs that reported current negative mood side effects 
did not differ significantly in their emotional reactions to the mood inductions in the 
laboratory compared to women on OCs with no current negative mood side effects and 
with nonusers. 
Finally, a MANCOVA was run with group (OC mood, OC no mood, and non 
users) as the independent variable and scores on the Affect Intensity Measure, Hamilton 
Rating Scale for Depression, Reactivity Subscale of the Mood Survey, Big Five 
Inventory-Neuroticism Scale, and Behavioural Inhibition System as the dependent 
variables (see Table 7 for mean scores of the affect measures for each group). Again, 
results do not show an overall multivariate group effect, F(16, 132) = 1.095, p =.366, 
partial η2 = .117, power = .696. However, follow up univariate tests showed significant 
group differences on three of the five measures: the Affect Intensity Measure, the 
Reactivity Subscale of the Mood Survey, and the Behaviour Inhibition System (see Table 
7). There was also a trend for a group effect on the Big Five Inventory-Neuroticism 
Scale. 
The follow up ANCOVAs reveal that the OC mood group had significantly higher 
mean scores on the Affect Intensity Measure and the Reactivity Subscale of the Mood 
Survey, and significantly lower mean scores on the Behavioural Inhibition System 
compared to nonusers (see Table 7). Pairwise comparisons show a trend for the OC mood 
group to have higher mean scores on the Big Five Inventory-Neuroticism Scale than 
nonusers.  
These results indicate that OC users with current negative mood side effects differ 
from OC users with no negative mood side effects and from nonusers on some important 
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Table 7 
Means (Standard Deviations) of Scores on Affect Measures from the Screening Questionnaire and Univariate ANCOVA Results for 
Women on OCs with Mood Side Effects (OC Mood; n - 15), Women on OCs with No Mood Side Effects (OC No Mood; n = 35), and 
Nonusers (n = 45) 
____________________________________________________________________________________________________________ 
Variable    OC Mood  OC No Mood  Nonusers   df    F      p     Partial η2 Power 
 
 
AIM*    83.71 (9.54)a  77.39 (8.29)  73.97 (12.22)a  2, 72  4.73     .012         .116 .774 
 
HRSD   24.71 (19.43)  18.21 (12.42)  15.91 (11.38)  2, 72 2.041     .137           .054  .408 
 
Mood Reactivity* 23.36 (6.08)a  19.75 (4.80)  19.41 (5.08)a  2, 72 3.235     .045          .082 .599 
 
BFI-N   28.21 (4.51)  25.46 (5.95)  24.06 (6.33)  2, 72 2.390     .099           .062  .468 
 
BIS*   11.21 (2.60)a  12.79 (3.71)  14.03 (3.59)a  2, 72 3.861      .026          .097 .682 
 
Note. OC = Oral Contraceptives. AIM = Affect Intensity Measure. HRSD = Hamilton Rating Scale for Depression. Mood Reactivity 
= Reactivity Subscale of the Mood Survey. BFI-N = The Neuroticism scale form the Big Five Inventory. BIS = Behavioural Inhibition 
System. Shared letter subscripts in a row indicate significant differences for the specified groups. a OC Mood and Nonusers differ.   
*p <.05.  
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self-report measures of affect. Results indicate that overall, OC users with current 
negative mood side effects report higher affect intensity, more mood reactivity, more 
behavioural inhibition (such as being easily hurt by criticism, fear of judgment from 
others), and a trend toward overall higher neuroticism. However, the results only 
indicated significant group differences between OC users with current negative mood 
side effects and nonusers and the results did not show significant differences between OC 
users with current negative mood side effects and OC users without current negative 
mood side effects. It should be noted that the OC mood group had a small group size of n 
= 15. Therefore, power issues may make it more difficult to find evidence to support the 
validity of this group with such a small sample size.  
Data Screening 
Prior to analyses, all variables were inspected for data entry accuracy, outliers, 
normality, linearity, and homoscedasticity. All variables were screened separately for the 
three groups (e.g., OC users, nonusers, and men). Outliers were identified based on z-
score values of ≥ ⎸3.29 ⎸ (Tabachnick & Fidell, 2001). Skewness and kurtosis values that 
differed significantly from zero were considered non-normal (Tabachnick & Fidell, 
2001). As confirmation of normality, visual inspections of histograms were also 
completed and all distributions looked reasonably normally distributed. Given that the 
outliers appeared to represent accurate extreme data points, we decided not to simply 
delete outliers. Instead, the decision was made to run each analysis twice, once with 
outliers included, and once with outliers removed.  This was done to satisfy any concerns 
about statistical assumptions as well as maximizing available data. As the results were 
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very similar in analyses with and without outliers, the results presented here exclude 
outliers and the number of outliers are noted.  
Statistical Considerations 
For all of the main analyses, and examination of group equivalency, a significance 
level of .05 was used. Pillai’s criterion was used to evaluate multivariate significance. All 
group comparisons were analyzed using MANCOVAs and follow-up univariate 
ANCOVAs. The Bonferroni adjustment was used for follow-up pairwise comparisons. 
All means reported are untransformed unadjusted means, unless otherwise indicated. For 
all significant results involving group differences between OC users and men, follow up 
tests were run to examine sex differences on the same dependent variables. If there were 
no sex differences between men and women on certain dependent variables that showed 
differences between OC users and men, it indicates that OC use, rather than sex, was 
likely the driving force behind the group difference. 
Examination of Group Equivalency 
The three groups (OC users, nonusers, and men) were examined for equivalency 
in the following variables: time of laboratory session, age, caffeine consumption, alcohol 
consumption, hours of sleep, handedness, and self-reported effort and enjoyment of 
laboratory tasks (see top panel of Table 8 for means and standard deviations). Univariate 
ANOVAs and chi-square analyses were used to examine group equivalency on the 
continuous and categorical variables, respectively. The groups only differed significantly 
in age, F(2, 139) = 3.415, p = .036, and pairwise comparisons revealed that OC users 
were significantly younger than non-users (see Table 8). Due to these group differences, 
age was used as a covariate in all subsequent group analyses.  




Unadjusted Means (Standard Deviations) or Frequencies (Percentages) of 10 Variables 
Used to Examine Group Equivalency between OC Users, Nonusers, and Men  
________________________________________________________________________ 
Variable   OC Users   Nonusers   Men 
   (n = 57)  (n = 45)  (n = 38) 
 
Means (SD) 
Age*    20.75(2.81)a  22.82(5.94)a  22.37(3.44) 
Caffeine   0.574 (0.881)  1.06(2.00)  0.730(1.04) 
Alcohol   0.345(1.00)  0.250(0.673)  0.243(0.796) 
Hours of Sleep  7.44(1.21)  7.37(1.07)  7.05(1.29) 
Handedness   1.48(1.02)  1.50(1.05)  1.35(1.09) 
Effort in Session  16.91(2.32)  16.78(3.08)  17.04(2.51) 
Enjoyment in Session   17.26(3.85)  16.96(3.59)  17.23(3.00) 
Time of Session   12:03(1:58)  12:08(2:03)  13:04(2:06)  
 
Frequencies (Percentages) 
Cycle Phase 1      
    Early Follicular 1(1.7)   2(4.7) 
    Mid Follicular   2(3.4)  2(4.7) 
    Late Follicular   17(29.3)  11(25.6) 
    Early Luteal   4(6.9)  7(16.3) 
    Mid Luteal    28(48.3)  14(32.6) 
    Late Luteal    4(6.9)  7(16.3) 
 
Cycle Phase 2 
    Follicular  20(34.5)  15(34.9) 
    Luteal  36(62.1)  28(65.1) 
________________________________________________________________________ 
Note. OC = Oral Contraceptive. Cycle Phase 1 = Cycle phase partitioned into 6 different 
categories. Cycle Phase 2 = Cycle phase partitioned into 2 overarching categories. Shared 
letter subscripts in a row indicate significant differences for the specified groups, a OC 
users and Nonusers differ.  
* p < .05  
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In order to ensure that cycle phase was not a potential limitation of the design and 
that OC users and nonusers were equally likely to be tested during the different menstrual 
cycle phases, group equivalence on this variable was examined. The two groups did not 
differ when testing in the follicular versus luteal phase was examined, χ2 (2, N = 142) = 
1.520, p =.468. Similarly, when cycle phase was partitioned into six categories that differ 
in hormone levels (early follicular, mid follicular, late follicular, early luteal, mid luteal, 
and late luteal) the OC user and nonuser group also did not differ in terms of the 
likelihood of being tested in a particular cycle phase, χ2 (6, N = 101) = 7.868, p =.248 
(see bottom panel of Table 8 for frequencies and percentages). This indicates that OC 
users and nonusers were tested during similar times in their menstrual cycle. Furthermore 
many of the nonusers were tested during the highest hormone times (i.e., 25.6% during 
late follicular phase and 32.6% during the mid luteal phase) which maximizes the 
sensitivity of the design and decreases the likelihood of a Type II error.  
Main Analyses 
Hypothesis 1: OC users will show blunted positive affect reactivity across the 
laboratory session compared to nonusers and men. The data for hypothesis 1 were 
screened for normality. Assumptions of normality were met and no outliers were found. 
A 3-group MANCOVA with group (OC users, non-users, and men) as the independent 
variable, and mean Positive Affect (PA) change and mean Negative Affect (NA) change 
scores as the dependent variables. The group means and standard deviations are found in 
the top of Table 9. Results indicate an overall multivariate group effect, F(4, 270) =2.413, 
p = .049, partial η2 = .035, power = .690. Follow-up univariate ANCOVAs showed no 
group effect for mean PA change, F(2, 135) = 0.833, p =.437, η2 = .012, power = .190, 
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but a significant group effect for mean NA change, F(2, 135) = 3.787, p = .025, partial η2 
= .053, power = .682. Planned post-hoc tests found that men had significantly less mean 
NA change than OC users, Mean Difference = 3.103, SE = 1.194, p = .031, and a trend 
for less NA change for men compared to nonusers, Mean Difference = -2.707, SE = 
1.235, p = .09. 
In order to examine group differences in affect level (as opposed to the above 
examination of affect variability or change), another MANCOVA was run using mean 
PA and mean NA scores as the dependent variables (see the bottom panel of Table 9 for 
means and standard deviations). Each mean score was calculated from the four affect 
measures across the laboratory session. Results indicated an overall multivariate group 
effect, F(4, 270) = 7.259, p < .001, partial η2 = .097, power = .996; and significant 
univariate main effects for both mean PA score, F(2, 135) = 8.463, p < .001, partial η2 
=.1121, power =.962; and mean NA score, F(2, 135) = 4.885, p = .009, partial η2 = .067, 
power =.796. Post-hoc Bonferroni contrasts show that men have higher mean PA scores 
than OC users, Mean Difference = 4.070, SE = 1.00, p < .001, and non users, Mean 
Difference = 2.873, SE = 1.036, p = .019. Post-hoc Bonferroni contrasts also show that 
men have lower mean NA scores than OC users, Mean Difference = -2.347 SE = 0.755, p 
= .007. There were no significant differences between men and nonusers in mean NA 
score. See Figure 2 for a graphical depiction of NA and PA change scores as a function of 
group, and Figure 3 for a graphical depiction of and mean PA and NA scores as a 









Means and Standard Deviations for Hypothesis 1 Variables: Mean Positive and Negative 
Affect Scores and Change Scores Across the Laboratory Session as a Function of Group 
________________________________________________________________________ 
Variable     OC users Nonusers Men   Women 
   (n = 56) (n = 45)  (n = 38)  (n = 106) 
________________________________________________________________________ 
PA Change  11.77 (5.62) 10.17 (5.28) 10.20 (5.22)  10.87 (5.48) 
NA Change*  11.99 (5.86)a  10.90(6.05)t 8.33 (5.12)ta,c   11.40 (5.91)c 
____________________________________________________________________________________________________________ 
PA Score **  24.19 (4.84)a 25.71 (4.77)b 28.51 (4.46)a,b,c    24.96 (4.91)c 
NA Score*  19.19 (4.32)a 17.81 (3.24) 16.38(3.18)a,c     18.53 (3.90)c 
________________________________________________________________________ 
Note. OC = oral contraceptives, PA = positive affect and NA = negative affect as 
determined by scores on the Positive and Negative Affect Scale (PANAS). Shared letter 
subscripts in a row indicate significant differences for the indicated groups: a OC users 
and men differ, b non users and men differ, c males and females differ. Shared t 
superscripts in a row indicate a trend towards a significant difference between groups, p < 









Figure 2. Adjusted Mean Positive Affect (PA) and Negative Affect (NA) Change Scores 
as a Function of Group in Response to Mood Primes. Men had lower mean NA change 
compared to OC users (p = .031) and Women as a whole (p  = .009) across the laboratory 



































Figure 3. Adjusted Mean Positive Affect (PA) and Negative Affect (NA) Scores as a 
Function of Group in Response to Mood Primes. Groups differed with men experiencing 
higher mean PA than OC users (p < .001), Nonusers (p = .019), and Women (p < .001), 
and with men experiencing lower NA than OC users (p = .007), and Women as a whole 
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One important finding of the Jarva and Oinonen (2007) study, was that duration 
of OC use was related to the observed blunting of PA. The women in their study that 
were taking OCs for less than 24 months showed the highest level of PA blunting. 
Therefore, additional analyses were run for the current study to examine whether duration 
of OC use was related to mean PA and NA change scores across the laboratory session 
(see top panel of Table 10 for means and standard deviations). A MANCOVA was run 
using OC users with group (OC use duration ≤23 months, OC use duration ≥ 24 months, 
nonusers, and men) as the independent variable and all four affect scores as the dependent 
variables (i.e. PA and NA scores and PA and NA change scores).  
Results from the MANCOVA indicated an overall multivariate group effect, 
F(12, 384) = 3.336, p  < .001, partial η2 =  .094, power = .996. Follow-up univariate tests 
show significant group differences for mean PA scores, F(3, 129) = 5.889, p = .001, 
partial η2 =  .120, power = .950; mean NA scores,  F(3, 129) = 4.309, p = .006, partial η2 
=   .091, power = .57, and NA mean change, F(3, 129) = 3.045, p = .031, partial η2 =  
.066, power = .704. There were no significant group differences for PA change, although 
there was a weak trend, F(3, 129) = 1.989, p = .119, partial η2 = .044, power = .502.  
Pairwise comparisons show that for mean PA score, men have higher PA levels 
compared to OC users on OCs for 23 months or less, Mean Difference = 5.205, SE = 
1.304, p = .001; and non users, Mean Difference = 2.867 SE = 1.029, p = .037; and a 
trend for higher mean PA score compared to OC users on OCs for 24 months or more, 
Mean Difference = 2.801, SE = 1.138, p = .091. For mean NA levels, men had 
significantly lower NA score compared to OC users who were taking OCs for 24 months 
or more, Mean Difference = -2.997, SE = .853, p = .004. For NA change, men had  





Means (Standard Deviations) for Mean Positive Affect (PA) and Mean Negative Affect 
(NA) Change Scores and Mean NA and PA Scores as a Function of Group (short OC 
duration, long OC duration, nonuser, and men) Use Duration 
________________________________________________________________________ 
Variable  OC use < 23months OC use > 24months Nonusers Men 
   (n = 20)  (n = 31) (n = 45) (n = 38) 
________________________________________________________________________ 
PA Changet  10.35 (5.12)  13.08 (5.42) 10.17 (5.28) 10.20 (5.22)  
NA Change*  12.15 (5.01)  12.58 (6.44)c 10.89 (6.05) 8.33 (5.12)c 
________________________________________________________________________ 
PA Score**  23.04 (3.99)a  25.52 (5.19)t 25.71 (4.77)b   28.51 (4.46)ta,b  
NA Score*  18.99 (3.99)  19.76 (4.50)c 17.81 (3.24) 16.38 (3.18)c 
________________________________________________________________________ 
Note. OC = Oral contraceptives. PA Change and NA Change = mean change score in 
Positive Affect, or Negative Affect, respectively. PA score and NA score = mean Positive 
Affect score and mean Negative Affect score. NA and PA are calculated using the 
Positive and Negative Affect Schedule (PANAS). Shared letter subscripts in a row 
indicate significant differences for the indicated groups: a OC users on OCs for 23 months 
or less and men differ, b Nonusers and men differ, c OC users on OC for 24months or 
more and men differ, Super script t denotes a trend for group differences, p < 1.0.  
* p < .05 ** p < .001  
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significantly lower NA change compared to OC users who were taking OCs for 24 
months or more, Mean Difference = - 3.790, SE =1.369, p =.039. For PA change, there 
was a weak trend for women on OCs for 24 months or more to have more PA change 
compared to nonusers, Mean Difference = 2.833, SE = 1.208, p = .123, and men, Mean 
Difference = 2.892, SE = 1.259, p = .139. See Figure 4 for a graphical depiction of the 
mean affect scores as a function of OC length.  
Along with potential differences in affect reactivity as a function of length of OC 
use, previous research has also indicated mood side effects may differ depending on type 
of synthetic progesterone in certain OCs: drospirenone (new generation), levonorgestrel 
or norethindrone (second generation) and gestodene, desogestrel, or norgestimate (third 
generation) (Wharton et al., 2008). Furthermore, it follows that PA and NA mean change 
may also differ depending on whether OCs are monophasic or triphasic. For example, one 
may expect more variability in those individuals taking a triphasic OC than those taking 
monophasic OCs. Therefore, additional analyses were run to examine whether OC 
composition affected mood responsivity in the laboratory (see top panel of Table 11 for 
means and standard deviations for mean PA and NA change for the various OC user 
groups and the nonusers).  
A 4-group MANCOVA was run to compare participants taking the three differing 
generations of OCs (new, second, and third) and nonusers on mean PA and NA change 
across the laboratory session (see means and SDs in Table 11). Results showed no 
evidence of a multivariate group effect, F(6, 190) = 1.077, p = .378, partial η2 =  .033, 
power = .419. However, because the sample size for new generation was so low, n = 3,  





Figure 4. Adjusted Mean Positive Affect (PA) and Negative Affect (NA) Scores and 
Change Scores Following Mood Primes as a Function of Group. Groups differed with 
men experiencing: (a) higher mean PA than OC users taking OCs for 23 months or less (p 
= .001) and Nonusers (p = .037), (b) lower NA score than OC users on OCs for 24 
months or more (p = .004), and (c) less NA change compared to OC users on OCs for 24 
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the analysis were re-run using only second and third generation OC users and nonusers as 
the independent variables and PA and NA change as the dependent variables. Again, 
there was no evidence of a multivariate group effect, F(4, 192) = 1.696, p = .153, partial 
η2 = .034, power = .514.   Another 3-group MANCOVA was run to compare participants 
taking monophasic OCs, triphasic OCs, and nonusers on their mean PA and NA change 
scores (see means in Table 11). Results showed no significant group effect, F(4, 192) = 
1.9929, p =.107, partial η2 =  .039, power = .575. These analyses suggest that PA and NA 
change or affect reactivity was not influenced by type of OC.  
Finally, to further examine the significance of group differences on the dependent 
variables, a MANCOVA was run using sex as the independent variable and mean NA and 
PA change scores, and mean NA and PA scores as the dependent variable (see Table 11 
for means and standard deviations for NA and PA change and PA and NA scores for men 
and women). Results show an overall significant multivariate group effect, F(4, 138) = 
7.438, p < .001, partial η2 = .177, power = .996. Follow-up univariate tests show 
significant sex differences for NA mean change, F(1, 141) = 7.074, p  = .009, partial η2 = 
.048, power = .752; mean PA score, F(1, 141) = 14.337, p < .001, partial η2 = .092, power 
= .964; and mean NA score, F(1 , 141) = 8.197, p = .005, partial η2 =  .055, power = .812, 
but not for PA mean change score, F(1, 141) = .256, p = .614, partial η2 =  .002, power = 
.079. Planned pairwise comparisons show that men had significantly lower NA mean 
change (Mean Difference = -2.811, SE =1.057, p = .009), higher mean PA mean scores, 
(Mean Difference = 3.421, SE = .094, p < .001) and lower mean NA scores (Mean 
Difference = -1.923, SE = .672, p = .005) compared to women. Given these sex 
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Table 11 
Means (Standard Deviations) for Mean Positive Affect (PA) and Mean Negative Affect (NA) Scores and Change Scores as a Function 
of OC User groups (first generation user, second generation user, third generation user, monophasic user, triphasic user, Nonuser) 
____________________________________________________________________________________________________________ 
Variable    First   Second Third  Monophasic       Triphasic  Nonuser 
     Generation       Generation Generation 
      (n =3)    (n=32)  (n =20)   (n = 45)         (n = 10)        (n =45)   
____________________________________________________________________________________________________________ 
PA Change 9.00 (9.06) 11.94 (4.52)   11.87 (5.82)    12.11 (5.01)       10.13 (6.05)  10.17 (5.28) 
NA Change 9.56 (6.36) 10.78 (5.81)   13.70 (5.67)   11.25 (5.92)       14.13 (5.23) 10.90 (6.05)   
____________________________________________________________________________________________________________ 
PA Score 24.50 (3.25) 23.76 (4.86)   26.46 (5.08)     25.71 (4.78)       25.76 (5.73) 25.71 (4.78) 
NA Score 16.42 (4.04) 18.67 (4.29)   20.08 (4.46)   18.91 (4.60)       19.73 (3.21) 17.81 (3.24)  
____________________________________________________________________________________________________________
Note. OC = Oral contraceptive. PA Change and NA Change = mean change score in Positive Affect, or Negative Affect, respectively. 
PA score and NA score = mean Positive Affect score and mean Negative Affect score. NA and PA are calculated using the Positive 
and Negative Affect Schedule (PANAS).  
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differences, the above findings suggest that the sex differences on NA change, mean PA, 
and mean NA may be driven by the OC user group as their scores are more extreme than 
the nonusers on all three of these affect variables (See Figure 2 for a graphical depiction 
of NA and PA change scores as a function of group, and Figure 3 for a graphical 
depiction of and mean PA and NA scores as a function of group).  
Overall, Hypothesis 1 was not supported, as the results indicated no evidence of 
reduced PA reactivity across the lab session among OC users compared to nonusers and 
men. Instead, the results revealed no significant differences in PA reactivity between 
groups. However, results did show sex differences for NA reactivity (women > men) and 
that OC users had higher NA reactivity across the lab session compared to men. 
Furthermore, the largest sex difference effects were found for NA reactivity were found 
in OC users taking OCs 24 months or longer. Results also showed a sex difference in PA 
level and NA level. Men had overall higher mean PA scores than both OC users and 
nonusers, especially OC users that have been taking OCs for 23months or less. Men had 
lower mean NA scores than women as a whole and to the OC users, especially OC users 
that have been taking OCs for 24months or more.   
Hypothesis 2: Women on OCs with current negative mood side effects will 
have quicker reaction times when identifying negative facial expressions, especially 
after the negative mood inductions, and have overall more facial emotion 
recognition errors compared to women on OCs with no current negative mood side 
effects, nonusers, and men. Data for Hypothesis 2 was screened for normality. There 
were 7 outliers detected and removed from the analyses.  
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To determine if women on OCs with current negative mood side effects had 
quicker reaction times to negative faces compared to women on OCs with no current 
negative mood side effects, nonusers, and men, a 4-group ANCOVA was conducted with 
group as the independent variable and mean response times to all negative faces (across 
the three mood inductions) as the dependent variable (see descriptive data in top panel of 
Table 12). Analysis revealed an overall significant group effect for mean response time to 
negative faces F(3, 128) = 3.85, p = .011 partial η2 = .083, power = .812. Post-hoc 
Bonferroni contrasts showed that men had significantly slower mean response times than 
OC users with no negative mood side effects, Mean Difference = 0.246, SE = 0.77, p = 
.01. Therefore, results did not support the hypothesis that women on OCs with current 
negative mood side effects would have the quickest response times to negative faces. 
Instead women on OCs with no negative mood side effects showed the fastest mean 
response times to negative faces (although the three groups of women did not differ 
significantly). 
  It was also predicted that the effect of negative faces on response times would be 
strongest during the negative mood induction. Therefore, a MANCOVA was conducted 
with group (women on OCs with current negative mood side effects, women on OCs with 
no current negative mood side effects, nonusers, and men) as the independent variable 
and mean response times to negative faces after each mood induction (sad, happy, and 
fear) as the three dependent variables (see second panel of Table 12 for means). Analysis 
reveals a significant overall multivariate group effect F(9, 384) = 2.164, p = .024, partial 
η2 = .048, power = .886. Follow up univariate analyses show significant group difference 
in mean response times to negative faces in the sad condition, F(3,128) = 4.846, p =.003,  





Means (and Standard Deviations) for Hypothesis 2 Variables (Mean Response Time (RT) 
(ms) to Recognize Negative Emotional Expressions, Total Errors, and Total Correct) as a 
Function of Group 
________________________________________________________________________ 
Variable     OC Mood OC No Mood Nonusers Men 
   (n = 15) (n = 39) (n = 43)  (n = 36) 
________________________________________________________________________ 
 
Mean RTOverall*  1.81 (.223) 1.63 (.235)a 1.75(.370)  1.91(.427)a  
Mean RTsad*   1.91 (.246) 1.67 (.281)a 1.77 (.375)b 2.00 (.492)a,b 
Mean RThappy     1.80 (.257) 1.69 (.306) 1.76 (.380) 1.90 (.387)  
Mean RTfear*  1.73 (.255) 1.53 (.242)a 1.71 (.455) 1.84 (.453)a 
________________________________________________________________________ 
Total Errors    16.93 (6.39)  22.49 (9.13)  22.37 (11.05)  19.31 (6.21) 
________________________________________________________________________ 
Total Correctsad 68.60 (2.70) 67.49 (3.24) 66.74 (3.53) 68.31 (3.13) 
Total Correcthappy 69.87 (2.07) 67.56 (2.81) 68.19 (4.21) 68.61 (2.27) 
Total Correctfear 69.60 (2.97) 67.46 (4.42) 67.70 (5.35) 68.78 (4.34) 
________________________________________________________________________ 
Note. All response times are in milliseconds. OC = Oral Contraceptives. The subscripts 
sad. happy,fear all refer to response times or correct responses after the sad, happy, or fear 
mood inductions, respectively. Shared letter subscripts in a row indicate significant 
differences for the indicated groups: a OC users with no mood side effects and men differ, 
b Nonusers and men differ.  
* p < .05.  
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partial η2 =  .102, power = .898; and the fear condition, F(3,128) = 3.474, p = .018, partial 
η2 = .075, power = .766. No group difference was found for mean response times to 
negative faces in the happy condition, F(3, 128) =1.997, p =.118, partial η2 = .045, power 
= .504.  
However, planned post-hoc tests show that, for the sad mood induction, men had 
slower mean response time to negative faces than OC users with no negative mood side 
effects, Mean Difference =  0.278, SE = .084, p = .007; and non-users, Mean Difference = 
0.236, SE =.081, p = .027. After the fear induction, men also showed slower mean 
response times to negative faces compared to OC users with no negative mood side 
effects, Mean Difference = 0.277, SE = .087, p = .011.  
It was also hypothesized that women on OCs with current negative mood side 
effects would make overall more errors than OC users with no mood side effects, 
nonusers and men, especially after the negative mood inductions. An ANCOVA was 
conducted with group as the independent variable (OC users with negative mood side 
effects, OC users with no negative mood side effects, non users, and men) and overall 
error score as the dependent variable (see descriptive data in bottom panels of Table 12). 
There was no significant univariate group effect for errors overall, F(3, 128) = 2.33, p = 
.077, partial η2 =  .052, power = .574, and no significant multivariate group effect for 
overall number of correct responses after each emotion induction, F(9, 384) = 1.419, p = 
.178, partial η2 =  .032, power = .683.  
The hypothesis that OC users with current negative mood side effects would have 
quicker response times to negative faces, and make overall more errors especially after 
negative mood induction was not supported. However, because the group of women  




Means (Standard Deviations) for Mean Response Time (RT) to Negative Emotional 
Faces as a Function of Group 
________________________________________________________________________ 
Variable   OC users Nonusers Men  Women 
   (n = 53) (n = 43) (n =36) (n =  101) 
________________________________________________________________________ 
Mean RT*  1.67 (0.24)a 1.75 (0.37) 1.91 (0.43)a,c 1.72 (0.30)c 
________________________________________________________________________ 
Mean RTsad*   1.73 (0.29)a 1.77 (0.37)b 2.00 (.49)a,b,c 1.76 (0.33)c  
Mean RThappyt  1.71 (0.29) 1.76 (0.38)t 1.90 (3.87)tc 1.75 (0.33)c  
Mean RTfear*  1.57 (0.25)a 1.71 (0.45) 1.84 (.45)a,c 1.64 (0.36)c  
________________________________________________________________________ 
Total Errors   21.21 (8.63) 22.37 (11.05) 19.31 (6.21) 21.43 (9.70) 
________________________________________________________________________ 
Total Correctsadt 67.68 (3.02) 66.74 (3.53)t 68.31 (3.13)t 67.40 (4.00) 
Total Correcthappy 68.11 (2.75) 68.19 (4.21) 68.61 (2.27) 68.26 (3.43) 
Total Correctfear 68.00 (4.18) 67.70 (5.54) 68.11 (4.36) 67.91 (4.72) 
________________________________________________________________________ 
Note. OC = Oral Contraceptives. The Subscripts sad, happy, fear refer to the mean response 
times subsequent to the indicated mood induction. Shared letter subscripts in a row 
indicated significant differences for the indicated groups: a OC users and men differ, b 
mean and nonusers differ, c men and women differ. The superscript t indicates a trend 
towards significant group differences, p < .1. 
* p < .05.   
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
107 
using OCs with current negative mood side effects was small (n = 15), the analyses were 
re-run using only three groups (i.e., OC users, non users, and men) to examine whether 
there was an association between OC use and response time to negative faces and overall 
facial emotional recognition errors (see means in Table 13).  
An ANCOVA was run using group (OC users, non users, and men) as the 
independent variable and mean response time to negative faces as the dependent variable. 
There was an overall univariate effect F(2, 128) = 4.290, p = .016, partial η2 =  .063, 
power = .739. Planned post hoc comparisons indicated that OC users had significantly 
faster mean response times to negative faces than men, Mean Difference =.203, p = .018 
(see top panel of Table 13 for means).  
The above finding was examined further by looking at whether mean response 
times to negative faces differ depending on type of mood induction. A MANCOVA was 
run with group (OC users, non users, and men) and mean response times to negative faces 
after each emotion induction (sad, happy, and fear) as the dependent variables (see means 
in Table 13). There was an overall multivariate group effect F(6, 254) = 2.439, p = .026, 
partial η2 =  .054, power = .821; and significant follow-up univariate group effects for the 
sad condition, F(2,128) = 4.985, p =.008, partial η2 = .072, power = .805; and the fear  
condition, F(2, 128) =3.984 p = .021, partial η2 =  .059, power = .705. There was no 
significant group effect difference for mean response times after the happy induction, 
F(2, 128) = 2.552, p =.082, partial η2 = .038, power =.502, although there was a trend.  
Planned post hoc comparisons show significant differences in mean response time to 
negative faces between men and OC users after sad mood induction, Mean Difference = 
2.18, SE = 0.08, p = .022; and after the fear mood induction, Mean Difference = 2.32, SE  




Figure 5. Adjusted Mean Response Times (in milliseconds) to Recognize Negative 
Emotional Facial Expressions as a Function of Group (OC users, nonusers, men, women). 
Groups differed with men having slower overall response times compared to OC users (p 
= .018) and women as group (p = .006); and with men having slower response times after 
the sad condition compared to OC users (p = .022), nonusers ( p = .015), and women (p = 
.002), after the fear condition compared to OC users (p = .017), and women (p =.016), 
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= 0.082, p = .017. Men also showed a significant difference in mean response time to 
negative faces compared to nonusers after the sad mood induction, Mean Difference 
=.236 SE = 0.083, p = .015. See Figure 5 for a graphical depiction of mean response 
times as a function of group.  
The three groups (OC users, non users, and men) were further examined to 
determine if there were group differences in overall incorrect responses for the face 
emotion recognition task (see bottom panels of Table 13). A 3-way ANCOVA revealed 
no significant difference in overall incorrect responses between groups, F(2, 128) = 
1.296, p = .277, partial η2 =  .020, power = .277. Additionally, a MANCOVA with group 
(OC users, non users, and men) as the independent variable and overall correct scores 
after each emotion induction (sad, happy, fear) as the dependent variables was conducted. 
There were no significant difference in overall correct responses after each emotion 
induction F(6,254) = 1.31, p =.344, partial η2 = .026, power = .444.  
There was unequal variance across groups for the mean response times to 
negative faces after each mood condition, Box’s M Test of equality of covariance 
matrices, F(12, 65336.924) =3.496, p < .001. Therefore, to check on the validity of the  
above findings, a non-parametric Kruskal-Wallis test was run to ensure significant results 
were not due to inequality of variance. Results from the non-parametric test confirmed 
group differences in mean response times to negative faces after the sad mood condition 
(p = .012) and group differences in mean response times to negative faces after the fear 
mood condition  (p = .003).  
Finally, the response time dependent variables were further analyzed to determine 
if there were overall sex differences in the above analyses that demonstrated significant 
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results. An ANCOVA was performed using sex (male, female) as the independent 
variable and overall mean response time to negative faces as the dependent variable. An 
overall sex difference was found, F(1, 134) = 7.881, p = .006, partial η2 =  .056, power = 
.796 with men showing significantly slower response times than women when identifying 
negative emotional expressions, Mean Difference = 0.179, SE = 0.64, p = .006.  (See top 
of Table 13 for means and standard deviations).  
A MANCOVA was also run with sex (male, female) as the independent variable 
and mean response times to negative faces after each mood induction (sad, happy, fear) 
as the three dependent variables. An overall significant multivariate group effect was 
found as expected given the above finding, F(3, 132) = 3.256, p =.024, partial η2 =  .069, 
power = .736. Follow up univariate analyses showed that men had significantly slower 
response times to negative faces than women after the sad induction, F(1, 134) = 9.504, p 
= .002, partial η2 =  .066, power = .865; after the fear induction, F(1, 134) = 6.00, p =.016 
partial η2 =  .043, power = .682, and after the happy induction, F(1, 134) = 4.643, p 
=.033, partial η2 =  .033, power = .571. See Figure 5 for a graphical depiction of mean 
response times as a function of group.  
In summary, our sample of women on OCs with current negative mood side 
effects was likely not large enough to adequately test the hypothesis related to negative 
mood side effects. Instead, all OC users were examined together regardless of current 
mood side effects.  Results indicated that OC users had quicker response times to 
negative faces compared to men. When response times were examined as a function of 
mood induction type, men showed slower response times than both OC users and 
nonusers after the sad induction, and slower response times than OC users after the fear 
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induction. There were no group differences in response times after the happy induction, 
or in overall correct or incorrect scores. Examination of sex differences paralleled these 
results, however, a sex difference was found in reaction times to negative faces for all 
three mood conditions. 
Hypothesis 3: OC users will make overall more errors of commission on the 
GoNogo task compared to nonusers and men, especially during the positive mood 
induction. Data for Hypothesis 3 was screened for normality. There were 3 outliers 
detected and removed from the analyses.  
To determine if OC users had higher errors of commission on the GoNogo task 
compared to nonusers and men, an ANCOVA was run with group (OC users, nonusers, 
and men) as the independent variable and total errors of commission as the dependent 
variable (see Table 14 for means and standard deviations). There was no overall 
significant univariate group effect, however there was a trend, F(2, 125) = 2.778, p = 
.066, partial η2 =  .043, power = .539. An examination of the pairwise comparisons reveal 
a trend for OC users to have more errors of commission than men, Mean Difference = -
5.387, SE = 2.344, p = .070. 
To examine if errors of commission differ as a function of the mood priming 
types, a MANCOVA was conducted with group (OC users, nonusers, and men) as the 
independent variable and total errors of commission after each emotion induction (sad, 
happy, fear) as the three dependent variables (see means in bottom panel of Table 14). 
There was not a significant multivariate group effect, F(6, 248) = 1.253, p = .280, partial 
η2 =  .029, power = .489. However, as predicted, follow up univariate tests reveal a 
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 Table 14 
Means (Standard Deviations) of Errors of Commission on the GoNogo task as a Function of Group for Hypothesis 3 
______________________________________________________________________________________________________ 
Variable  OC Users Nonusers Men   OC Mood OC No Mood  Women 
   (n = 51) (n = 43) (n = 35)  (n =15)  (n = 37)  (n = 99) 
______________________________________________________________________________________________________ 
Total Errorst  17.71 (12.70)t 14.05 (9.44) 12.09 (7.74)t  13.07 (12.26) 19.30 (12.54)  16.13 (11.91) 
______________________________________________________________________________________________________ 
Errorssad  6.31 (5.14) 4.81 (3.44) 4.57 (3.39)  3.73 (4.13)b 7.22 (5.21)b  5.58 (4.53) 
Errorshappy*  4.55 (4.36)a 3.58 (2.92) 2.51 (2.86)a,c  3.93 (4.18) 4.76 (4.41)  4.24 (4.03)c 
Errorsfear  6.84 (5.44) 5.65 (4.73) 5.00 (3.15)  5.40 (5.04) 7.32 (5.53)  6.31 (5.27) 
______________________________________________________________________________________________________ 
Note. OC = Oral Contraceptives. OC Mood = Oral contraceptives users with current negative mood side effects. OC No Mood 
= OC users with no current negative mood side effects. Errorssad = errors of commission after the sad mood induction, 
Errorshappy =errors of commission after the happy mood induction, Errorsfear = Errors of commission after the fear mood 
induction. Shared letter subscripts in a row indicate significant differences for the indicated groups. a OC users and Men 
differ, b OC Mood and OC No Mood differ,  c males and females differ. t denotes a trend for a difference between OC users 
and men, p < .1.  
* p < .05
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significant group difference in errors of commission after the happy induction F(2, 125) = 
3.348, p = .038, partial η2 =  .051, power = .624; but not after the sad induction, F(2, 125) 
= 1.930, p =.149, partial η2 = .030, power = .394; or after the fear induction, F(2, 125) = 
1.334, p = .267, partial η2 = .021, power = .284. Planned post hoc comparisons reveal that 
OC users made more commission errors than men after the happy mood induction, Mean 
Difference = 2.053, SE = .795, p = .033. See Figure 6 for a graphical depiction of errors 
of commission as a function of group.  
For both of the above analyses, the tests of Equality of Error Variances indicated 
significant results. Therefore, nonparametric Kruskal-Wallis tests were conducted to 
verify that the results were not due to inequality of variance between groups. For the 
ANCOVA with overall errors of commission as the dependent variable, the Levene’s 
Test of Equality of Error variance indicated unequal error variance, F(2, 126) = 6.324, p 
=.002. However, results of the nonparametric tests support the ANCOVA result in that 
there was not a significant group difference in overall errors of commission (p = .340). 
For the MANCOVA, with errors of commission after each mood induction as the 
dependent variables, the Box’s M Test of Equality of Covariance Matrices indicated 
significant error variance, Box’s M = 39.076, F(12, 62606.70) = 3.141, p <.001. 
However, results of the nonparametric test supported the above result of a significant 
group difference on errors of commission after the happy induction (p = .048) but not 
after the fear induction (p = .456), or the sad induction (p = .621).  
Because errors of commission are more likely to be made in positive mood 
contexts (Albert, Lopez-Martin, & Carretie, 2010), the current mood of the participant 
may further influence performance on the GoNogo task. Therefore, follow up t-tests were  
Running head: ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY 114 
 
 
Figure 6. Adjusted Means for Errors of Commission Overall (total) and After 
Each Mood Induction Type as a Function of Group. The groups differed with men 
having significantly fewer errors of commission compared to OC users (p = .033) 
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conducted to specifically examine if errors of commission on the GoNogo task 
would be higher in OC users with no current negative mood side effects compared 
to OC users with negative mood side effects (see middle of bottom panel in Table 
14).  
Results from the t-tests revealed that there were no group differences in 
overall errors of commission, t(50) = -1.634, p =.109; errors of commission after 
the happy mood induction, t(50) = -.619, p =.539; or error of commission after the 
fear induction, t(50) = -1.165, p =.249. However, errors of commission after the 
sad mood induction revealed a significant group difference, t(50) = -2.545, p = 
.016, where  OC users with current negative mood side effects had significantly 
fewer errors of commission after the sad mood induction compared to OC users 
with no negative mood side effects. See Figure 7 for a graphical depiction of 
errors of commission for the OC users with mood and without mood side effects 
 Finally, data were analyzed to determine if there were any overall sex 
differences in errors of commission on the GoNogo task after the mood 
inductions. A MANCOVA was run with sex (male, female) as the independent 
variable and errors of commission after each mood induction (sad, happy, fear) as 
the dependent variables (see Table 14 for means and standard deviations). There 
was no significant multivariate group effect, F(3, 129) = 1.774, p = .155, partial  




Figure 7. Errors of Commission on the GoNogo task overall (Total), and after 
each of three Mood Inductions as a function of Group [OCs users with Current 
Negative Mood Side Effects (OC Mood), and OC Users with No Negative Mood 
Side Effects (OC No Mood)]. The OC Mood group made fewer commission 
errors than the OC No Mood (p = .016) group in the sad condition. Error bars 
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η2 =   .040, power = .454. Follow up univariate tests, however, revealed 
significant sex differences for errors of commission after the happy induction, 
F(1,131) = 5.21, p = .024, partial η2 =   .038, power = .621. Men had fewer errors 
of commission compared to women after the happy mood induction, Mean  
Difference = -1.702, SE = 0.745, p =.024. No significant sex differences were 
found for errors of commission after the sad condition, F(1 ,131) = 1.21, p =.273, 
partial η2 =  .009, power = .194; or after the fear condition F(1, 131) = 1.603, p = 
.208, partial η2 =  .012, power = .242 (See Figure 6 above).  
To summarize, hypothesis 3 was partially support by the results. Although 
there was no significant group difference for overall errors of commission, there 
was a trend for OC users to make more errors of commission compared to men. 
Also, the results supported the hypothesis that OC users would make more errors 
of commission after the happy mood induction. There were only significant group 
differences between OC users and men, however, and no significant differences 
between OC users and nonusers on errors of commission. Additional analyses 
also revealed that OC users with current negative mood side effects made 
significantly fewer errors of commission than OC users with no negative mood 
side effects after the sad mood induction. Finally, there was a significant sex  
difference showing that men made significantly fewer errors of commission 
compared to women after the happy condition.  
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Hypothesis 4: OC users differ in their overall performance on the 
cognitive and perceptual tasks as a function of the mood primes compared to 
nonusers and men. Data for Hypothesis 4 was screened for normality. There 
were 7 outliers detected and removed from the analyses.  
In order to examine group differences in performance on the cognitive 
tasks, a 3-way multivariate analysis was conducted to determine if the groups (OC 
users, nonusers, and men) differed in their overall performance on the two 
cognitive tasks (facial emotion recognition and GoNogo task) as a function of the 
mood inductions. Group was used as the independent variable and total 
performance scores were used as the dependent variables. Total performance 
scores were derived from total correct scores from the facial emotion recognition 
task and total scores from the Go Nogo task after each emotion induction (sad, 
happy and fear), resulting in six scores: Total correct score on the facial emotions 
recognition task after the sad mood induction, total correct scores on the GoNogo 
task after the sad mood induction, total correct score on the facial emotions 
recognition task after the happy mood induction, total correct scores on the 
GoNogo task after the happy mood induction, total correct score on the facial 
emotions recognition task after the fear mood induction, and total correct scores 
on the GoNogo task after the fear mood induction. These scores were then 
converted into z-scores. The means for the two scores for each induction were 
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then added together to create 3 scores: overall mean performance after the sadness 
induction, overall mean performance after the happy induction, and overall mean 
performance after the fear induction (see Table 15 for means and standard 
deviations).  
A MANCOVA was run with group (OC users, nonusers, and men) as the 
independent variable and overall mean performance scores after each emotion 
induction (sad, happy, fear) as the dependent variable. The analysis showed there 
was not a significant overall multivariate group effect for performance on the 
cognitive tasks after each mood inductions, F (6, 244) = 0.927, p = .476 partial η2 
= .022, power = .364. To explore overall performance on the tasks regardless of 
mood side effects, a follow up ANCOVA was conducted with group (OC users, 
nonusers, and men) as the independent variable and overall total mean 
performance (mean of the performance z-scores across each mood induction) as 
the dependent variable. Results revealed no significant univariate effects, F(2, 
123) = 1.374, p = .257, partial η2 = .022, power = .291.  
Finally, sex differences were examined. A 3-way MANCOVA was 
conducted with sex (male, female) as the independent variable and total 
performance scores after each mood induction (sad, happy, fear) as the three 
dependent variables. There was no overall multivariate group effect F(3, 127) = 
.719, p = .542, partial η2 = .017, power = .200.  




Means (and Standard Deviations) of the Total Performance z-Scores on Cognitive 
Tasks Performed after Three Mood Inductions (sad, happy, fear) as a function of 
group (OC users, Nonusers, Men, Women) for Hypothesis 4 
__________________________________________________________________ 
Variable  OC Users Nonusers Men  Women 
   (n = 50) (n = 42) (n =35) ( n = 97) 
__________________________________________________________________ 
Performancesad -.014 (.817) .046 (.551) .225 (.520) .023 (.743) 
Performancehappy -.008 (.650) .157 (.492) .223 (.438) .062 (.621) 
Performancefear -.051 (.852) .105 (.600) .163 (.490) .021 (.767) 
__________________________________________________________________ 
Performanceoverall -.024 (.698) .102 (.407) .204 (.385) .035 (.623) 
__________________________________________________________________ 
Note. OC = Oral contraceptives. The subscripts below Performance: sad, happy, fear 
refer to performance on two cognitive and perceptual tasks (i.e., Facial Emotions 
Recognition task and GoNogo task) after each emotion induction; sad, happy, 
fear, or overall performance, respectively. 
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Overall, the hypothesis that OC users differ compared to nonusers and 
men in their overall performance on the cognitive and perceptual tasks as a 
function of mood prime was not supported. Instead no group differences were 
found in overall performance on the cognitive and perceptual tasks. 
Discussion 
Summary of the Results 
Hypothesis 1 was not supported, as the results indicated no evidence of 
reduced PA reactivity across the lab session among OC users compared to 
nonusers and men. However, results did show that OC users and women as a 
group had higher NA reactivity across the lab session compared to men, and 
higher mean NA scores compared to men.  The higher NA reactivity and higher 
NA scores in OC users compared to men appears to be due to particularly high 
NA and NA reactivity in longer term OC users (i.e., > 23 months) as opposed to 
shorter duration users (i.e., < 24 months). Results also showed that men had 
overall higher mean PA scores than OC users, nonusers, and women, especially 
OC users that have been taking OC users for 23 months or less. No differences 
were found in NA and PA reactivity as a function of type of OC (e.g., phasic 
formulation or progesterone generation).  
For Hypothesis 2, results did not support the hypothesis that OC users 
with current negative mood side effects would have quicker response times and 
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have overall more errors on the facial emotion recognition task than OC users 
with no negative mood side effects, nonusers, and men. OC users with negative 
mood side effects and OC users with no mood side effects were collapsed onto 
one OC users group for analyses. Results indicated that OC users had the quickest 
response times to negative faces compared to men. When response times were 
examined as a function of mood induction type, men had slower response times 
compared to both OC users and nonusers after the sad induction, and slower 
response times than OC users after the fear induction. There were no group 
differences in response times after the happy induction, or in overall correct or 
incorrect scores. Examination of sex differences paralleled these results (women 
faster than men in response times to negative faces), but only after the happy 
mood induction condition.  
Results for Hypothesis 3 showed partial support for the hypothesis that 
OC users would make more errors of commission, especially after the positive 
mood induction compared to nonusers and men. There were no significant group 
differences for overall errors of commission, however there was a trend for OC 
users to make more errors of commission compared to men. Also, the results 
supported the hypothesis that OC users would make more errors of commission 
after the happy mood induction. There were only significant group differences 
between OC users and men, however, and no significant differences between OC 
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users and nonusers on errors of commission. Additional analyses also revealed 
that OC users with current negative mood side effects made significantly fewer 
errors of commission than OC users with no negative mood side effects after the 
sad mood induction. Finally, there were significant sex differences showing that 
men have lower errors of commission compared to women after the happy 
condition. 
Finally, for Hypothesis 4, the hypothesis that OC users would differ 
compared to nonusers and men in their overall performance on the cognitive and 
perceptual tasks as a function of mood prime was not supported. Instead no group 
differences were found in overall performance on the cognitive and perceptual 
tasks. 
Men Had Lower NA Scores, Lower NA Reactivity, and Higher PA Scores 
Compared to Women Using OCs and all Women (both OC Users and 
Nonusers) 
Hypothesis 1 was an attempt to replicate the findings in the Jarva and 
Oinonen study (2007). The hypothesis was also based on evidence that women on 
OCs have been shown to have lower levels of endogenous neurosteroids (both 
progesterones and estrogens) (Folessa et al. 2002) and a blunting of the cortisol 
response (Kirschbaum, Pirke & Hellhammer, 1995).  Thus, the logic followed, 
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that women on OCs may have a blunting of affect as a result of the blunting of 
neurosteroids and cortisol.   
The results indicated no evidence of reduced PA reactivity across the lab 
session among OC users compared to nonusers and men. Instead, the results 
revealed no significant differences in PA reactivity between groups. An 
examination of the Jarva and Oinonen (2007) study revealed several important 
differences from this current study that could explain the discrepancy in results. 
The Jarva and Oinonen study induced different types of moods and used different 
mood induction methods than this current study. Jarva and Oinonen (2007) 
induced positive affect by having the participants view a comedic video, jealousy 
by having participants read and visualize a script designed to induce jealousy, 
social ostracism by having the participants play a Cyberball game in which they 
were systematically excluded, and parental feelings by having participants view a 
slide show of human babies. Additionally, the methods of mood induction in their 
study were varying in format (i.e. reading a vignette, watching a video, or playing 
a game) whereas the methods of mood induction in our current study were 
consistent in format (i.e. emotional videos paired with mood congruent music). 
Therefore, the mood induction methods in the Jarva and Oinoen (2007) study may 
not be directly comparable to the mood induction methods used in this current 
study. It is possible that a blunted PA response in OC users is more easily 
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demonstrated when a variety of mood priming techniques are used or when some 
specific types of emotions are primed.  
As an example, the Jarva and Oinonen (2007) finding of a blunting of PA 
among OC users compared to nonusers and men may have been due to the fact 
that women on OCs may not have reacted as strongly positively to the slideshow 
aimed at inducing parental feelings. It can be presumed that most women on OCs 
do not have any current desire to get pregnant and, therefore, may not have felt as 
positively as other groups towards pictures of human babies. The positive mood 
induction used in our study evoked a variety of different positive emotions rather 
than comedy and parental feelings. The happy induction for this current study 
included videos of humans of all ages and races laughing, people winning game 
shows and celebrating, and families being re-united with pets that were excited to 
see them. Therefore, our positive mood induction was more general, and not 
targeted to parental feelings, which may explain the lack of difference in PA 
reactivity between groups in our study.  
Despite not being able to replicate the Jarva and Oinonen (2007) finding 
of blunted PA in OC users, the results from analyses related to the first hypothesis 
did reveal some noteworthy findings worth discussing. First, the results indicated 
that OC users had higher NA reactivity compared to men and higher mean NA 
scores than men. The higher NA reactivity and higher mean NA scores compared 
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to men were also especially found among women who were taking OCs for 24 
months or more. This demonstrates that overall, OC users endorsed higher 
feelings of negativity, distress, and unpleasant mood states throughout the study, 
and had greater change in their negativity scores from one induction to the other, 
especially if OC users were taking OCs for 24 months or longer. On the other 
hand, the lower levels of negative affect endorsed by men indicate that men felt 
overall more calm and secure throughout the study and from one mood induction 
to the other.  
The findings of OC users and negative affect are somewhat consistent 
with previous research on OCs and affect when OC type is taken into 
consideration. Interestingly, although we did not find significant differences in PA 
or NA reactivity as a function of type of OC, most of the women in the OC group 
were on a second generation OC containing levonorgestrel or norethindrone 
progesterones (n =32). Previous research has indicated that levonorgestrel 
containing OCs are most highly associated with negative mood side effects 
(Gingnell at al., 2013; Kurshan & Epperson, 2006). On the other hand, for this 
current study, only a few women were taking new generation OCs containing 
drospirenone progesterone (n = 3). In their review, Kurhsan and Epperson (2006) 
found that new generation pills containing drospirenone progesterone were related 
to positive mood side effects. Therefore, it is possible that the OC users in this 
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current study were ones that were most susceptible to negative affect. Moreover, 
the longer the women have been taking the OC (i.e. 24 months or longer) the 
more pronounced the negative affect may be. Jarva and Oinonen (2007) did not 
investigate generation of OCs or type of progesterone in OCs as it related to PA 
and NA variability (reactivity). Therefore, it is not known if there is a certain 
progesterone component found in certain types of OCs that may be related to a 
blunting of PA.  Future research should continue to investigate the varying 
reactions to emotional stimuli as a function of OC type.  
Additionally, along with OC users showing higher NA reactivity and 
higher mean NA score compared to men, the results showed that OC users and 
nonusers had overall lower mean PA scores than men. Lower PA scores are 
indicative of feeling of low mood and lethargy whereas higher PA scores are 
indicative of feelings of high energy, concentration, and pleasurable engagement 
(Watson, Clark, & Tellegen, 1988). This result is interesting because, at face 
value, it may suggest that men experience more positive affect than women (both 
OC users and nonusers). However, previous research has demonstrated minimal 
sex differences in self-reported positive affect with some studies finding women 
having higher PA than men and women generally experiencing all emotions more 
intensely than men (Fujita, Diener, & Sandvik, 1991; Grossman & Wood, 1993; 
Kring and Gordon, 1998). Therefore, instead of indicating that men are generally 
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more positive than women, the results may instead indicate a unique way in which 
men react to negative stimuli compared to women.  
In this current study, along with higher mean PA scores, men also had 
lower mean NA scores than OC users and women. This may suggest that men are 
less likely to endorse negative reactions to negative mood inductions, possibly 
due to a social desirability effect or a social-cultural response set. For example, a 
study by Kring and Gordon (1998) had men and women view happy, sad, and fear 
related movie clips and complete the Bem Sex Role Inventory to collect 
information about gender roles, masculinity, and femininity. They found men 
were more likely to be higher in elecotrodermal reactivity (as measured by skin 
conductance tests) but lower on facial emotion expressions compared to women 
which, as the researchers described, indicated internalizing emotions. 
Additionally, they found that more androgynous men were more facially 
expressive during mood inductions compared to more masculine men. This 
suggests that that socio-cultural gender roles may influence emotion expression.  
Furthermore, there is evidence that emotion suppression may be reflected 
in performance on cognitive and perceptual tasks. Pu, Schmeichel, and Damaree 
(2009) found that participants who were suppressing their emotions during a 
negative emotional video performed worse on verbal and spatial working memory 
tasks than those who did not suppress emotions and than those in the neutral film 
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condition. Pu, Schmeichel, and Damaree (2009) explained that emotion 
suppression taxes one’s cognitive resources and thus may explain differing 
performances on tasks compared to individuals that did not suppress emotions. 
While men did not perform worse on the tasks in this current study, perhaps their 
differing response times compared to women (on the Facial emotion recognition 
tasks: see Hypothesis 2) may be indicative of more cognitive effort required when 
suppressing emotional reactions. 
In order to investigate whether or not men suppress their negative 
emotional reactions to mood inductions, future studies should include more 
sensitive measures of emotion or physiological measures that reflect emotion, 
rather than explicit self-report measures such as the PANAS. This current study 
included the Physical Experiences of Emotions Questionnaire (PEEQ) as a 
measure designed to capture physical sensations after each emotion induction. It 
may be valuable to examine men’s physical symptoms after the mood inductions. 
Perhaps men do not differ in their physical responses to the mood inductions 
compared to OC users and nonusers, but only their self-reported emotional 
reactions differ. If this were the case, it may lend support for the idea that men are 
experiencing the mood inductions similarly to the other groups of women, 
however they are suppressing or downplaying their self-reported emotional 
reactions. Additionally, future research should compare response times to each of 
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the items on the PANAS among groups. If men, for example, take longer when 
responding to certain PANAS items related to the mood induction, it may also 
lend support for the idea that men are suppressing their emotional reactions.  
Furthermore, the higher NA scores and higher NA reactivity in OC users 
compared to men was strongest for women that have taken OCs for 24 months or 
more whereas the lower mean PA scores for OC users compared to men was 
strongest in OC users that have been using OCs for 23 months or less. These 
results indicate that perhaps lower PA may affect OC users during the beginning 
of OC use, whereas higher negative affect level and reactivity may develop later, 
after prolonged use. However, an examination of the means reveals that the earlier 
OC users and later OC users do not differ significantly from each other, and their 
mean scores on the PA and NA variables are not significantly different from one 
another. While it may therefore be valid to include OC users of varying lengths in 
one group, one should keep in mind that the survivor effect is more likely apply to 
the longer-term than the shorter-term users and the longer-term users are more 
likely to be women who have not experienced mood problems due to OC use.  
As noted above, there was no support for the hypothesis that OC use is 
associated with a blunting of PA. While various explanations for the finding are 
discussed above, it is important to note that the failure to find support for this 
hypothesis may be due to an absence of an effect. Given the noted strengths of the 
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current study, it is possible that the previous finding of blunted PA in OC users 
from the Jarva and Oinonen (2007) study was a spurious finding or a Type I error.  
Men Had Slower Response Times Compared to Women Using OCs with No 
Mood Side Effects, and Women Using OCs in General, Especially After 
Negative Mood Inductions 
The second hypothesis was based on the findings from Gingnell et al. 
(2013) who found that women on OCs with current negative mood side effects 
had quicker response times for angry and fearful faces. Moreover, Gingnell et al. 
(2013) found that when women on OCs with current negative mood side effects 
were viewing negative faces, there was lower activity in brain areas responsible 
for emotional distraction, and processes related to executive control and social 
interactions such as response inhibition and empathy (the inferior frontal gyri) 
(Hampshire et al., 2010; Liakakis et al. 2011; Wang et al., 2008). Thus, it was 
hypothesized that for this current study, women on OCs with current negative 
mood side effects would have quicker response times to negative faces. Faster 
response times to negative faces were then hypothesized to be further pronounced 
after negative mood induction. Moreover, it was predicted that they would make 
overall more facial emotion recognition errors compared to OC users with no 
negative mood side effects, nonusers, and men.  
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Our results did not show that women on OCs with current negative mood 
side effects had quicker response times to negative faces and overall more errors 
on facial recognition task than the other groups. There are some methodological 
differences that may explain the discrepancy in the findings between the current 
study and that of Gingnell et al. (2103). For example, the Gingnell at el. (2013) 
study did not induce mood prior to administering their facial identification task. 
Therefore the inconsistent findings related to response times to negative faces 
between the current study and the Gingnell et al. (2013) study may be due to the 
fact that the OC users with current negative mood side effects respond differently 
to negative faces when mood is induced. Data from Gingnell et al. (2013) 
indicated that women on OCs with current negative mood side effects showed 
brain patterns indicative of low emotional distraction when viewing angry and 
fearful faces. In their study, however, there were no other distractions or mood-
related stimuli beyond the presentation of negative faces. In this current study, the 
facial emotion recognition task was administered immediately after a highly 
emotional video, and music continued playing throughout the task. Therefore, the 
current study had far more emotional distractions that could have washed out the 
effects related to low emotional distraction as seen in Gingnell et al. (2013).  
Additionally, the Gingnell et al. (2013) facial task differed from the facial 
task in this current study. Gingnell et al. (2013) required their participants to view 
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a target face, and then choose out of two other faces which one matched the 
emotion expressed in the target face. Therefore, their participants were required to 
make nonverbal judgments about the emotional likeness of two faces, rather than 
choose between two verbal labels of emotions. The two facial tasks may have 
been tapping into different brain processes, one with a verbal component and one 
without a verbal component. Interestingly, previous research has indicated that 
hormones are related to brain lateralization patterns during cognitive tasks. For 
example, Hausmann et al. (2000) found that during low progesterone phase (early 
follicular phase) women showed lateralization on tasks for which lateralization is 
typically found, such as a verbal task, whereas during high progesterone phase 
(mid luteal phase), women show less lateralization on tasks where lateralization is 
typically found. Furthermore, it has been found that women on OCs have overall 
lower levels of neurosteroids (including progesterones) compared to naturally 
cycling women (Folessta et al., 2002; van Heusdan, & Fauser, 1999). Therefore, it 
follows that women on OCs may be more likely to show lateralization on tasks 
where lateralization is typically found such as verbal tasks or visual spatial tasks 
(Hausmann et al., 2000). Incidentally, the Gingnell et al. (2013) facial emotion 
recognition task may have been tapping into right brain processes, while the facial 
emotion recognition task in the current study may have been tapping more into 
left brain processes. Future research should examine if effects of OCs on 
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emotional expression identification are more likely using facial emotion 
expression recognition tasks that focus more activation on the right hemisphere as 
opposed to those with relatively higher left hemisphere activation (as in language 
or verbal tasks). It is possible that a tasks’ relative activation of the right versus 
left hemisphere may be related to the likelihood that OC use and emotional side 
effects affect performance.  
Aside from methodological differences, there were also group differences 
between the current study and the Gingnell et al. (2013) that may also explain the 
discrepancy in the results. Gingnell et al. compared OC users with current 
negative mood side effects to nonusers with previous negative mood side effects 
from OCs. On the other hand, this current study had OC users with no negative 
mood side effects, nonusers, and men as the comparison groups. Therefore, the 
results of quicker response times to negative faces and possible differences in 
emotional distraction among OC users with current negative mood side effects 
may only be relevant when compared to nonusers with previous negative mood 
side effects from OCs.  
It is important to note, however, that this current study had a number of 
methodological similarities and strengths compared to the Gingnell et al. (2013) 
study. The current study included women in the group with current negative OC 
mood side effects if they endorsed one negative emotional symptom from a list of 
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14 negative symptoms. In the Gingnell et al. (2013) study, the women on OCs 
with current negative mood side effects were determined by a semi-structured 
interview in which the women were required to endorse at least one of the 
following symptoms as a result of OC use: depressed mood, decreased interest in 
usual activities, anxiety, mood swings, and irritability.  Therefore, the criteria for 
inclusion in the group of current OC users with negative mood side effects were 
similar for both studies. However, for this current study, participants had a longer 
list of negative mood side effects to select. Therefore, the OC users with current 
negative mood side effects in our study may be a more robust or representative 
sample of women on OCs with current negative mood side effects.  
Additionally, the sample of women on OCs with current negative mood 
side effects for both studies was similarly small. For the current study, the sample 
size for women on OCs with current negative mood side effect was n = 15. For 
the Gingnell et al. (2013) study, their sample size for women on OCs with current 
negative mood side effects was n = 17 and their sample size for women on 
placebo with previous negative mood side effects from OCs was n = 18.  
Therefore both sample sizes may not have been large enough to detect an effect if 
it exists. This increases the likelihood of both Type I and Type II errors.  In fact, 
an examination of the response time means for this current study indicates that the 
response times for OC users with current negative mood side effects were in the 
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opposite direction than was expected. Although non-significant, OC users with 
current negative mood side effects in this current study had the slowest response 
times to negative faces after men. Therefore, even if the current study included a 
larger sample of OC users with current negative mood side effects, there still may 
not have been a significant effect. Instead, it is possible that OC users with current 
negative mood side effects in fact do not typically show faster response time to 
negative faces and that the results from the Gingnell et al. (2013) may instead be 
spurious findings (i.e., a Type I error). 
Nevertheless, because the sample of OC users with current negative mood 
side effects was small, the analyses were re-run by grouping all OC users together 
regardless of current mood side effects. When OC users were compared to 
nonusers and men, an interesting pattern was found that approached the 
hypothesis of OC use being associated with response times to negative faces. OC 
users had the quickest response times to negative faces and were significantly 
faster than men. Moreover, when response times were examined as a function of 
mood induction, men showed the slowest response times compared to both OC 
users and nonusers after the sad induction, and slower response times than OC 
users after the fear induction. There were no group differences in response times 
after the happy induction. Because there were no group differences in response 
time after the positive (happy) mood induction, the results suggest that response 
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times in specific groups (i.e., OC users versus men) were indeed influenced by 
negative mood primes, especially the fear induction. This may indicate that OC 
users differ in some important way in their fear response compared to men and 
nonusers.  
No previous research appears to have specifically examined differences in 
fear response as a function of OC use. However, previous research has examined 
stress and cortisol responses in women on OCs. Previous studies have indicated 
that women on OCs have an attenuated cortisol response (i.e., Kirschbaum, Pirke 
& Hellhammer, 1995; Het & Wolf, 2007) and that cortisol enhances fear 
conditioning (Merz et al., 2012). If women on OCs would have weaker a cortisol 
response and a weaker conditioned-unconditioned stimulus differentiation, then 
women taking OCs would be less able to implicitly or automatically differentiate 
relevant fearful stimuli from irrelevant stimuli and may thus overreact to 
irrelevant stimuli. Faster response times after the fear condition, therefore, may be 
a manifestation of this overreaction to stimuli. Future research should further 
investigate how OC users may differ from other groups in their response to fear as 
well as other negative emotions.   
Examination of sex differences was similar to the results found when 
investigating OC users, nonusers, and men. Men showed overall significantly 
slower response times to negative faces than women regardless of mood 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
138 
induction, and men showed significantly slower response times to negatives faces 
after all the mood inductions (sad, happy, and fear) compared to women. Because 
sex differences were found, it is difficult to determine if the above differences 
between OC users and men are driven by OC use itself or if the difference are 
simply indicative of an overall sex difference. However, there were no significant 
differences between men and nonusers on overall response times, and response 
times after the fear mood induction. Therefore, on variables where men and 
women differ, but men and nonusers do not, the sex differences found may appear 
because the OC users group is driving those differences. Indeed, results reveal 
important differences specifically between OC users and men that are consistent 
across hypotheses.  
For instance, men showed less NA reactivity, endorsed lower mean NA 
scores, and responded more slowly to identify negative facial expressions as 
compared to OC users. Two possible explanations for these group differences in 
response times to negative faces are discussed below. First, men’s longer response 
times to negative faces may be indicative of the fact that they are responding to 
mood incongruent stimuli whereas OC users’ faster response times may be 
indicative of responding to more mood congruent stimuli. Second, men’s longer 
response times may be indicative of more cognitive effort required when 
suppressing emotions (as discussed above in Hypothesis 1), whereas OC users’ 
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faster response times may be indicative of higher emotional reactivity compared 
to men.  
First, the possibility that men’s longer response times are indicative of 
responding to mood incongruent stimuli will be discussed. Previous research has 
indeed found a link between faster response times and mood congruent stimuli 
and longer response times and mood incongruent stimuli (Albert, Martin, & 
Carretie, 2010; Cavanagh & Geisler, 2006; Gasbarri et al., 2008). Along with 
lower NA scores, and lower NA reactivity, as discussed above, men also endorsed 
higher mean PA scores compared to OC users, and women. Therefore, men 
generally endorsed more positive affect throughout the study and may have taken 
longer to respond to the negative faces because of the cognitive effort required to 
respond to mood incongruent stimuli. On the other hand, OC users and women as 
a group endorsed higher NA scores and NA reactivity across the laboratory 
session. Therefore, their shorter response times for the negative faces may be 
indicative of the relative ease of responding to mood congruent stimuli. In order 
to test this hypothesis, an ANCOVA was run with group (OC users, nonusers, and 
men) as the independent variable, response times to negative faces as the 
dependent variable, and NA scores, PA scores, NA change and PA change scores 
as four new covariates. Age was also used as a covariate consistent with the above 
analyses. Results indicated that the univariate group effect remained, F(2, 131) = 
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4.098, p =.019, partial η2 =  .059, power = .718. Therefore, when affect is 
controlled for, group differences in response times remain. Thus, the slower 
response times seen in men compared to OC users cannot necessarily be 
explained by group differences in affect which would play a role in the extent to 
which the groups differed in exposure to mood incongruent or mood congruent 
stimuli.  
Moreover, in order to further determine if response times are a function of 
mood incongruent or congruent stimuli, response times to positive faces would 
also have to be examined. Since men had higher PA scores, their response times 
may be faster for positive faces compared to their response times to negative 
faces. Moreover, since OC users had higher NA scares, their response times may 
be slower for positive faces relative to their response times to negative faces. 
Future research should be conducted in order to examine how OC users, nonusers, 
and men differ in their responses to negative and positive faces subsequent to 
mood induction. However, if it was found that men had slower response times and 
OC users had faster response times regardless of whether facial expressions were 
negative or positive, then the theory that response times are due to mood 
congruent or incongruent stimuli would not be supported. Instead, it may then 
lend support to the possibility that men’s longer response times to faces (both 
positive and negative) are reflective of men suppressing their emotional reaction, 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
141 
thus using more cognitive effort, and resulting in longer response times 
(Grossman & Wood, 1993; Kring and Gordon, 1998; Pu, Schmeichel, & 
Damaree, 2009). Additionally, it may provide support for the possibility that OCs 
users are generally more emotionally reactive to emotional stimuli resulting in 
faster response times regardless of whether the faces are negative or positive.  
As discussed above with reference to hypothesis 1, Pu, Schmeichel, and 
Damaree (2009) explained that emotion suppression taxes one’s cognitive 
resources and thus may explain differing performances on tasks compared to 
individuals that do not suppress emotions. Therefore men’s slower response times 
to negative faces compared to women may indicate that men are suppressing their 
emotional reaction to negative stimuli, which requires more cognitive effort, and 
therefore are taking longer to respond to the stimuli. In order to investigate this 
speculative possibility, however, future studies should have OC users, nonusers, 
and men perform similar tasks at baseline, and then compare their performance on 
the same tasks after mood inductions. If men do not show a delay in response 
times at baseline, but do show a delay in response after mood inductions, it may 
provide evidence to support the theory that slower response times in men are 
related to emotion suppression. Similarly, if OC users do not show faster response 
times at baseline, but do show faster response times after mood inductions, it may 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
142 
provide evidence to support the possibility that faster response times are related to 
higher emotional reactivity.  
Despite the group differences found in response times, there were no 
group differences in overall correct scores or overall errors. The theory behind the 
hypothesis that there would be a group difference in correct responses was based 
on the Gingnell et al. (2013) study that indicated that the women on OCs with 
current negative mood side effects showed higher activity in the left insula 
(related to emotional distraction) when viewing the negative faces. One limitation 
of the current study, however, is that MRI scans were not used. Therefore, it is 
difficult to determine if the facial emotion recognition tasks tapped into the 
intended brain areas (i.e. the left insula) as in the Gingnell et al. (2013) study.  
An additional explanation for a lack of significant difference in 
performance on this task is that facial emotion recognition tasks are relatively 
easy to complete for most adults. The task used for this current study included 
faces that expressed emotions that had high inter-rater reliability for 
identification. Moreover, the task only provided two possible options for the 
emotion. Although this task was created by systematically choosing response 
options with the intention of making the task slightly more difficult, the emotions 
expressed in the images may have been too obvious resulting in a ceiling effect. 
Overall, the participants got 90.53% of the answers correct on the facial emotion 
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recognition task across all mood inductions. In order to make the task more 
difficult for the future, it might be a good idea to add more response options, or 
only use facial expressions that tend to be more ambiguous such as surprise or 
disgust. Also, as discussed previously, the current task included a verbal 
component that required participants to choose a verbally labeled emotion 
response option for each facial expression, whereas the participants in the 
Gingnell at al. (2013) study were required to use their nonverbal skills to match 
faces based on expression. This methodological difference may also account for 
the different results between the two studies.   
Although no overall group differences in number of correct or incorrect 
response were found, it would be interesting to analyze the errors that were made 
in order to determine if there was a response bias. For example, when women on 
OCs did make errors on the facial emotion task, it would be interesting to 
investigate if they were more likely to incorrectly choose a negative emotion (as 
opposed to a positive emotion) for a neutral face. Furthermore, it would be 
interesting to investigate the pattern of response times. As mentioned above, 
because men demonstrated longer response times than women, especially OC 
users, it would be interesting for future studies to examine if men also had longer 
response times when viewing positive faces compared to women in general, as 
well as OC users, and non users.  
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Women on OCs Make More Errors of Commission on the GoNogo task than 
Men, Especially During the Positive Mood Induction 
Hypothesis 3 was based on previous evidence suggesting that it is more 
difficult to inhibit a response when the background image on a GoNogo task was 
a positive image, rather than a negative or neutral image  (Albert, Lopez-Martin, 
& Carretie, 2010), and that women on OCs tend to have lower levels of PPI which 
may be indicative of GABAeric disturbances (Borgstrom et al., 2008; Follesa et 
al., 2002; Schultheiss, Patalakh, & Rosch, 2012) and difficulty in filtering out 
unnecessary stimuli compared to nonusers and men (Borgstrom et al 2008; 
Holloway, Beck, & Servatius, 2011). Therefore, it was hypothesized that women 
on OCs would make overall more errors of commission than nonusers and men, 
especially after the positive mood induction.  
Results from the analyses show partial support for hypothesis 3. There was 
no significant group difference in overall errors of commission. However there 
was a trend in the expected direction with OC users making more errors of 
commission than men. Indeed, this trend became significant when commission 
errors were examined after each emotion induction. Women on OCs made 
significantly more errors of commission than men after the happy mood 
induction. Albert, Lopez-Martin, and Carretie (2010) concluded, in their study, 
that withholding a prepared response (i.e. not pressing the space bar when you see 
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a W) within a positive context consumes greater inhibitory resources than within a 
negative context. Therefore, examining errors of commission after positive mood 
induction was a more sensitive method of examining differences in inhibitory 
response between groups.  
The results from this current study suggest that women on OCs may be 
more impulsive and have a harder time inhibiting their responses compared to 
men. Additionally, the results from this third hypothesis are congruent with other 
findings from tests of the previous hypotheses in that all three findings show that 
women on OCs are more highly reactive then men. Higher mean NA level, higher 
NA reactivity across the laboratory session, faster response times to negative 
emotional faces, and higher errors of commission on a task of inhibition all lend 
support to the possibility that OC users may be a more reactive group than men. If 
OC users are indeed a more reactive group, it makes sense that they would have a 
decreased ability to inhibit their responses compared to men. Indeed previous 
literature on both clinical and non-clinical populations has linked high emotional 
reactivity with more difficulty inhibiting responses or more activated states and 
low emotional reactivity with more inhibited states (Hare, Tottenham, Galvan, 
Voss, Glover,  & Casey, 2008; Henry, M’Bailara, Desage, Gard, Misdrahi, & 
Vieta, 2007).  
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Interestingly, previous studies have indicated a possible mechanism 
underlying lower levels of inhibition or reactivity among women on OCs. Past 
studies have found that OCs are related to GABAergic disturbances which are, in 
turn, related to inhibitory processes. For example, Schultheiss, Patalakh, and 
Rosch (2012) explained that progesterone influences cognition, emotion, and 
behaviour by binding to the GABA receptors, which have an inhibitory effect on 
neural signal transmission. Also, it has been shown that levonorgestrel OCs 
(second generation OC) have resulted in decreased levels of progesterone and its 
GABAA receptor-active metabolite allopregnanolone in both rats and women 
(Follessa et al., 2002). Therefore, certain OCs have been shown to reduce GABAA 
receptor-active metabolites and decrease inhibitory responses. Moreover, 
alterations in GABAergic systems have been shown to contribute to deficits in 
inhibitory responses such as deficits in PPI (Borgstrom et al., 2008).  
Indeed, our results indicated that women on OCs had lower inhibition 
compared to men. Moreover, the majority of women in the current study were 
taking a levonorgestrel OC (second generation OC). Therefore, differences in 
GABAergic processes may have been the underlying mechanism behind the 
differences in inhibitory responses between men and OC users in this study. 
Future research should investigate GABAergic processes as a potential underlying 
mechanism for inhibitory responses. For example, future research could have one 
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group of women on OCs take a GABAA receptor metabolite allopregnanolone, 
and one group of women on OCs take a placebo. If group differences appeared in 
responses of inhibition, it would support the idea that GABAergic processes are a 
potential underlying mechanism for the differing inhibitory responses found 
between groups of women, and men.   
Along with group differences between OC users and men, results from the 
current study also revealed differences between groups of OC users. Indeed, OC 
users with current negative mood side effects had significantly fewer errors of 
commission after the sad mood induction compared to OC users with no negative 
mood side effects. These results are interesting because they suggests that OC use 
may differentially affect response inhibition depending on mood side effects. An 
examination of the trends indicates that OC users with negative mood side effects 
also had more correct responses overall, and higher mean correct responses after 
the sad mood induction compared to OC users with no negative mood side effects. 
Therefore, women on OCs with current negative mood side effects outperformed 
women on OCs with no current negative mood side effects on the GoNogo task. 
One possible explanation for OC users with current negative mood side 
effects outperforming OC users with no current negative mood side effects is that 
response inhibition is easier when the emotional context of the response inhibition 
is negative or neutral (i.e. the respondent is required to inhibit a response while 
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viewing a negative or neutral photograph) (Albert, Lopez-Martin, & Carretie, 
2010). Furthermore, previous research has correlated depression and depressed 
mood with psychomotor retardation and delayed responses to stimuli (see review 
by Lecrubier, 2005). Therefore, when individuals are currently experiencing 
negative mood side effects, they may outperform others on tasks of response 
inhibition, especially after a sad mood induction. Also, because OC users with 
negative mood side effects only showed lower errors of commission during the 
sad emotion induction, it indicates that OC users with negative mood side effects 
were able to outperform OCs users with no negative mood side effects only when 
the mood induction was congruent with their current mood. For example, most 
women on OCs with current negative mood side effects in this current study 
endorsed symptoms related to sad mood such as: cried more than usual, more 
moody, and sadness. All of these symptoms could have been especially enhanced 
after the sad mood induction.  
Future research should also include an analysis of response times on the 
GoNogo task. Longer response times, for example, may be related to fewer errors 
of commission. If OC users with current negative mood side effects showed 
longer response times compared to OC users with no negative mood side effects, 
it may lend support for the idea that OCs users with current negative mood side 
effects were slower in their responses possibly due to a psychomotor delay related 
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to negative mood symptoms. Moreover, if men show longer response times 
compared to OC users, it may indicate that men were suppressing their emotions, 
thus using more cognitive effort and slowing their response times to the stimuli in 
the GoNogo task. To test these possibilities two MANCOVAs were run (using 
age a covariate). For the first MANCOVA, group (OC users with negative mood 
side effects, and OC users with no negative mood side effects) was the 
independent variable, and mean response times after each emotion induction (sad, 
happy, fear) was the dependent variable. Results indicate a trend for an overall 
multivariate effect, F(3, 48) = 2.244, p = .095, partial η2 = .123, power = .534.  
Follow up univariate tests confirm that mean response times for women on OCs 
with current negative mood side effects (M = 0.398 SD = 0.041) were 
significantly longer than response times for women on OCs with no negative 
mood side effects (M = 0.372, SD = 0.032) only after the sad mood induction, 
F(1, 50) = 6.789, p = .012, partial η2 = .120, power = .724.  
For the second MANCOVA, group (OC users, nonusers, and men) were 
the independent variable and mean response times on the GoNogo task after each 
emotion induction (sad, happy, fear) were the dependent variables.  Interestingly, 
despite men’s lower errors of commission, there were no group differences on 
overall response times, F(2, 127) = 2.293, p = .105, partial η2 =  .035, power = 
.459, or response times after each emotion induction, F(6, 252) = 1.371, p = .227, 
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partial η2 = .032, power = .532. Therefore, if men are indeed suppressing their 
emotional reaction to the mood induction stimuli, the suppression is not reflected 
in longer response times.  
Finally, sex differences were found in the current study with men showing 
significantly lower errors of commission compared to women after the happy 
induction. These results parallel the above results that found women on OCs had 
higher errors of commission than men after the happy mood induction.  Therefore, 
since men and nonusers did not differ significantly in their errors of commission 
after the happy induction, this suggest that the sex difference found may be driven 
by the OC user group. 
It would be interesting to further investigate the sex differences in 
inhibitory responses as they related to GABAergic systems as discussed above. 
For example, future studies could test levels of progesterone (or specifically 
allopregnanolone which has been shown to bind to a GABAA receptor) in women 
and men. If lower levels of GABAA receptor progesterones are found in women 
compared to men, it may support the idea that these progesterones are the 
potential mechanisms behind inhibitory responses. Moreover, it would be 
expected that levels of GABAA receptor progesterones would differ between OC 
users and nonusers, with OC users having the least amount (Folessa at al., 2002). 
Future studies should further investigate the differences in inhibitory responses 
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between men, nonusers, and OC users using tasks of inhibition such as the 
GoNogo task and other known tasks that tap into inhibitory processes such as a 
Stroop task. 
One limitation for this current study was that there were no baseline 
measures for inhibitory responses without the influence of mood induction. 
Therefore, it is difficult to conclude that group difference on the GoNogo tasks 
would occur without mood induction. Future studies could include a baseline 
measure of inhibition. Therefore, scores after each subsequent mood condition 
could be compared to the baseline measure and potentially be a more sensitive 
measure of how response inhibition is influenced by mood induction.  
Women Taking OCs Do Not Differ in their Overall Performance on the 
Cognitive and Perceptual Tasks as a Function of the Mood Primes 
Compared to Women Not Taking OCs and Men 
Hypothesis 4 was an exploratory hypothesis based on previous research 
that indicated group differences in performance on various cognitive and 
perceptual tasks across many studies as a function of mood prime. For example, 
positive mood induction has been shown to improve performance on cognitive 
tasks (Brand & Opwis, 2007; Fried et al., 2001; & Lesiuk, 2010). However, 
positive mood may also be related to worse performance and more errors on 
certain tasks, such as a task of inhibition (Albert, Lopez-Martin, & Carretie, 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
152 
2010). Moreover, previous research has shown differing performance on 
cognitive tasks based on hormones. For example, women on second generation 
OCs outperformed women on first generation OCs on a mental rotation task 
(Wharton et al., 2008) and post-menopausal women taking estrogen replacement 
therapy (ERT) outperformed post-menopausal women with no ERT on tasks of 
working memory and attention. No previous research has examined overall 
performance on both a facial emotion recognition task and a GoNogo task as a 
function of OC use. 
Results from this current study did not support the hypothesis that groups 
would differ in their performance on the cognitive and perceptual tasks as a 
function of mood prime. Instead, results indicated no difference in overall 
performance on the cognitive and perceptual tasks between OC users, nonusers 
and men, or between men and women regardless of mood induction. Indeed, 
many other studies have failed to find differences between men and women on 
overall performance on cognitive tasks such as tasks of calculation, mental 
rotation tasks, spatial attention, word generation and motor tasks (Bell, Willson, 
Wilman, Dave,  & Silverstone, 2006; Kucian, Loenneker, Dietrich, Martin, &Von 
Aster, 2005; Rumberg et al., 2010).  
Additionally, some previous studies found that negative mood had a more 
complex effect on cognition. For example, rather than negative mood influencing 
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overall correct and incorrect responses, Spering, Wagener, and Funke (2005) 
found that positive and negative mood influenced their participants strategies used 
to complete the tasks. Therefore, lack of differences between OC users, nonusers 
and men on the tasks of cognition and perception may be due the fact that overall 
correct scores was not the most sensitive measure to use when looking for group 
differences on performance. Evidence from the results of the previous hypotheses, 
for example, indicated that overall mean response times, rather than overall 
correct responses, was a more sensitive measure of group differences on the facial 
emotions recognition task. Additionally, overall number of errors of commission, 
rather than total number of correct responses, was shown to be a more sensitive 
measure of group differences for the GoNogo task.  
The cognitive and perceptual tasks chosen for this study were based on 
previous research that indicated group differences on performance as well as 
evidence that each task tapped into specific brain areas related to hormone use. 
For example, the inferior frontal gyrus was shown to be activated in different 
ways depending on hormones during performance on both a task of facial emotion 
recognition (Gingnell et al., 2013) and a GoNogo task (Bannbers, et al., 2012). 
However, one limitation of this current study is that information from MRI or 
fMRI scans were not collected. Therefore, it cannot determine if the tasks were 
tapping into the intended regions of the brain.  
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Another explanation for lack of group differences in overall performance 
on the cognitive and perceptual tasks is that there may have been too much 
variance within groups. Indeed, many studies do not find differences between 
groups of women when all OC users are put into one category. The differing 
effects of current OC type (i.e. second or third generation OCs) and differing 
effects of mood side effects from OCs could lead to high group variance that may 
ultimately wash out differences between OC users and nonusers. Although this 
current study made all efforts to reduce reactivity within and between groups by 
examining group equivalency, controlling for age, and by examining Box’s M and 
Levene tests for errors of covariance, there may have still be variance within the 
groups that influenced the lack of differences found, specifically between OC 
users and nonusers. Future research should continue examining the overall group 
differences in performance on cognitive tasks as a function of mood prime. More 
participants are required, however, in order to further investigate how OC mood 
effects, OC type, for example, may further influence performance on cognitive 
and perceptual tasks.   
Limitations of The Current Study 
There were seven limitations to this study that are worth addressing. 
Firstly, one limitation of this study is regarding the representativeness of the 
sample. Almost all of the participants in the study were young university students 
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taking a psychology course. Therefore, this sample may not be representative of 
the larger population of Canada and findings may not be generalizable to 
nonstudents. Moreover, the mean age of participants in this study was 22 years 
old, therefore the results on emotional reactivity and inhibition may not be 
applicable for men and women older in age. However, it is worth noting the early 
20s is a time of high OC use and thus the sample is a relevant one. The majority 
of the sample was made up of individuals of Caucasian, or European heritage 
(84.4%), who were university educated (65.6%). Although effort to recruit outside 
of the University setting was made, the majority of the participants still fell within 
the general age, ethnicity, and education level.  
Secondly, another limitation of the current study is that the sample size of 
women on OCs with current negative mood side effects was small (n = 15) and 
may not have been powerful enough to provide a representative sample of women 
on OCs with current negative mood side effects. Moreover, women that endorsed 
as few as one current negative emotional symptom from OCs were included in the 
OC mood group. This may not have been a sensitive enough criterion to truly 
capture women with current negative mood side effects. Additionally, not all 
negative mood side effects are equal. If one individual endorsed feeling “cried 
more than usual” for example, they may not be experiencing negative mood in the 
same way as another individual that endorsed feeling “depressed”. Furthermore, 
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some of the negative mood side effects were qualitatively different such as “lower 
self-esteem” or “more self-critical” which represent general negative views 
towards the self, “pessimistic” which represents a general negative worldview, 
and “less trust in partner” which may represent a negative view towards others, or 
someone specific. Nevertheless, the examination of validity of this group 
indicated that these women did indeed differ from OC users with no mood side 
effects on some other independent important measures of affect at baseline (i.e., 
the affect intensity measure, the Hamilton rating scale for depression, and the 
behavioural inhibition system subscale). Also, it is important to note that neither 
the criteria for negative mood side effects nor the sample size were vastly 
different from other established studies. For example, the Gingnell et al. (2013) 
study also had one negative mood side effect as their minimum inclusion criteria 
for the current negative mood side effects on OCs group and they had a sample 
size of n = 17 for their negative mood side effect group.  
A third limitation was that there were not enough women in this sample 
that were taking a new generation OC (n = 3). Previous research has indicated that 
this group of women differs most significantly from women taking second and 
third generation OCs. Future studies should continue to recruit women on OCs 
and examine differences within the OC group as a function of OC type.  
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A fourth limitation to this study is that general premorbid measures of 
disinhibition or impulsivity were not collected (i.e., measures prior to OC use). 
When examining the differences in inhibition between OC users and other groups 
an important caveat is that OC users may represent a generally more impulsive or 
disinhibited group of women compared to nonusers and men. Therefore, rather 
than the results indicating a possible underlying mechanisms of GABAergic 
disturbances, another possibility is that that the OC user group is generally more 
impulsive. Nevertheless, the OC users did not differ significantly from nonusers 
and only differed from the men. There do not appear to be any studies using 
cognitive measures that suggest that OC users are a more impulsive or 
disinhibited group than men. However, it is possible that women who choose to 
use OCs do so because they are concerned about their own ability to inhibit or 
stop sexual activity in order to use a condom. Regardless, if higher disinhibition 
in OC users is replicable, it will be important for future research in the area to rule 
out premorbid impulsivity or disinhibition as a potential confound. No  
A fifth limitation is related to the measures of emotional reactivity. While 
this study did include a well-established measure of affect, the PANAS, the 
analysis of emotional reactions to the mood inductions may have been improved 
if other, subtler or implicit measure of affect were also included. It may be that 
self-reported measures that inquire about explicit emotional reactions may not be 
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the most sensitive measure of affect especially in groups where the individuals 
may be more likely to suppress their emotions. For example, men may be more 
likely to endorse physical rather than affect symptoms after a mood induction. 
Future studies should include physical sensations and approach/avoid reactions as 
well as physiological measures of affect such as heart rate and galvanic skin 
response in the analysis as additional measure of affect. These measures may 
resolve bias towards those who are reluctant to endorse NA and PA symptoms.  
A sixth limitation to this study was that brain imaging (e.g., MRI) was not 
used to track brain changes and brain differences between groups as a function of 
the mood primes and the cognitive and perceptual tasks. Therefore, the 
researchers cannot know if the relevant targeted brain areas were in fact activated 
during the tasks.  
Finally, a seventh limitation of the study is that there were no baseline 
comparisons for the cognitive tasks because each cognitive task was presented 
after a mood condition. Therefore, there was no baseline measure of cognitive 
performance with which the researcher could use to further examine cognitive 
performance as a function of mood primes. Future studies should include a 
baseline measure of cognitive tasks in order to investigate changes in performance 
based on different mood inductions. For example, if men do not show a delay in 
facial emotion recognition response times at baseline, but do show a delay in 
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facial emotion recognition response times after mood inductions, it may provide 
evidence towards the theory that slower response times are related to emotion 
suppression.  
Strengths of The Current Study 
 There were also five noteworthy strengths of this current study. Firstly, 
this study was the first to explore differences between OC users, OC users with 
current negative mood side effects, nonusers, and men on measures of cognitive 
performance as a function of mood primes. The combination of looking at 
cognition within the context of different moods provides some ecological validity 
to the design.  Indeed, outside of the laboratory setting, one may expect to 
experience a variety of different emotions throughout the day or over a period of 
time. Furthermore, individuals are often required to make social judgments based 
on facial emotion expressions or make quick inhibitory or excitatory decisions 
such as while driving. Understanding how various emotional experiences 
influence these everyday processes, and the role exogenous hormones can have on 
these effects, may be an integral part of deciding on a hormonal contraceptive 
method.  
 A second strength of this study was that, despite the limitations of the 
small sample of current OC users with mood side effects, the researchers were 
able to collect data on a relatively large sample size (N = 149) including relatively 
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large and equal numbers of OC users (n = 57), nonusers (n = 45), and men (n = 
38). Additionally, the groups were relatively equal on several baseline measures 
such as time of laboratory session, alcohol and caffeine consumption, hours of 
sleep, and self-reported effort and enjoyment of laboratory tasks. This evidence of 
group equivalency lends support for the subsequent results. Since groups were 
shown to be relatively equal on all measures, it can be determined with higher 
confidence that the group differences found in our analyses were reflective of true 
group differences rather than the result an external factor such as time of day or 
alcohol use.  
 A third strength of this study is that it included OC type (i.e., phasic type 
and generation), as well as a subgroup of women on OCs with current negative 
mood side effects. Although there were no noteworthy differences between the 
groups, previous research has indicated that these groups do differ on mood and 
cognitive tasks. It is important for future studies examining OCs to collect 
information on OC type and OC mood side effects and to use the variables as 
factors in the analyses.  
 A fourth strength of this study is that an examination of the validity of the 
mood induction revealed that the mood induction video did induce the intended 
mood change as determined by levels of PA and NA, direction of change, scores 
from the PEEQ, and the approach/avoid measure. The validity of the mood 
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induction was an integral strength in this study as it indicates that the participants 
reacted to the inductions in the appropriate and predicted ways. This provides us 
with confidence that cognition or performance was in fact examined within the 
context of particular types of mood (i.e., sadness, happiness, fear). Moreover, the 
mood congruent music played throughout the videos and into the cognitive tasks. 
This was a strength in the design of the study as it helped ensure mood was 
prolonged for as long as possible, thus increasing the chances that performance on 
the cognitive and perceptual tasks were influenced by the mood primes.  
Finally, a fifth strength in this study is that it included two qualitatively 
different negative mood primes: sadness and fear. Previous OC mood studies have 
typically included sad mood as a measure of negative affect. However, previous 
research has also indicated that negative affect is variable, and instead may be 
more complicated depending on the type of negative affect. Therefore, by 
including two measures of negative affect, the researchers were able to analyze 
group differences across a wide array of emotions.  
Summary and Conclusions 
Previous research has indicated that women taking OCs have inconsistent 
emotional responses to OCs (Oinonen & Mazmanian, 2002). Additionally, it has 
been established that there are some structural brain differences between OC 
users, nonusers, and men (Protopopescu et al., 2008; Pletzer, Kronbichler, 
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Aichhorn, Bergmann, Ladurner & Kerschbau, 2010) and group differences in 
performance on certain cognitive tasks (Borgstrom et al., 2008; Follesa et al., 
2002; Gasbarri et al., 2008; Gingnell et al., 2013; Holloway, Beck, & Servatius, 
2011; Kimura, 1996; Torres, Gomez-Gil, Vidal, Puig, Boget & Salamero, 2006; 
Wharton et al., 2008).  
 The results of this study were that OC users had higher NA reactivity to 
the mood primes and higher NA scores than men. OC users also had faster 
response times when identifying negative emotional facial expressions compared 
to men after the negative mood inductions. OC users also had more errors of 
commission during the GoNogo task compared to men after the positive mood 
induction. Taking all the results together, they suggest that OC users were more 
emotionally reactive to the mood inductions (higher NA and NA reactivity), faster 
to respond to negative facial expressions, and had a lower ability to inhibit 
responses (higher errors of commission on the GoNogo task) compared to men.   
 Some evidence suggests that the reactivity and the impulsivity of the OC 
users seen in this study may be explained by GABAergic disturbances (Borgstrom 
et al., 2008; Follessa et al., 2002; Schultheiss, Patalakh, & Rosch, 2012). 
Alternatively, the lower reactivity of men in this study may be explained by the 
cognitive effort required when suppressing emotions (Pu, Schmeichel, & 
Damaree, 2009). In order to investigate both of these possibilities future studies 
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should use designs aimed at tapping into both reactivity and suppression. For 
example, future studies should include facial emotion recognition tasks and tasks 
of inhibition at baseline as well as after mood inductions. Therefore, researchers 
may be able to determine if men differ in their response times and inhibition at 
baseline, or only after mood inductions. Also, in order to identify GABAergic 
processes as a possible mechanism for reactivity in OC users, future research 
might include known GABAergic blockers to give to women on OCs to determine 
group differences as a function of GABAergic activities. Indeed, future research 
is needed to investigate whether OC reactivity is related to GABAergic 
disturbance and if men’s low reactivity is related to active emotional suppression. 
This current study was the first to investigate group differences between 
OC users, nonusers and men on their performance on cognitive and perceptual 
tasks as a function of mood primes. Results from this study further contributed to 
the literature on OC use and its possible influences on affect and cognition. 
Additionally, results from this study may lend preliminary support towards the 
theory that OC side effects (e.g., emotional and cognitive changes) are related to 









Albert, J., López-Martín, S., & Carretié, L. (2010). Emotional context modulates 
response inhibition: Neural and behavioral data. NeuroImage, 49(1), 914-
921. doi:10.1016/j.neuroimage.2009.08.045 
Bagozzi, R. P., & Moore, D. J. (2011). On the dimensionality and construct 
validity of the affect intensity measure, Applied Psychology, 18(1), 3-18.  
Baker, K. … & Graepel, S. (2012). Birth control pills, patch or ring. Retrieved 
from http://www.healthlinkbc.ca/kb/content/drugdetail/te7768.html 
Baker, F. C., Waner, J., I., Viera, E. F., Taylor, S. R., Driver, H. S. & Mitchell, D. 
(2001). Sleep and 24 hour body temperatures: A comparison in young 
men, naturally cycling women and women taking hormonal 
contraceptives. Journal of Physiology, 530(3), 565-574.  
Bannbers, E., Gingnell, M., Engman, J., Morell, A., Sylvén, S., Skalkidou, A., ... 
Poromaa, I. S. (2012). Prefrontal activity during response inhibition 
decreases over time in the postpartum period. Behavioural Brain 
Research, 241, 132-138. 
Baron‐ Cohen, S., Wheelwright, S., Hill, J., Raste, Y., & Plumb, I. (2001). The 
“Reading the mind in the eyes” test revised version: A study with normal 
adults, and adults with asperger syndrome or high‐ functioning autism. 
Journal of Child Psychology and Psychiatry, 42(2), 241-251.  
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
165 
Bartolic, E. I., Basso, M. R., Schefft, B. K., Glauser, T., & Titanic-Schefft, M. 
(1999). Effects of experimentally-induced emotional states on frontal lobe 
cognitive task performance. Neuropsychologia, 37(6), 677-683. 
Basso, M. R., Schefft, B. K., & Hoffmann, R. G. (1994). Mood-moderating 
effects of affect intensity on cognition: sometimes euphoria is not 
beneficial and dysphoria is not detrimental. Journal of personality and 
social psychology, 66(2), 363. 
Batur, P., Elder, J., & Mayer, M. (2003). Update on contraception: benefits and 
risks of the new formulations. Cleveland Clinic journal of medicine, 70(8), 
681-682. 
Baumgartner, T., Esslen, M., & Jäncke, L. (2006). From emotion perception to 
emotion experience: Emotions evoked by pictures and classical music. 
International Journal of Psychophysiology, 60(1), 34-43. 
Bell, E. C., Willson, M. C., Wilman, A. H., Dave, S., & Silverstone, P. H. (2006). 
Males and females differ in brain activation during cognitive tasks. 
Neuroimage, 30(2), 529-538. 
Black, A., Francoeur, D., Rowe, T., Collins, J., Miller, D., Brown, T., ... & 
Henneberg, E. (2004). SOGC clinical practice guidelines: Canadian 
contraception consensus. Journal of obstetrics and gynaecology Canada: 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
166 
JOGC= Journal d'obstetrique et gynecologie du Canada: JOGC, 26(3), 
219. 
Borgström, A., Kask, K., Gulinello, M., Odlind, V., & Sundström-Poromaa, I. 
(2008). Patients with adverse mood effects from combined oral 
contraceptives have lower levels of prepulse inhibition than healthy 
controls. Psychoneuroendocrinology, 33(4), 487-496. 
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001). Human studies of prepulse 
inhibition of startle: normal subjects, patient groups, and pharmacological 
studies. Psychopharmacology, 156(2-3), 234-258. 
Brand, S., & Opwis, K. (2007). Effects of mood and problem solving in dyads on 
transfer. Swiss journal of psychology, 66(1), 51-65. 
Brown, T. J., Scherz, B., Hochberg, R. B., MacLusky, N. J. (1996). Regulation of 
estrogen receptor concentrations in the rat brain: effects of sustained 
androgen and estrogen exposure. Neuroendocrinology, 63, 53–60. 
Carver, C. S., & White, T. L. (1994). Behavioral inhibition, behavioral activation, 
and affective responses to impending reward and punishment: The 
BIS/BAS scales. Journal of Personality and Social Psychology, 67, 319-
333 
Cavanagh, J., & Geisler, M. W. (2006). Mood effects on the ERP processing of 
emotional intensity in faces: a P3 investigation with depressed students. 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
167 
International Journal of Psychophysiology, 60(1), 27-33. 
Chepenik, L. G., Cornew, L. A., & Farah, M. J. (2007). The influence of sad 
mood on cognition. Emotion, 7(4), 802. 
Collins, D. W., & Kimura, D. (1997). A large sex difference on a two-
dimensional mental rotation task. Behavioral Neuroscience, 111, 845–849. 
Cosgrove, K. P., Mazure, C. M., & Staley, J. K. (2007). Evolving knowledge of 
sex differences in brain structure, function, and chemistry. Biological 
psychiatry, 62(8), 847-855. 
Cusin, C., Yang, H., Yeung, A., & Fava, M. (2010). Rating scales for depression. 
In Handbook of clinical rating scales and assessment in psychiatry and 
mental health (pp. 7-35). Humana Press. 
Du, S., & Martinez, A. M. (2011). The resolution of facial expressions of 
emotion. Journal of Vision, 11(13), 24. 
Elliot, A.J., & Thrash, T.M. (2002). Approach-avoidance motivation in 
personality: Approach and avoidance temperament and goals. Journal of 
Personality and Social Psychology, 82, 804–818. 
Farage, M. A., Osborn, T. W., & MacLean, A. B. (2008). Cognitive, sensory, and 
emotional changes associated with the menstrual cycle: a review. Archives 
of gynecology and obstetrics, 278(4), 299-307. 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
168 
Fisher, W. A., & Black, A. (2007). Contraception in Canada: a review of method 
choices, characteristics, adherence and approaches to counselling. 
Canadian Medical Association Journal, 176(7), 953-961. 
Fisher, W.A., Boroditsky, R., Bridges, M.L. (1999). The 1998 Canadian 
contraception study. Canadian Journal of Human Sexuality, 8, 161—226. 
Follesa, P., Porcu, P., Sogliano, C., Cinus, M., Biggio, F., Mancuso, L., ... & 
Concas, A. (2002). Changes in GABAA receptor 2 subunit gene 
expression induced by long-term administration of oral contraceptives in 
rats. Neuropharmacology 42, 325–336. 
Freeman, E. W., Kroll, R., Rapkin, A., Pearlstein, T., Brown, C., Parsey, K., ... & 
Foegh, M. (2001). Evaluation of a unique oral contraceptive in the 
treatment of premenstrual dysphoric disorder. Journal of women's health 
& gender-based medicine, 10(6), 561-569.  
Fried, I., Wilson, C. L., Morrow, J. W., Cameron, K. A., Behnke, E. D., 
Ackerson, L. C., & Maidment, N. T. (2001). Increased dopamine release 
in the human amygdala during performance of cognitive tasks. Nature 
Neuroscience, 4(2), 201-206. 
Fujita, F., Diener, E., & Sandvik, E. (1991). Gender differences in negative affect 
and well-being: the case for emotional intensity. Journal of Personality 
and Social Psychology, 61(3), 427. 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
169 
Funke, J., Wagener, D., & Spering, M. (2005). The role of emotions in complex 
problem-solving. Cognition and Emotion, 19, 1252-1261. 
Gasbarri, A., Pompili, A., d’Onofrio, A., Cifariello, A., Tavares, M. C., & Tomaz, 
C. (2008). Working memory for emotional facial expressions: role of the 
estrogen in young women. Psychoneuroendocrinology, 33(7), 964-972. 
Gilet, A. L. (2008). Mood induction procedures: a critical review. L'Encephale, 
34(3), 233-239. 
Glasier, A., 2006. Combined hormonal contraception. Medicine, 34, 1—5. 
Goldsmith, R. E., & Walters, H. (1989). A validity study of the affect intensity 
measure. Journal of Social Behavior and Personality; 4(1), 133.  
Goldstein, J. M., Seidman, L. J., Horton, N. J., Makris, N., Kennedy, D. N., 
Caviness, V. S., ... Tsuang, M. T. (2001). Normal sexual dimorphism of 
the adult human brain assessed by in vivo magnetic resonance imaging. 
Cerebral Cortex, 11(6), 490-497. 
Graham, C. A., & Sherwin, B. B. (1993). The relationship between mood and 
sexuality in women using an oral contraceptive as treatment for 
premenstrual syndrome. Psychoneuroendocrinology 18, 273–281. 
Gingnell, M., Engman, J., Frick, A., Moby, L., Wikström, J., Fredrikson, M., & 
Sundström-Poromaa, I. (2013). Oral contraceptive use changes brain 
activity and mood in women with previous negative affect on the pill—A 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
170 
double-blinded, placebo-controlled randomized trial of a levonorgestrel-
containing combined oral contraceptive. Psychoneuroendocrinology, 
38(7), 1133-1144.  
Grossman, M., & Wood, W. (1993). Sex differences in intensity of emotional 
experience: a social role interpretation. Journal of personality and social 
psychology, 65(5), 1010. 
Hamilton, M. (2000). Hamilton rating scale for depression (Ham-D). In 
Handbook of Psychiatric Measures (pp. 526-528). Washington DC: APA. 
Hampshire, A., Chamberlain, S. R., Monti, M. M., Duncan, J., & Owen, A. M. 
(2010). The role of the right inferior frontal gyrus: inhibition and 
attentional control. Neuroimage, 50(3), 1313-1319. 
Hausmann, M., Slabbekoorn, D., Van Goozen, S. H., Cohen-Kettenis, P. T., & 
Güntürkün, O. (2000). Sex hormones affect spatial abilities during the 
menstrual cycle. Behavioral neuroscience, 114(6), 1245. 
Het, S., & Wolf, O. T. (2007). Mood changes in response to psychosocial stress in 
healthy young women: Effects of pretreatment with cortisol. Behavioral 
neuroscience, 121(1), 11. 
Holloway, J. L., Beck, K. D., & Servatius, R. J. (2011). Facilitated acquisition of 
the classically conditioned eyeblink response in females is augmented in 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
171 
those taking oral contraceptives. Behavioural Brain Research, 216(1), 
301-307. 
Jabbi, M., Swart, M., & Keysers, C. (2007). Empathy for positive and negative 
emotions in the gustatory cortex. Neuroimage, 34(4), 1744-1753. 
Jacobs, E., & D’Esposito, M. (2011). Estrogen shapes dopamine-dependent 
cognitive processes: Implications for women’s health. The Journal of 
Neuroscience, 31(14), 5286-5293. 
Japha, K., & Koch, M. (1999). Picrotoxin in the medial prefrontal cortex impairs 
sensorimotor gating in rats: reversal by haloperidol. Psychopharmacology, 
144(4), 347-354. 
Jarva, J. A., & Oinonen, K. A. (2007). Do oral contraceptives act as mood 
stabilizers? Evidence of positive affect stabilization. Archives of Women's 
Mental Health, 10(5), 225-234. 
John, O. P., Donahue, E. M., & Kentle, R. L. (1991). The Big Five Inventory--
Versions 4a and 54. Berkeley, CA: University of California, Berkeley, 
Institute of Personality and Social Research. 
Kask, K., Gulinello, M., Bäckström, T., Geyer, M. A., & Sundström-Poromaa, I. 
(2007). Patients with premenstrual dysphoric disorder have increased 
startle response across both cycle phases and lower levels of prepulse 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
172 
inhibition during the late luteal phase of the menstrual cycle. 
Neuropsychopharmacology, 33(9), 2283-2290. 
Kimura, D. (1996). Sex, sexual orientation and sex hormones influence human 
cognitive function. Current opinion in neurobiology, 6(2), 259-263. 
Kirschbaum, C., Pirke, K. M., & Hellhammer, D. H. (1995). Preliminary evidence 
for reduced cortisol responsivity to psychological stress in women using 
oral contraceptive medication. Psychoneuroendocrinology, 20(5), 509-
514. 
Kring, A. M., & Gordon, A. H. (1998). Sex differences in emotion: Expression, 
experience, and physiology. Journal of Personality and Social 
Psychology, 74(3), 686-703. doi:http://dx.doi.org/10.1037/0022-
3514.74.3.686. 
Kucian, K., Loenneker, T., Dietrich, T., Martin, E., & Von Aster, M. (2005). 
Gender differences in brain activation patterns during mental rotation and 
number related cognitive tasks. Psychology Science, 47(1), 112. 
Kurshan, N., & Epperson, C. N. (2006). Oral contraceptives and mood in women 
with and without premenstrual dysphoria: A theoretical model. Archives of 
women's mental health, 9(1), 1-14. 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
173 
Krug, R., Pietrowsky, R., Fehm, H. L., & Born, J. (1994). Selective influence of 
menstrual cycle on perception of stimuli with reproductive significance. 
Psychosomatic medicine, 56(5), 410-417. 
Larsen, R. J. (1984). Theory and measurement of affect intensity as an individual 
difference characteristic.  
Lecrubier, Y. (2005). Physical components of depression and psychomotor 
retardation. The Journal of Clinical Psychiatry, 67, 23-26. 
Lesiuk, T. (2010). The effect of preferred music on mood and performance in a 
high-cognitive demand occupation. Journal of music therapy, 47(2), 137. 
Liakakis, G., Nickel, J., & Seitz, R. J. (2011). Diversity of the inferior frontal 
gyrus—a meta-analysis of neuroimaging studies. Behavioural brain 
research, 225(1), 341-347. 
McClure, E. B. (2000). A meta-analytic review of sex differences in facial 
expression processing and their development in infants, children, and 
adolescents. Psychological bulletin, 126(3), 424. 
McEwen, B. S., Alves, S. E., Bulloch, K., & Weiland, N. G. (1997). Ovarian 
steroids and the brain implications for cognition and aging. Neurology, 
48(5), 8-15. 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
174 
Merz, C. J., Tabbert, K., Schweckendiek, J., Klucken, T., Vaitl, D., Stark, R., & 
Wolf, O. T. (2012). Oral contraceptive usage alters the effects of cortisol 
on implicit fear learning. Hormones and Behavior, 62, 531-538.  
Merz, C. J., Stark, R., Vaitl, D., Tabbert, K., & Wolf, O. T. (2013). Stress 
hormones are associated with the neuronal correlates of instructed fear 
conditioning. Biological psychology, 92(1), 82-89. 
Miller, E. N. (1990). California computerized assessment battery (CalCAP) 
manual. Los Angeles: Norland Software. 
Miller, E. N. (1995). Cognitive testing using reaction time and traditional 
neuropsychological procedures. Journal of the International 
Neuropsychological Society, 1, 393. 
Miller, E. N.  (2013). CALCAP California computerized assessment package. 
Retreived from http://www.calcaprt.com/calcap.htm 
Miller, K. J., Conney, J. C., Rasgon, N. L., Fairbanks, L. A., & Small, G. W. 
(2002). Mood symptoms and cognitive performance in women estrogen 
users and nonusers and men. Journal of the American Geriatrics Society, 
50(11), 1826-1830. 
Merck Research Laboratories (2003), Merck Manual of Medical Information. 
Beers, M. H. & Fletcher A. J. eds. Whitehouse Station: N.J. 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
175 
Moberg, P. J., Lazarus, L. W., Mesholam, R. I., Bilker, W., Chuy, I. L., Neyman, 
I., & Markvart, V. (2002). Comparison of the standard and structured 
interview guide for the Hamilton Depression Rating Scale in depressed 
geriatric inpatients. The American Journal of Geriatric Psychiatry, 9(1), 
35-40. 
Morey, L. C. (2007).Personality Assessment Inventory professional manual (2nd 
ed.). Lutz, FL: Psychological Assessment Resources. 
Mosher, W.D., Martinez, G.M., Chandra, A., Abma, J.C., Wilson, S.J. (2004). 
Use of contraception and use of family planning services in the United 
States: 1982—2002. Advanced Data From Vital and Health Statistics, 
350. 
Oinonen, K. A., & Mazmanian, D. (2002). To what extent do oral contraceptives 
influence mood and affect? Journal of Affective Disorders, 70, 229-240.  
Oinonen, K.A. (2009). Putting a finger on potential predictors of oral 
contraceptive side effects: 2D:4D and middle-phalangeal hair. 
Psychoneuroendocrinology, 34(5), 713-726.  
doi:10.1016/j.psyneuen.2008.11.009 
Papousek, I., Schulter, G., & Lang, B. (2009). Effects of emotionally contagious 
films on changes in hemisphere-specific cognitive performance. Emotion, 
9(4), 510. 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
176 
Parry, B. L., Berga, S. L., Mostofi, N., Klauber, M. R., & Resnick, A. (1997). 
Plasma melatonin circadian rhythms during the menstrual cycle and 
after light therapy in premenstrual dysphoric disorder and normal control 
subjects. Journal of Biological Rhythms, 12(1), 47-64.  
Parsey, K. S., & Pong, A. (2000). An open-label, multicenter study to evaluate 
Yasmin, a low-dose combination oral contraceptive containing 
drospirenone, a new progestogen. Contraception, 61, 105–111. 
Pleil, K. E., & Williams, C. L. (2010). The development and stability of estrogen-
modulated spatial navigation strategies in female rats. Hormones and 
Behavior, 57(3), 360-367. 
Pletzer, B., Kronbichler, M., Aichhorn, M., Bergmann, J., Ladurner, G., & 
Kerschbaum, H. H. (2010). Menstrual cycle and hormonal contraceptive 
use modulate human brain structure. Brain research, 1348, 55-62. 
Postma, A., Winkel, J., Tuiten, A., & van Honk, J. (1999). Sex differences and 
menstrual cycle effects in human spatial memory. 
Psychoneuroendocrinology, 24(2),175-192. 
Protopopescu, X., Butler, T., Pan, H., Root, J., Altemus, M., Polanecsky, M., ... & 
Stern, E. (2008). Hippocampal structural changes across the menstrual 
cycle. Hippocampus, 18(10), 985-988. 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
177 
Pu, J., Schmeichel, B. J., & Demaree, H. A. (2010). Cardiac vagal control predicts 
spontaneous regulation of negative emotional expression and subsequent 
cognitive performance. Biological psychology, 84(3), 531-540. 
Rammstedt, B., & John, O. P. (2007). Measuring personality in one minute or 
less: A 10-item short version of the Big Five Inventory in English and 
German. Journal of Research in Personality, 41, 203-212. 
Rizzolatti, G., & Buchtel, H. A. (1977). Hemispheric superiority in reaction time 
to faces: A sex difference. Cortex, 13(3), 300-305. 
Rumberg, B., Baars, A., Fiebach, J., Ladd, M. E., Forsting, M., Senf, W., & 
Gizewski, E. R. (2010). Cycle and gender-specific cerebral activation 
during a verb generation task using fMRI: Comparison of women in 
different cycle phases, under oral contraception, and men. Neuroscience 
research, 66(4), 366-371. 
Sanders, S. A., Graham, C. A., Bass, J. L., Bancroft, J. (2001). A prospective 
study of the effects of oral contraceptives on sexuality and well-being and 
their relationship to discontinuation. Contraception, 64, 51–58. 
Schultheiss, O. C., Patalakh, M., & Rösch, A. G. (2012). Salivary progesterone is 
associated with reduced coherence of attentional, cognitive, and 
motivational systems. Brain and cognition, 80(2), 214-222. 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
178 
Sillem, M., Schneidereit, R., Heithecker, R., & Mueck, A. O. (2003). Use of an 
oral contraceptive containing drospirenone in an extended regimen. 
European Journal of Contraception and Reproductive Healthcare, 8(3), 
162-169.  
Stratton, V. N., & Zalanowski, A. H. (1991). The effects of music on cognition 
and mood. Psychology of Music, 19, 121-127.  
Sutton, S. K., & Davidson, R. J. (1997). Prefrontal brain asymmetry: A biological 
substrate of the behavioral approach and inhibition systems. Psychological 
Science, 8, 204–210. 
Tabachnick, B.G., & Fidell, L.S. (2001). Using multivariate statistics (4th ed.). 
Needham Heights, MA: Allyn & Bacon. 
Takahashi, H., Matsuura, M., Koeda, M., Yahata, N., Suhara, T., Kato, M., & 
Okubo, Y. (2008). Brain activations during judgments of positive self-
conscious emotion and positive basic emotion: pride and joy. Cerebral 
Cortex, 18(4), 898-903. 
Thayer, J., & Johnsen, B. H. (2000). Sex differences in judgement of facial affect: 
A multivariate analysis of recognition errors. Scandinavian journal of 
psychology, 41(3), 243-246. 
Tottenham, N., Borscheid, A., Ellertsen, K., Marcus, D.J., Nelson, C.A. (April, 
2002). Categorization of Facial Expressions in Children and Adults: 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
179 
Establishing a Larger Stimulus Set. Poster presented at the Cognitive 
Neuroscience Society annual meeting, San Francisco. 
Torres, A., Gómez-Gil, E., Vidal, A., Puig, O., Boget, T., & Salamero, M. (2006). 
Gender differences in cognitive functions and influence of sex hormones. 
Actas Españolas De Psiquiatría, 34(6), 408-415 
Underwood, B., & Froming, W. J. (1980). The mood survey: A personality 
measure of happy and sad moods. Journal of Personality Assessment, 44, 
404-414.  
van Heusden, A. M., & Fauser, B. C. (1999). Activity of the pituitary- ovarian 
axis in the pill-free interval during use of low-dose combined oral 
contraceptives. Contraception, 59, 237—243. 
Västfjäll, D. (2002). Emotion induction through music: A review of the musical 
mood induction procedure. Musicae Scientiae, 5(1 suppl), 173-211. 
Vranić, A., & Hromatko, I. (2008). Content-specific activational effects of 
estrogen on working memory performance. The Journal of general 
psychology, 135(3), 323-336. 
Wang, L., LaBar, K. S., Smoski, M., Rosenthal, M. Z., Dolcos, F., Lynch, T. R., 
... & McCarthy, G. (2008). Prefrontal mechanisms for executive control 
over emotional distraction are altered in major depression. Psychiatry 
Research: Neuroimaging, 163(2), 143-155. 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
180 
Watson, D., Clark, L. A., & Tellegren, A. (1988). Development and validation of 
brief measures of positive and negative affect: The PANAS scales. 
Journal of Personality and Social Psychology, 54, 1063-1070.  
Wharton, W., Hirshman, E., Merritt, P., Doyle, L., Paris, S., & Gleason, C. 
(2008). Oral contraceptives and androgenicity: Influences on visuospatial 
task performance in younger individuals. Experimental and clinical 
psychopharmacology, 16(2), 1. 
Wilcox, A. J., Dunson, D., & Baird, D. D. (2000). The timing of the “fertile 
window” in the menstrual cycle: day specific estimates from a prospective 
study. Bmj, 321(7271), 1259-1262






Today’s date (dd/mm/yyyy): _____________________ 
 
1. What is your age _______ 
 
a. Are you 45 years of age or older? 
 
YES  NO 
 
b. Are you a woman who is going through, or has gone through menopause? 
 
YES  NO  MAYBE NOT APPLICABLE, I AM MALE 
 
c. Are you a woman who has had her period (menses) in the last 12 months?  
(Select “NO” ONLY IF you HAVE NOT had your period in the last 12 months or more) 
 
YES  NO  NOT APPLICABLE, I AM MALE 
 
d. Are you currently taking any hormonal contraceptives other than oral contraceptives 
(e.g., contraceptive patch, vaginal ring, DepoProvera, hormonal implants, 
etc.) ? 
 
YES  NO  NOT APPLICABLE, I AM MALE 
 
e. Have you taken any emergency contraception pill (i.e. Plan B) in the last 6 months? 
 
YES  NO  NOT APPLICABLE, I AM MALE 
 
2. Please choose the response that best represents your ethnic background. If you 
need to select more than one response, then select “other” and please specify. 
 
Caucasian/White     _____ Middle Eastern  _____ 
African-Canadian/American/Black   _____ East Indian   _____ 
First Nation/Aboriginal/American Indian   _____ European  _____ 
Hispanic/Latino    _____     Asian    _____ 
Other (please specify)    ______ 
 
3. Please check the box that best describes the highest level of education that you 
have completed:   




[   ] some elementary [   ] completed high school [   ] some university 
[   ] completed grade 8 [   ] some college  [   ] completed a university degree 
[   ] some high school [   ] completed college [   ] some graduate studies 
       [   ] completed a graduate degree 
 
5.  Are you currently taking any antidepressant medication(s)?  
 
YES   NO  
 




6.  Are you currently taking any medication(s) other than antidepressants? 
 
YES   NO 
 




7. Have you ever been diagnosed with or treated for depression?  
 
YES  NO  MAYBE  
 
8.  Have you ever been diagnosed with or treated for bipolar disorder or manic 
depression?  
 
YES  NO  MAYBE 
 
9.  Please list any medical or psychological conditions that you have been 
diagnosed with (e.g. hypothyroidism, depression, asthma, cancer, diabetes, etc.)  
       __________________________________________________________________ 
 
10.           Below are a number of statements about your experience of moods. We would 
like you to consider your usual behaviour OVER THE PAST TWO MONTHS 
when you respond. Using the scale, indicate the appropriate number below each 
question and try to be as honest as you can.  
 
a) I may change from happy to sad and back again several times in a single week. 
 
Strongly     Moderately    Somewhat       Somewhat      Moderately      Strongly    
Disagree    Disagree      Disagree          Agree          Agree        Agree 
1  2  3  4  5  6 
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b) Compared to my friends, I’m less up and down in my mood states. 
 
Strongly     Moderately    Somewhat       Somewhat      Moderately      Strongly    
Disagree    Disagree      Disagree          Agree          Agree        Agree 
1  2  3  4  5  6 
 
c) Sometimes my mood swings back and forth very rapidly. 
 
Strongly     Moderately    Somewhat       Somewhat      Moderately      Strongly    
Disagree    Disagree      Disagree          Agree          Agree        Agree 
1  2  3  4  5  6 
 
d) My moods are quite consistent; they almost never vary. 
 
Strongly     Moderately    Somewhat       Somewhat      Moderately      Strongly    
Disagree    Disagree      Disagree          Agree          Agree        Agree 
1  2  3  4  5  6 
 
e) I’m a very changeable person. 
 
Strongly     Moderately    Somewhat       Somewhat      Moderately      Strongly    
Disagree    Disagree      Disagree          Agree          Agree        Agree 
1  2  3  4  5  6 
 
f) I’m not as “moody” as most people I know. 
 
Strongly     Moderately    Somewhat       Somewhat      Moderately      Strongly    
Disagree    Disagree      Disagree          Agree          Agree        Agree 
1  2  3  4  5  6 
 
a) If 1 = hardly ever and 99 = extremely frequently, how frequently do your moods 
change? ____ 
b) If 1 = not at all and 99 = extremely intensely, how intensely do you react to mood 
experiences? ___ 
 
11.           The following questions refer to emotional reactions to typical life events. 
Please indicate how YOU react to these events by selecting a number from 1 
(Never) to 6 (Always). Please base your answers on how YOU react, NOT on 
how you think others react or how you think a person should react. Please 
consider your reactions over the PAST TWO MONTHS in particular: 
 
a) When I feel happiness, it is a quiet contentment 
    
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
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b) When a person in a wheelchair can’t get through a door, I have strong feelings of pity 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
c) I get upset easily 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
d) When I succeed at something, my reaction is calm contentment 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
e) I get really happy or really unhappy 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
f) I’m a fairly quiet person 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
g) When I’m happy, I feel very energetic 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
h) Seeing a picture of some violent car accident in a newspaper makes me feel sick to my 
stomach 
 
Never      Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
i) When I’m happy, I feel like I’m bursting with joy 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1   2  3  4  5  6 
 
j) I would be very upset if I got a traffic ticket 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
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k) Looking at beautiful scenery really doesn’t affect me much 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
l) The weather doesn’t affect my mood 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1 2  3  4  5  6 
 
m) Other tend to get more excited about things than I do 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
n) I am not an extremely enthusiastic individual 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
o) ‘Calm and cool’ could easily describe me 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
p) When I’m feeling well it’s easy for me to go from being in a good mood to being really 
joyful 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
q) When I worry, it is so mild that I hardly notice 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
r) I get overly enthusiastic 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
s) My happy moods are so strong that I feel like I’m ‘in heaven’ 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
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t) When something bad happens, other tend to be more unhappy than I 
 
Never     Very Rarely Rarely    Occasionally     Very Frequently      Always 
1  2  3  4  5  6 
 
12. Compared to how you feel when you are in an even or normal mood state, how would 
you rate yourself on the following items during the past 2 weeks ? 
 
I have been feeling: 
 
a) Down and depressed 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
b) Less interesting in doing things 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
c) Less interested in sex 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
d) Less interested in eating 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
e) That I’ve lost some weight 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
f) That I can’t fall asleep at night 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
187 
g) That my sleep is restless 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
h) That I wake up too early 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
 i) Heavy in my limbs or aches in back, muscles, or head, more tired than usual 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
j) Guilty or like a failure 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
k) Tense, irritable, or worried 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
l) Sure I’m ill or have a disease 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
m) That my speech and thoughts are slow 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
n) fidgety, restless, or antsy 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 




o) that morning is worse than evening 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
p) that evening is worse than morning 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
q) physical symptoms when worried 
 
Not at all       just a little   more than just     quite a bit/  marked or severely 
    a little         moderately 
1   2   3   4     5 
 
13. Please use the following scale to indicate which hand you use for each activity 
 
a) Writing  
 
Always Left              Both     Always Right 
1   2   3   4  5  
 
b) Throwing  
 
Always Left              Both     Always Right 
1   2   3   4  5  
      
c) Using scissors  
 
Always Left              Both     Always Right 
1   2   3   4  5  
   
d) Using a toothbrush 
 
Always Left              Both     Always Right 
1   2   3   4  5  
    
e) Using a knife without a fork  
 
Always Left              Both     Always Right 
1   2   3   4  5  
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f) Using a spoon  
 
Always Left              Both     Always Right 
1   2   3   4  5  
    
g) Striking a match 
 
Always Left              Both     Always Right 
1   2   3   4  5  
     
14. Read each statement and decide whether it is an accurate statement about you 
 
a) Sometimes I cannot remember who I am 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
b) I have vision in which I see myself forced to commit crimes  
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
c) Since the day I was born, I was destined to be unhappy 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
d) I think I have three or four completely different personalities inside of me 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
e) People don’t understand how much I suffer 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
f) Every once in a while, I totally loose my memory 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
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1   2   3   4 
 
g) Sometimes my vision is only in black and white 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
h) I don’t have any good memories from my childhood 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
i) I have severe psychological problems that began very suddenly 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
j) Sometimes I let little things bother me too much 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
k) Sometimes I’ll avoid someone I really don’t like 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
l) I sometimes complain too much 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
m) Sometimes I’m too impatient 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
n) I don’t take criticism very well 
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False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
o) Sometimes I put things off until the last minute 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
p) I sometimes make promises I can’t keep 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
q) There have been times when I could have been more thoughtful than I was 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
r) I rarely get in a bad mood 
 
False,    Slightly true   Mainly true   Very true 
Not at all true 
1   2   3   4 
 
15.  Here are a number of characteristics that may or may not apply to you.  
For example, do you agree that you are someone who likes to spend time 
with others?  Please indicate under each statement the extent to which you 
agree or disagree with that statement. . Please consider your characteristics 
over the PAST TWO MONTHS in particular 
 
I am some who: 
 
a. is depressed, blue 
 
disagree disagree Neither agree  Agree  Agree 
strongly a little  nor disagree  a little  strongly 
1  2  3   4  5 
 
b. is relaxed, handles stress well 
 
disagree disagree Neither agree  Agree  Agree 
strongly a little  nor disagree  a little  strongly 
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1  2  3   4  5 
 
c. can be tense 
 
disagree disagree Neither agree  Agree  Agree 
strongly a little  nor disagree  a little  strongly 
1  2  3   4  5 
 
d. worries a lot 
 
disagree disagree Neither agree  Agree  Agree 
strongly a little  nor disagree  a little  strongly 
1  2  3   4  5 
 
e. is emotionally stable, not easily upset 
 
disagree disagree Neither agree  Agree  Agree 
strongly a little  nor disagree  a little  strongly 
1  2  3   4  5 
 
f. can be moody 
 
disagree disagree Neither agree  Agree  Agree 
strongly a little  nor disagree  a little  strongly 
1  2  3   4  5 
 
g. remains calm in tense situtations 
 
disagree disagree Neither agree  Agree  Agree 
strongly a little  nor disagree  a little  strongly 
1  2  3   4  5 
 
h. gets nervous easily 
 
disagree disagree Neither agree  Agree  Agree 
strongly a little  nor disagree  a little  strongly 
1  2  3   4  5 
 
16. Each item of this next questionnaire is a statement that a person may either agree with 
or disagree with.  For each item, indicate how much you agree or disagree with what the 
item says.  Please respond to all the items; do not leave any blank.  Choose only one 
response to each statement.  Please be as accurate and honest as you can be.  Respond to 
each item as if it were the only item.  That is, don't worry about being "consistent" in 
your responses. Please consider how you have been feeling over the PAST TWO 
MONTHS in particular 
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a. A person's family is the most important thing in life.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
b. Even if something bad is about to happen to me, I rarely experience fear or 
nervousness.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
c. I go out of my way to get things I want.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
d. When I'm doing well at something I love to keep at it.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
e. I'm always willing to try something new if I think it will be fun.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
f. How I dress is important to me.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
g. When I get something I want, I feel excited and energized.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
h. Criticism or scolding hurts me quite a bit.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
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i. When I want something I usually go all-out to get it.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
j. I will often do things for no other reason than that they might be fun. 
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
k. It's hard for me to find the time to do things such as get a haircut.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
l. If I see a chance to get something I want I move on it right away.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
m. I feel pretty worried or upset when I think or know somebody is angry at me.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
n. When I see an opportunity for something I like I get excited right away.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
o. I often act on the spur of the moment.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
p. If I think something unpleasant is going to happen I usually get pretty "worked 
up."  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
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q. I often wonder why people act the way they do. 
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
r. When good things happen to me, it affects me strongly.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
s. I feel worried when I think I have done poorly at something important.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
t. I crave excitement and new sensations 
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
u. When I go after something I use a "no holds barred" approach.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
v. I have very few fears compared to my friends.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
w. It would excite me to win a contest.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 
x. I worry about making mistakes.  
1         2              3             4 
Very true for me   somewhat true for me    somewhat false for me very false for me 
 




17. Stress can be experienced as a result of both positive and negative life events and can 
be defined as physical or emotional strain/tension. Compared to other people your age 
and sex, to what extent did you experience . . . 
Stressful negative life events in the past year? 
Much Less    Average                   Much More 
1        2         3         4         5         6         7 
Stressful positive life events in the past year? 
Much Less    Average                   Much More 
1        2         3         4         5         6         7 
Stressful negative life events in the past two months? 
Much Less    Average                   Much More 
1        2         3         4         5         6         7 
Stressful positive life events in the past two months? 
Much Less    Average                   Much More 
1        2         3         4         5         6         7 
18. What is your sex ? 
Male  Female 
19. Reproductive Questions: 
 
a) Have you ever been pregnant? (Only say YES if you were 100% sure)   
YES      NO 
 b)  If yes, how many times have you been pregnant?  _______ 
 c)  How many children have you given birth to?  ________ 
b)  Are you currently pregnant?   
YES  NO MAYBE 
 
20. Some women experience changes in mood and physical functioning during the week 
prior to their menstrual period. As best as you can, please indicate the frequency, 
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severity, and level of impairment encountered for the following 11 symptoms during 
your pre-menstrual phase over the past year. 
1. Markedly depressed mood, feelings of hopelessness, or self-deprecating thoughts 
during the week prior to my menstrual period? 
 
a. Number of menstrual cycles in which the above symptom(s) have been 
experienced during the premenstrual phase over the past 12 months 
0 1 2 3 4 5 6 7 8 9 10 11 12 
b. To what extent do these symptoms cause impairment in work, school, or 
occupational functioning: 
 
1-not at all     2- a little    3- moderately  4- quite a bit   5- extremely 
c. Please rate the degree of severity of these symptoms: 
1- not at all severe     2- mild       3- moderate      4-severe         5-extremely severe/debilitating 
 
2. Marked anxiety, tension, or feelings of being “keyed up,” or “on edge?” during 
the week prior to my menstrual period 
 
a. Number of menstrual cycles in which the above symptom(s) have been 
experienced during the premenstrual phase over the past 12 months 
0 1 2 3 4 5 6 7 8 9 10 11 12 
b. To what extent do these symptoms cause impairment in work, school, or 
occupational functioning: 
 
1-not at all       2- a little    3- moderately  4- quite a bit   5- extremely 
c. Please rate the degree of severity of these symptoms: 
 
1- not at all severe      2- mild   3- moderate   4-severe   5-extremely severe/debilitating 
 
3. Affective lability (e.g. feeling suddenly sad or tearful, or increased sensitivity to 
rejection) during the week prior to my menstrual period? 
a. Number of menstrual cycles in which the above symptom(s) have been 
experienced during the premenstrual phase over the past 12 months 
0 1 2 3 4 5 6 7 8 9 10 11 12 
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b. To what extent do these symptoms cause impairment in work, school, or 
occupational functioning: 
 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
 
c.  Please rate the degree of severity of these symptoms: 
 
1- not at all severe     2- mild       3- moderate      4-severe         5-extremely severe/debilitating 
4. Persistent and marked anger or irritability, or increased interpersonal conflicts 
during the week prior to my menstrual period? 
a. Number of menstrual cycles in which the above symptom(s) have been 
experienced during the premenstrual phase over the past 12 months 
0 1 2 3 4 5 6 7 8 9 10 11 12 
b. To what extent do these symptoms cause impairment in work, school, or 
occupational functioning: 
 
       1-not at all       2- a little       3- moderately     4- quite a bit        5- extremely 
c. Please rate the degree of severity of these symptoms: 
 
1- not at all severe     2- mild       3- moderate      4-severe         5-extremely severe/debilitating 
5. Decreased interest in usual activities (e.g. work, school, friends, hobbies) during 
the week prior to my menstrual period? 
a. Number of menstrual cycles in which the above symptom(s) have been 
experienced during the premenstrual phase over the past 12 months 
0 1 2 3 4 5 6 7 8 9 10 11 12 
b. To what extent do these symptoms cause impairment in work, school, or 
occupational functioning: 
 
 1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
c. Please rate the degree of severity of these symptoms: 
 
1- not at all severe     2- mild       3- moderate      4-severe         5-extremely severe/debilitating 
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6. A subjective sense of difficulty concentrating during the week prior to my 
menstrual period? 
a. Number of menstrual cycles in which the above symptom(s) have been 
experienced during the premenstrual phase over the past 12 months 
0 1 2 3 4 5 6 7 8 9 10 11 12 
b. To what extent do these symptoms cause impairment in work, school, or 
occupational functioning: 
 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
c. Please rate the degree of severity of these symptoms: 
 
1- not at all severe       2- mild 3- moderate 4-severe        5-extremely severe/debilitating 
7. Lethargy, easy fatigability, or marked lack of energy during the week prior to my 
menstrual period? 
a. Number of menstrual cycles in which the above symptom(s) have been 
experienced during the premenstrual phase over the past 12 months 
0 1 2 3 4 5 6 7 8 9 10 11 12 
b. To what extent do these symptoms cause impairment in work, school, or 
occupational functioning: 
 
1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
c. Please rate the degree of severity of these symptoms: 
 
1- not at all severe       2- mild 3- moderate 4-severe        5-extremely severe/debilitating 
 
8. Marked change in appetite, overeating, or specific food cravings during the week 
prior to my menstrual period? 
a. Number of menstrual cycles in which the above symptom(s) have been 
experienced during the premenstrual phase over the past 12 months 
0 1 2 3 4 5 6 7 8 9 10 11 12 
b. To what extent do these symptoms cause impairment in work, school, or 
occupational functioning: 
 
1-not at all     2- a little         3- moderately     4- quite a bit  5- extremely 
c. Please rate the degree of severity of these symptoms: 
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1- not at all severe       2- mild 3- moderate 4-severe        5-extremely severe/debilitating 
9. Sleeping too much or too little during the week prior to my menstrual period? 
a. Number of menstrual cycles in which the above symptom(s) have been 
experienced during the premenstrual phase over the past 12 months 
0 1 2 3 4 5 6 7 8 9 10 11 12 
b. To what extent do these symptoms cause impairment in work, school, or 
occupational functioning: 
 
 1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
c. Please rate the degree of severity of these symptoms: 
 
1- not at all severe       2- mild 3- moderate 4-severe        5-extremely severe/debilitating 
10. A subjective sense of being overwhelmed or out of control during the week prior 
to my menstrual period? 
a. Number of menstrual cycles in which the above symptom(s) have been 
experienced during the premenstrual phase over the past 12 months 
0 1 2 3 4 5 6 7 8 9 10 11 12 
b. To what extent do these symptoms cause impairment in work, school, or 
occupational functioning: 
 
 1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
c. Please rate the degree of severity of these symptoms: 
 
1- not at all severe       2- mild 3- moderate 4-severe        5-extremely severe/debilitating 
11. Other physical symptoms, such as breast tenderness or swelling, headaches, joint 
or muscle pain, or sensations of “bloating” or weight gain during the week prior to my 
menstrual period? 
 
a. Number of menstrual cycles in which the above symptom(s) have been 
experienced during the premenstrual phase over the past 12 months 
0 1 2 3 4 5 6 7 8 9 10 11 12 
b. To what extent do these symptoms cause impairment in work, school, or 
occupational functioning: 
 
       1-not at all  2- a little  3- moderately   4- quite a bit   5- extremely 
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c. Please rate the degree of severity of these symptoms: 
 
1- not at all severe       2- mild 3- moderate 4-severe        5-extremely severe/debilitating 
 
 21.  a. What is the average length of your menstrual cycle right now (i.e., How many 
days are there from the first day of one period to the first day of your next period – (most 
people range between 25 and 35)? ____________ days 
 
b. What is your average length of menstruation/bleeding when you are not taking oral  
contraceptives?  (i.e., how many days does your period last? Most people’s periods last 
between 1 and 10 days.)  ____________ days 
 
c. Which statement best describes your menstrual cycle when you are not taking oral   
contraceptives?  
 
   [   ]  I never have my period. 
   [   ]  My period is very unpredictable. Sometimes very few days pass before I get my 
next period, sometimes months pass before I get my next period. 
   [   ] My period is somewhat unpredictable. I usually get my period within four to seven 
days of when I expect it.          
   [   ]  My period is somewhat predictable. I usually get my period within two or three 
days of when I expect it. 
    [   ]  My period is very predictable. I can predict within one day when my next period will 
start. 
 
d. How old were you when you first started menstruating (started your period)?    
______ years old 
 
e. Using the calendars below, please indicate the first day of your last menstrual period.  
If you are not completely sure, please estimate the day that you believe you started 





September 2013           October 2013 
 
  S    M    T    W    T    F    S   S    M    T    W    T    F    S 
  1     2     3     4     5 6     7      1     2      3     4    5 
      8     9    10   11   12   13   14   6     7     8     9      10   11  12 
  15   16   17   18   19   20   21              13   14   15   16    17   18  19 
  22   23   24   25   26   27   28   20   21   22   23    24   25  26  
  29   30       27   28   29   30    31    
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November 2013    December 2013 
  
S    M    T    W    T    F    S    S    M    T    W    T    F    S 
                          1    2              1   
3    4      5     6     7     8    9    2    3      4     5      6    7     8 
10  11    12   13   14  15   16   9    10    11   12    13  14   15 
17  18    19   20   21  22   23   16  17    18   19     20  21  22 
24  25    26   27   28 29   30     23   24    25   26    27  28  29  
       30   31  
January 2014       February 2014 
  
S    M    T    W    T    F    S    S    M    T    W    T    F    S 
                  1    2     3    4              1   
5    6      7     8     9     10   11   2    3      4     5      6    7     8 
12  13    14   15   16   17   18   9    10    11   12    13  14   15 
19  20    21   22   23   24   25   16  17    18   19     20  21  22 




S    M    T    W    T    F    S 
                   1 
2    3      4     5      6    7     8 
9    10    11   12    13  14   15 
16  17    18   19     20  21  22 
23   24    25   26    27  28    
 
 
f. How confident are you that the above-indicated day was the first day of your last 
period?  
0%            25%           50%           75%          100% 
0 1 2 3 4 5 6 7 8  
g. Using the calendars below, please indicate your estimation of the first day of your 
NEXT menstrual period.  If you are not completely sure, please estimate 
the day that you believe you will start menstruating on. 
 
September 2013           October 2013 
 
  S    M    T    W    T    F    S   S    M    T    W    T    F    S 
  1     2     3     4     5 6     7      1     2      3     4    5 
      8     9    10   11   12   13   14   6     7     8     9      10   11  12 
  15   16   17   18   19   20   21              13   14   15   16    17   18  19 
  22   23   24   25   26   27   28   20   21   22   23    24   25  26  
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  29   30       27   28   29   30    31    
       
 
November 2013    December 2013 
  
S    M    T    W    T    F    S    S    M    T    W    T    F    S 
                          1    2              1   
3    4      5     6     7     8    9    2    3      4     5      6    7     8 
10  11    12   13   14  15   16   9    10    11   12    13  14   15 
17  18    19   20   21  22   23   16  17    18   19     20  21  22 
24  25    26   27   28 29   30     23   24    25   26    27  28  29  
       30   31  
January 2014       February 2014 
  
S    M    T    W    T    F    S    S    M    T    W    T    F    S 
                  1    2     3    4              1   
5    6      7     8     9     10   11   2    3      4     5      6    7     8 
12  13    14   15   16   17   18   9    10    11   12    13  14   15 
19  20    21   22   23   24   25   16  17    18   19     20  21  22 




S    M    T    W    T    F    S 
                      1 
2    3      4     5      6    7     8 
9    10    11   12    13  14   15 
16  17    18   19     20  21  22 
23   24    25   26    27  28    
 
 
h. How confident are you that the above-indicated day is the day that you will next get 
your period?  (Circle the best response) 
 
0%            25%           50%           75%          100% 
0 1 2 3 4 5 6 7 8  
i. Are you currently menstruating today and if so, how many days have menstruated?  
 
1  2  3  4  5  6  7  8  9  10  more than 10 
 
22. Have you ever taken Oral Contraceptives (the birth control pill)?  
 
YES  NO 




a.i. If you have ever taken Oral Contraceptives, look at the following side effects that 
some people might experience when taking Oral Contraceptives. Indicate any of the 
following Physical side effects that you experienced when taking Oral Contraceptives. 
Please indicate what OC brand you were taking when you experienced the side effect 




Nausea/Vomiting:    YES NO If yes, which brand: _____________  
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 




Headaches:     YES NO      If yes, which brand: _____________   
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Breast size increase   YES NO  If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
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Breast size decrease    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Decreased ability to orgasm   YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Weight loss     YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Increased ability to orgasm    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
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 ___No action taken, symptoms continue 
now 
   
Weight gain         YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Increased sex drive/arousal     YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
   
Decreased sex drive/arousal   YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Fewer menstrual cramps      YES NO If yes, which brand: _____________  
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
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___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
More menstrual cramps    YES NO If yes, which brand: _____________ 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
Tiredness/fatigue      YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Dizziness/Faintness     YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
208 
 ___No action taken, symptoms continue 
now 
 
High blood pressure   YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
  
Painful or tender breasts    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Irregular heartbeat            YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
  
Swelling of breast or abdomen   YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
209 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Clearer complexion   YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
  
Complexion Problems (e.g., acne)  YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Complete loss of periods   YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Heavier periods ( bleeding)    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
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___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Lighter periods ( bleeding)    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Breakthrough bleeding  YES NO If yes, which brand: _____________ 
(bleeding between periods)    
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 




Slept more than usual    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Slept less than usual     YES NO If yes, which brand: _____________ 




If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 




a.ii. If you have ever taken Oral Contraceptives, look at the following side effects that 
some people might experience when taking Oral Contraceptives. Indicate any of the 
following Emotional side effects that you experienced when taking Oral 
Contraceptives. Please indicate what OC brand you were taking when you experienced 





Positive Mood change     YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
            
Negative mood change       YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
More jealous     YES NO If yes, which brand: _____________ 




If yes, what action did you take as a result of this 
symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
   
More moody    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Less jealous    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
   
Less moody     YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
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 ___No action taken, symptoms continue 
now 
 
Depression              YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
        
Sadness      YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Lower self-esteem    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
More pessimistic    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
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___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
More optimistic    YES NO If yes, which brand: _____________ 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
   
Higher self-esteem    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
More irritable             YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Less irritable    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
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___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Cried more than usual   YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Cried less than usual    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Feelings of inferiority        YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
More sensitive to criticism      YES NO If yes, which brand: _____________ 
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If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Less sensitive to criticism   YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
More self-critical      YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Less self-critical             YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
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More content/happy   YES NO If yes, which brand: _____________ 
   
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
More aggressive    YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Less aggressive     YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
Less trust in partner (fidelity)   YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
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 ___No action taken, symptoms continue 
now 
 
More trust in partner (fidelity)  YES NO If yes, which brand: _____________ 
 
If yes, what action did you take as a result of 
this symptom?:  
___ Discontinued Oral Contraceptive use  
___ Switched OC brand because of this 
symptom 
___ Experienced symptom but did not 
change OC use 
 ___No action taken, symptoms continue 
now 
 
b. I believe that oral contraceptives have affected my mood  
 
Very        Slightly        In no way at all        Slightly     Very  
Negatively  Negatively                 Positively   Positively 
0                         1                                  2                               3                            4  
  
      c. Have you ever stopped oral contraceptive use due to reasons other than physical or 
emotional symptoms? 
YES NO  If yes, indicate the reason: 
 
Sexual relationship ended    YES NO  
Desire to become pregnant          YES NO  
Concerned about hormones    YES NO  
Too hard to use    YES NO   
Medical condition (Specify:        )  YES NO  
Too expensive                        YES NO  
 
d. Have negative mood side effects ever influenced you to stop taking oral 
contraceptives?   (Circle best answer)    
Yes            No        Somewhat 
 
e. If you have ever discontinued oral contraceptives due to mood side effects, 
approximately how many days or months did you experienced these negative 
mood side effects before discontinuing use?   
_____________ months and  _______ days  
 
f. Do you have a biological mother or sister who has experienced negative mood    
    effects while taking oral contraceptives? (Circle answer):   
 
YES  NO  UNSURE 
 




g. At what age did you first start using oral contraceptives? ______ years 
h. Why did you start taking oral contraceptives? (Check all that apply)   
  [   ]   Birth Control   [   ]   Treat acne 
  [   ]   For cycle regularity  [   ]   Other:  ___________________ 
  [   ]   Due to a hormonal medical condition (Specify):  ________________ 
  [   ]   I was taking another medication that could have produced birth defects 
 
i. For how long have taken oral contraceptivesI in total (i.e. the total amount of time 
you have taken on any/all brands of OCs)? 
 
_______ years and _______ months  
j. How many different types/brands of oral contraceptives have you taken?  ______ 
types/brands 
k. Please select all of the different types of oral contraceptives you have used? 
(select all that apply) 
 
     [   ] Alesse     [   ] Apri       [   ] Aviane    
           [   ] Brevicon 0.5/35   [   ] Brevicon 1/35        [   ] Cyclen     
           [   ] Demulen 50         [   ] Demulen 30           [   ] Linessa                     
           [   ] Lo-Femenal        [   ] Loestrin 1.5/30     [   ] Marvelon                
           [   ] Micronor             [   ] Min-Ovral            [   ] Minestrin 1/20              
 
           [   ] Next Choice        [   ] Norlevo                [   ] Ortho 0.5/35       
            
           [   ] Ortho 1/35           [   ] Ortho 10/11         [   ] Ortho 7/7/7             
 
           [   ] Ortho-Cept          [   ] Portia                   [   ] Seasonique            
 
           [   ] Seasonale            [   ] Select 1/35   [   ] Synphasic                                     
 
 [   ] Tri-Cyclen          [   ] Tri-Cyclen Lo        [   ]Triquilar                              
 
[   ] Yasmin               [   ] Yaz   
 
[   ] Other (please specify): __________________ 
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l. If you have previously taken OCs but are not taking them right now, how many       
years and months has it been since you last took OCs?  
 _____ years and ______months 
 
m. Have you ever taken a contraceptive that contained hormones but that was not 
taken orally or by mouth? (e.g., contraceptive patch, vaginal ring, DepoProvera, 
hormonal implants, etc.)?  
YES  NO  UNSURE 
 
23. Are you currently taking oral contraceptives? 
YES  NO 
 
a. If NO, how long has it been since you last took OCs?  
______ years and _____months ___ I am still currently using Oral Contraceptives 
 
b. If NO, how long has it been since you last took ANY hormonal contraceptive? 
(e.g., contraceptive patch, vaginal ring, DepoProvera, hormonal implants, etc.) 
 
______ years and _____months ___ I am still currently taking a hormonal          
       contraceptive 
24. If you are currently taking OCs, for how many years and months have you been 
taking your current OC? 
_______ years and _______ months 
 
b. Why are you currently taking OCs? (Check all that apply) 
  [   ]   Birth Control   [   ]   Treat acne 
  [   ]   For cycle regularity  [   ]   Other:  ___________________ 
  [   ]   Due to a hormonal medical condition (Specify):  ________________ 
  [   ]   I am currently taking another medication that could produce birth defects 
 
b. Please indicate the type of OC you are currently taking. 
     [   ] Alesse     [   ] Apri       [   ] Aviane    
           [   ] Brevicon 0.5/35   [   ] Brevicon 1/35        [   ] Cyclen     
           [   ] Demulen 50         [   ] Demulen 30           [   ] Linessa                     
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           [   ] Lo-Femenal        [   ] Loestrin 1.5/30     [   ] Marvelon                
           [   ] Micronor             [   ] Min-Ovral            [   ] Minestrin 1/20              
 
           [   ] Next Choice        [   ] Norlevo                [   ] Ortho 0.5/35       
            
           [   ] Ortho 1/35           [   ] Ortho 10/11         [   ] Ortho 7/7/7             
 
           [   ] Ortho-Cept          [   ] Portia                   [   ] Seasonique            
 
           [   ] Seasonale            [   ] Select 1/35   [   ] Synphasic                                     
 
 [   ] Tri-Cyclen          [   ] Tri-Cyclen Lo        [   ]Triquilar                              
 
[   ] Yasmin               [   ] Yaz   
 
[   ] Other (please specify): _______________ 
 
24. Do you believe Oral Contraceptives are currently affecting your mood in a 
negative way? 
 
YES  NO 
  







1. Today’s date (dd/mm/yyyy): ____________________      
2. Age: _______ 
3. Has anything happened during the course of the day that may have affected your mood 
(either negatively or positively)?   
YES NO 
4. How many hours of sleep did you get last night? ______hours 
1. 5. During the past 24 hours, how many minutes were you physically active at a 
moderate to intense level?  
[   ]   0 minutes   
[   ]   1 to 15 minutes   
[   ]   16 to 30 minutes  
[   ]   31 to 45 minutes 
[   ]   46 or more minutes 
 
6. Have you taken any drugs/medications today (other than oral contraceptives)? If so list 
the amount and the brand. 
________________________________________________________________________
________________________________________________________________________ 
7. Did you consume any caffeine today (e.g. coffee, tea, soft drinks)?   
YES NO  
                             
a. If yes, how much did you drink? (One cup is equal to 250 mL) 
 
[   ]   1-3 cups [   ]   4-7 cups  [   ]   8-12 cups  [   ]   12 or more cups 
 
8. Did you consume any alcohol in the last 24 hours?   
YES NO  
 
 a. If yes, how many drinks did you consume? (e.g. ONE drink is equal to 1oz of distilled 
alcohol i.e. vodka rum, whiskey etc., a 5oz glass of wine, or a 12oz bottle of beer) 
 
Please indicate: ______________ 
 
c. If yes, have you had any drinks today (since waking up)?  
YES NO 
 
ORAL CONTRACEPTIVES AND EMOTIONAL REACTIVITY  
 
223 
d.  If yes, how many drinks did you consume? (e.g. ONE drink is equal to a 1oz 
distilled alcohol i.e. vodka rum, whiskey etc., 5oz glass of wine, or12oz bottle of 
beer) 
 
Please indicate: ______________ 
 
9. Circle the response that best describes the extent to which you agree/disagree with the 
following statements: 
 
a. During the session, I craved a lot more excitement than the tasks provided. 
 
Strongly Agree Somewhat Agree Neutral Somewhat Disagree Strongly Disagree 
1  2       3     4   5 
 
b. During the session I got bored  
 
Strongly Agree Somewhat Agree Neutral Somewhat Disagree Strongly Disagree 
1  2       3     4   5 
 
e. During the session I had very little patience when performing the tasks. 
 
Strongly Agree Somewhat Agree Neutral Somewhat Disagree Strongly Disagree 
1  2       3     4   5 
 
    d. During the session I would have preferred tasks that were more exciting and   
       unpredictable. 
 
Strongly Agree Somewhat Agree Neutral Somewhat Disagree Strongly Disagree 
1  2       3     4   5 
 
e. During the session, I enjoyed the tasks that I was given. 
 
Strongly Agree Somewhat Agree Neutral Somewhat Disagree Strongly Disagree 
 1   2       3     4 5 
  
f. During the session I performed the tasks conscientiously. 
 
Strongly Agree Somewhat Agree Neutral Somewhat Disagree Strongly Disagree 
1  2       3     4   5 
 
g. I did the tasks carefully, since I wanted to do things right the first time. 
 
Strongly Agree Somewhat Agree Neutral Somewhat Disagree Strongly Disagree 
1  2       3     4   5 
 
h. I was not as dependent or reliable performing the tasks as I should have been. 




Strongly Agree Somewhat Agree Neutral Somewhat Disagree Strongly Disagree 
1  2       3     4   5 
 
i. Since I made a commitment, I could be relied upon to complete the tasks to the best of 
my ability. 
 
Strongly Agree Somewhat Agree Neutral Somewhat Disagree Strongly Disagree 
1  2       3     4   5 
 
10. What is your sex? 
 
MALE  FEMALE 
 
11. Using the calendars below, please indicate the first day of your last menstrual 
period.  If you are not completely sure, please estimate the day that you believe you 
started menstruating on.  
 
September 2013           October 2013 
 
  S    M    T    W    T    F    S   S    M    T    W    T    F    S 
  1     2     3     4     5 6     7      1     2      3     4    5 
      8     9    10   11   12   13   14   6     7     8     9      10   11  12 
  15   16   17   18   19   20   21              13   14   15   16    17   18  19 
  22   23   24   25   26   27   28   20   21   22   23    24   25  26  
  29   30       27   28   29   30    31    
       
 
November 2013    December 2013 
  
S    M    T    W    T    F    S    S    M    T    W    T    F    S 
                          1    2              1   
3    4      5     6     7     8    9    2    3      4     5      6    7     8 
10  11    12   13   14  15   16   9    10    11   12    13  14   15 
17  18    19   20   21  22   23   16  17    18   19     20  21  22 
24  25    26   27   28 29   30     23   24    25   26    27  28  29  
       30   31  
January 2014       February 2014 
  
S    M    T    W    T    F    S    S    M    T    W    T    F    S 
                  1    2     3    4              1   
5    6      7     8     9     10   11   2    3      4     5      6    7     8 
12  13    14   15   16   17   18   9    10    11   12    13  14   15 
19  20    21   22   23   24   25   16  17    18   19     20  21  22 
26  27    28   29   30   31       23   24    25   26    27  28     
 





S    M    T    W    T    F    S 
                   1 
2    3      4     5      6    7     8 
9    10    11   12    13  14   15 
16  17    18   19     20  21  22 
23   24    25   26    27  28    
 
a. How confident are you that the above-indicated day was the first day of your last 
period?  
0%            25%           50%           75%          100% 
0 1 2 3 4 5 6 7 8  
b. Using the calendars below, please indicate your estimation of the first day of your 
NEXT menstrual period.  If you are not completely sure, please estimate 




September 2013           October 2013 
 
  S    M    T    W    T    F    S   S    M    T    W    T    F    S 
  1     2     3     4     5 6     7      1     2      3     4    5 
      8     9    10   11   12   13   14   6     7     8     9      10   11  12 
  15   16   17   18   19   20   21              13   14   15   16    17   18  19 
  22   23   24   25   26   27   28   20   21   22   23    24   25  26  
  29   30       27   28   29   30    31    
       
 
November 2013    December 2013 
  
S    M    T    W    T    F    S    S    M    T    W    T    F    S 
                          1    2              1   
3    4      5     6     7     8    9    2    3      4     5      6    7     8 
10  11    12   13   14  15   16   9    10    11   12    13  14   15 
17  18    19   20   21  22   23   16  17    18   19     20  21  22 
24  25    26   27   28 29   30     23   24    25   26    27  28  29  
       30   31  
 
January 2014       February 2014 
  
S    M    T    W    T    F    S    S    M    T    W    T    F    S 
                  1    2     3    4              1   
5    6      7     8     9     10   11   2    3      4     5      6    7     8 
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12  13    14   15   16   17   18   9    10    11   12    13  14   15 
19  20    21   22   23   24   25   16  17    18   19     20  21  22 




S    M    T    W    T    F    S 
                   1 
2    3      4     5      6    7     8 
9    10    11   12    13  14   15 
16  17    18   19     20  21  22 
23   24    25   26    27  28    
 
c. How confident are you that the above-indicated day is the day that you will next get 
your period?  (Circle the best response) 
 
0%            25%           50%           75%          100% 
0 1 2 3 4 5 6 7 8  
d. Are you currently menstruating today and if so, how many days have menstruated?  
 
Please indicate: _______________ 
 
e. Please indicate which statement best describes your current use of oral contraceptives 
(i.e. The birth control pill) 
 
_____ I have never used oral contraceptives 
_____ I have used Oral contraceptives in the past, but I stopped taking oral contraceptives 
MORE than 2 months ago 
_____ I have used oral contraceptives in the past, but I stopped taking oral contraceptives 
LESS than 2 months ago 
_____ I am currently using oral contraceptives, and I have been using Oral contraceptives 
for MORE than 2 months  
_____ I am currently using oral contraceptives, and I have been using Oral contraceptives 
for LESS than 2 months  
_____ I am current using a hormonal contraceptive other than oral (e.g., contraceptive 














LABORATORY QUESTIONNAIRE A: Positive and Negative Affect Scale 
(PANAS) 
1. This scale consists of a number of words to describe different feelings and emotions. 
Read each item and indicate to what extent you feel this way right now, that is, at the 
present moment.  
 
a. Interested  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
        Or Not at All 
 
b. Distressed  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
c. Excited 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
d. Upset  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
e. Strong 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
f. Guilty 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 




g. Scared  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
h. Hostile 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
i. Enthusiastic    
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
j. Proud  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
k. Irritable 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
l. Alert  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
m. Ashamed 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
n. Inspired 
1      2            3            4        5 
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Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
o. Nervous 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
p. Determined 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
q. Attentive  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
r. Jittery 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
s. Active  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
t. Afraid  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  





LABORATORY QUESTIONNAIRE B: PANAS, PEEQ, and Approach/Avoid 
questionnaire 
 
1. This scale consists of a number of words to describe different feelings and emotions. 
Read each item and indicate to what extent you feel this way right now, that is, at the 
present moment. 
a. Interested  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
        Or Not at All 
 
b. Distressed  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
c. Excited 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
d. Upset  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
e. Strong 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
f. Guilty 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 




g. Scared  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
h. Hostile 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
i. Enthusiastic    
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
j. Proud  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
k. Irritable 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
l. Alert  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
m. Ashamed 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
n. Inspired 
1      2            3            4        5 
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Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
o. Nervous 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
p. Determined 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
q. Attentive  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
r. Jittery 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
  
s. Active  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
t. Afraid  
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
2. Please indicate the degree to which you experienced the following while watching the 
slideshow 
 
a. Numbness or tingling 
1      2            3            4        5 
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Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
b. Feeling hot 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
c. Felt dizzy or lightheaded 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
d. Heart Pounding or racing 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
e. Feelings of choking 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
f. Hands trembling 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
g. Shaky 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
h. Difficulty breathing 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
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i. Indigestion or discomfort in abdomen 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
j. Faint 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
k. Face flushed 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
l. Sweating 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
m. Feeling of floating/Feeling light in weight 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
n. Feeling of sinking/feeling heavy 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
o. Tightness in chest 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
p. Energized 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
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    Or Not at All 
 
q. Drained of energy/fatigue 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
r. Smiling 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
s. Tense muscles 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
t. Relaxed muscles 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
u. Stomach tightened 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
v. Nauseous 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
w. Fidgety/Restlessness 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
x. Hollow /empty 
1      2            3            4        5 
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Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
y. Goosebumps 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
z. Shivering 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
 aa. Felt a lowering in heart rate 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
  bb. Felt an increase in blood pressure 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
 cc. felt a decrease in blood pressure 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
 dd. Felt sick 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
ee. glowing or radiating “good energy”? 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
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ff. radiating bad energy 
1      2            3            4        5 
Very Slightly             A Little      Moderately     Quite a Bit 
 Extremely 
    Or Not at All 
 
3. Please indicate what affect the slideshow had on you personally  
a. The film aroused an unpleasant feeling in me 
1      2   3   4   5  
Very Slightly A Little      Moderately        Quite a Bit                  Extremely 
Or Not at All   
 
b. The film aroused a pleasant feeling in me 
1      2   3   4   5  
Very Slightly A Little      Moderately        Quite a Bit                  Extremely 
Or Not at All   
 
c. This film aroused the want to escape in me: 
1      2   3   4   5  
Very Slightly A Little      Moderately        Quite a Bit                  Extremely 
Or Not at All   
 
d. This film aroused the want to take action in me: 
1      2   3   4   5  
Very Slightly A Little      Moderately        Quite a Bit                  Extremely 
Or Not at All   
e. The film infected me with excitement 
1      2   3   4   5  
Very Slightly A Little      Moderately        Quite a Bit                  Extremely 
Or Not at All   
f. The film aroused my interest 
1      2   3   4   5  
Very Slightly A Little      Moderately        Quite a Bit                  Extremely 












Consent Form A: Letter to Participants  
SEX, HORMONES, AND EMOTIONS STUDY 
 
Dear potential participant, 
 
You are being invited to participate in the Sex, Hormones, and Emotions Study. The 
purpose of this study is to examine how sex and hormones influence emotions and 
cognition. This study is being conducted by Ms. Nicole Keir and Dr. Kirsten Oinonen 
from the Health Hormones and Behaviour Laboratory (HHABLAB) in the Department of 
Psychology at Lakehead University. A part of this project will be used to complete a 
Master’s thesis for Nicole Keir. Additional exploratory research questions in the same 
area may also be examined. The study will consist of a screening questionnaire and one 
laboratory session. The screening questionnaire is completed online and will take 
approximately 30 minutes to complete. Upon completion of the screening questionnaire, 
you will receive one 0.5 bonus point towards your Undergraduate Psychology mark, if 
relevant. The questionnaire will be used to select participants for the main study. If you 
are eligible to participate in the main study, you will be invited to a laboratory session 
taking place in the Health Hormones and Behaviour lab on Lakehead University Campus. 
During this laboratory session, you will be required to watch three emotional videos, and 
complete various cognitive tasks such as a facial recognition task. Those who participate 
in the lab session will be awarded an additional 1 bonus points towards their final mark in 
their Undergraduate Psychology course, if relevant.  
 
For participants that are not eligible for bonus marks, they will be provided with $2 for 
their participation in the laboratory portion of this study. This $2 can be used to cover 
parking expenses at Lakehead University or can be kept for personal use. Additionally, 
all participants in the laboratory portion of this study will be entered into a draw to win 
one of two $50 gift certificates to a local restaurant and/or a bookstore chain.  
 
The researchers will also be collecting additional information for use in future studies. 
For example, those who participate in the laboratory portion of this study will be 
presented with an option on the consent form to provide a saliva DNA swab sample. The 
DNA portion of the study is completely optional and further details will be presented 
during the laboratory session.  
 
Both sessions involve answering personal questions about your health, reproductive 
history, emotions, and personality. Benefits to participation in this research project 
involve a better understanding of the processes of psychological research, possible 
benefits from personal insight, as well as a general contribution to the field of psychology 
and the area of hormones, emotion, and cognition. There are no obvious risks involved in 
participating in this study. However, some participants may feel uncomfortable 
answering personal questions or have new positive or negative thoughts about oneself 
after answering the questions (i.e., new personal insight).  




Participants will also likely experience increases in positive mood and negative mood 
throughout the lab session. However, such mood changes are likely comparable to mood 
change one would experience as a result of exposure to television or other media. You are 
not required to answer all questions and can skip any question that makes you 
uncomfortable. This study is open to Lakehead University students 16 years or older as 
well as members of the general public who are 18 years or older.  
Participation in this experiment is voluntary and you may withdraw at any time without 
explanation and without penalty. All records of your participation will be kept in strict 
confidence and any reports of the study will not identify you as a participant. Individuals 
who meet specific criteria will be asked to participate in the study.  
 
Therefore, we have asked for your name, telephone number, and email address. This 
information is required so you can be contacted to participate in the laboratory session 
and so your responses from the screening questionnaire can be linked to the data from the 
laboratory session. Your information will only be used to contact you for the laboratory 
session and will not be given out to any third parties. Once the study is complete, all 
identifying information, including email, will be removed. At that point, no one, 
including the researchers, will be able to connect any information gathered to a specific 
individual. There is no obligation to provide an email address or any other identifying 
information, however such information is required if you are a student at Lakehead 
University in Introductory Psychology and you wish to receive bonus points. All 
identifying information will be removed once bonus points have been recorded.  
 
As per university requirements, all data will be stored for at least five years by Dr. 
Oinonen at Lakehead University and remain anonymous and confidential. If you have 
any questions or concerns regarding this study please contact Nicole Keir or Dr. Kirsten 
Oinonen. This study has been approved by the Lakehead University Ethics Board (807-
343-8283 or research@lakeheadu.ca) and they can also be contacted about any concerns. 
 
Upon completion of the study, interested participants are welcome to contact one of the 
researchers to request a summary of the results. Thank you very much for your time. We 
very much appreciate your contribution to our research. 
 
Nicole Keir, H.B.A.      Dr. Kirsten Oinonen Ph.D., C. Psych.  
M.A. Student Associate    Professor Department of Psychology 
Lakehead University     Lakehead University  
955 Oliver Road     955 Oliver Road  
Thunder Bay, Ontario P7B 5E1  Thunder Bay, Ontario P7B 5E1 
email: nkeir@lakeheadu.ca    email: koinonen@lakeheadu.ca 










DEBRIEFING FORM A: SEX, HORMONES, AND EMOTIONS STUDY 
Thank you for participating in the screening phase of our study on Sex, Hormones and 
Emotions. The study is being conducted by Dr. Oinonen, and Ms. Nicole Keir at 
Lakehead University. The data you have contributed will be used as part of Nicole Keir’s 
Master’s thesis. It may also be used to examine additional exploratory research questions 
in the laboratory. If you are selected to participate in the second part of the study, you 
will be contacted by Nicole in the next three weeks. Participants in the next phase will 
receive one additional bonus mark toward their final grade in the participating 
Undergraduate Psychology course, if relevant. If you are chosen for the next phase, you 
will be asked to come into the laboratory for a session lasting approximately 1 hour 
where you will be required to watch three separate slide shows of pictures, and complete 
various cognitive tasks such as a facial recognition task.  
 
All participants will be provided with $2 for their participation in the laboratory portion 
of this study. This $2 can be used to cover parking expenses at Lakehead University or 
can be kept for personal use. Additionally, all participants in the laboratory portion of this 
study will be entered into a draw to win one of two $50 gift certificates to a local 
restaurant and/or a bookstore chain.  
 
Please be assured that once participants have been selected for the study and their 
responses from both phases are linked, any identifying information (e.g., names) will be 
removed from the data file and there will be no way to identify your responses. All of 
your responses will be coded to conceal your identity on the questionnaires and all data 
will remain anonymous. If you have any questions, please feel free to contact Dr. 
Oinonen at the contact information below. If you would like to receive a summary of the 
results of the study, please email one of the researchers and, upon completion of the 
study, a summary of the results will be emailed to you. Please note that providing your 
email address does not jeopardize your anonymity. 
 
This study has been approved by the Lakehead University Research Ethics Board. If you 
have any questions related to the ethics of the research and would like to speak to 
someone outside of the research team please contact Sue Wright at the Research Ethics 
Board at 807-343-8283 or research@lakeheadu.ca. 
 
Thank you very much for your time. We very much appreciate your contribution to our 
research.  
 
Nicole Keir, H.B.A.             Dr. Kirsten Oinonen Ph.D., C. Psych. 
M.A. Student              Associate Professor 
Lakehead University                                                 Department of Psychology 
955 Oliver Road                                                        Lakehead University 
Thunder Bay, Ontario P7B 5E1                                955 Oliver Road 
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email: nkeir@lakeheadu.ca                                       Thunder Bay, Ontario P7B 5E1 
                                        email: koinonen@lakeheadu.ca 








CONSENT FORM B: SEX, HORMONES, AND EMOTIONS STUDY 
 
I agree to participate in this study that is investigating the influence of sex and hormones 
on emotions.  I understand that my participation is entirely voluntary: I can leave the 
experiment at any time and this will have no bearing on any remuneration I will receive, 
nor will it have any undesirable consequences. 
The following points have been explained to me:  
1. I have been selected to participate in a laboratory session at the HHAB Lab in the 
Department of Psychology at Lakehead University so that I may contribute to the 
understanding of how sex and hormones influence emotional responses and 
functioning. 
2. The procedure will be as follows: During an approximately hour-long session, I 
will watch three emotionally-based videos. Before and after each video, I will fill 
out questionnaires where I will be asked to indicate my current mood state. 
Additionally, after each slide show, I will perform three cognitive and perceptual 
tasks such as an emotion recognition task.  
3. I will be asked to respond to questions of a personal nature that include, but are 
not limited to, the following: personal health, mood, behaviour, and the menstrual 
cycle (for women). 
4. I am a volunteer and can withdraw at any time from this study and I may choose 
to not answer any question or part in the study 
1. There are no known serious risks involved in participating in this study. However, 
experiencing positive and negative changes in mood will likely occur during the 
session. The benefits I may expect from the study are: (a) an appreciation of 
research on health and hormones, (b) an opportunity to contribute to scientific 
research, (c) possible insight into myself, and (d) course credit (up to 1.5 bonus 
points for undergraduate psychology students). (e) Monetary compensation in 
the amount of $2 will be awarded to those who do not qualify for bonus 
marks. The $2 can be used for Parking Expenses or for other, personal use 
(f) each participant will have the potential to win one of two $50 gift 
certificates to a local restaurant and/or bookstore chain 
5. All of the data collected will remain strictly confidential.  My responses will not 
be associated with my name. Instead, my data will be associated with a code 
number when the researchers store the data. 
6. The data will be stored securely for at least 5 years by Dr. Oinonen and Lakehead 
University 
7. For the duration of the study, the researchers and I will have ongoing 
communication via the e-mail address(es) or the telephone number that I have 
provided below. This information will not be used for any other reason.  
8. Upon completion of my participation, I will receive a more detailed written 
explanation about the rationale underlying this experiment. 
9. The experimenter(s) will answer any other questions about the research either 
now or during the course of the experiment (other than specific questions about 
the hypotheses).  If I have any other questions or concerns, I can address them to 
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the experimenter(s) Nicole Keir (nkeir@lakeheadu.ca) or to the research director, 
Dr. Kirsten Oinonen 807-343-8096, (koinonen@lakeheadu.ca). 
10. I am interested in receiving a summary of the results upon completion of the 
study:  yes  no      
 
If yes, please indicate your email address: ____________________________ 
 
I have read and understood the above information and agree to participate in this study on 
Sex, Hormones and Emotions:   
 
Yes   No      
 




      12. There is preliminary evidence suggesting that some hormonal-related alleles are 
related to hormonal and behavioural experiences. As a result we are interested in 
obtaining a saliva swab from participants in order to conduct additional research on 
hormonal-related alleles. This would involve the researchers taking an oral sample swab 
on the inside of your cheek. Please indicate if you are willing to provide a DNA swab. 
Please note that ALL of the above criteria from 1-11 apply. Your DNA sample will 
remain anonymous and will be stored at Lakehead University by Dr. Oinonen for up to 5 
years. Declining consent for the DNA sample does NOT affect your participation in the 
overall study. You may decline consent for DNA sample and continue with the rest of the 
study with no consequences.  
 
I have read and understood the above information and agree to participate in this DNA 
portion of study on Sex, Hormones, and Emotions:   
 
Yes   No      
 
Name:  ____________________________________________ 
Signature: __________________________________________ 
 
Due to pending Biosafety approval, the researchers may not be able to collect the DNA 
sample at this time. If the DNA sample cannot be collected in the laboratory today, I 
agree to be contacted in the future for DNA sampling. 
  
Yes   No      
 
Name:  ____________________________________________ 
Signature: __________________________________________ 
Contact email __________________________________________ 
OR Contact phone __________________________________________ 
 
 




Debriefing Form B: SEX, HORMONES, AND EMOTIONS STUDY 
 
We appreciate your participation in our study, and thank you for spending your time 
to help us with our research. The purpose of this study was to investigate how sex and 
hormones influence emotions and cognition. Additionally, we are further interested in 
how hormones, specifically oral contraceptives (OCs), influence emotional reactivity as 
well as perception and cognition. In particular, we wanted to see how emotion induction 
(via emotionally charged slide shows) combines with hormonal factors such as OCs or 
sex to influence cognition. Previous research has suggested that there may be sex 
differences in emotional responses and that use of OCs may affect how women respond. 
Please see the references below if you are interested in reading more about this issue.   
 In case you have any concerns about your mood and would like to see a mental 
health professional, we have provided you with a list of such resources on the attached 
sheet. 
Given that this study involves some aspects of which you were not fully informed at 
the start, it is very important that you not discuss your experiences with other 
students until the end of the term.  If participants have prior knowledge of our specific 
predictions it could influence the results, and the data we collect would not be useable.  
Since you will be given a copy of this feedback to take home, please do not make it 
available to other students. If you do not keep this form, please dispose of it rather than 
leaving it somewhere where other students might read it.  
Please feel free to discuss with the experimenter any feelings you have about the 
study right away. We ask that you do not discuss this study with any other students as we 
do not want to diminish the mood induction effects of the slide shows. Therefore, it is 
very important that you do not discuss your experiences with other students until 
the end of the term. Should you have further questions, do not hesitate to contact Nicole 
Keir or Dr. Kirsten Oinonen, using the information listed below. This study was approved 
by the Lakehead University Research Ethics Board and they can also be contacted about 
any concerns (807-343-8283 or research@lakeheadu.ca). 
We hope that you have enjoyed participating in our study, and thank you very much 
for your assistance. As noted on the consent form, you will receive a summary of the 
results of the study at its completion if you have indicated an interest. 
Principal Investigators:    
Nicole Keir, H.B.A.              Dr. Kirsten Oinonen Ph.D., C. Psych. 
M.A. Student               Associate Professor 
Lakehead University                                                     Department of Psychology 
955 Oliver Road                                                              Lakehead University 
Thunder Bay, Ontario P7B 5E1                                  955 Oliver Road 
email: nkeir@lakeheadu.ca                                         Thunder Bay, Ontario P7B 5E1 
                                          email: koinonen@lakeheadu.ca 
               (807) 343-8096 
Mental Health Resource Sheet 
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Sometimes people can sometimes feel upset when thinking about their mood. Thus, it is 
possible that something occurred during your participation in the study that may have 
upset you.  If you feel as though you would like to talk to a mental health practitioner 
for any reason please consider the resources listed below: 
 Lakehead University Health and Counseling Centre: 343-8361 
 Family Services Thunder Bay: 626-1880 
 Catholic Family Development Centre: 345-7323 
 Emergency services are available at the Thunder Bay Health Sciences Centre 
 Thunder Bay Crisis Response (24 hours): 346-8282. 
 
The following are some references in case you are interested in reading more about 
research that is related to the study that you just participated in:  
 
Gingnell, M., Engman, J., Frick, A., Moby, L., Wikström, J., Fredrikson, M., & 
Sundström-Poromaa, I. (2013). Oral contraceptive use changes brain activity and mood in 
women with previous negative affect on the pill—A double-blinded, placebo-controlled 
randomized trial of a levonorgestrel-containing combined oral contraceptive. 
Psychoneuroendocrinology, 38(7), 1133-1144.  
 
Jarva, J. A., & Oinonen, K. A. (2007). Do oral contraceptives act as mood stabilizers? 
Evidence of positive affect stabilization. Archives of women's mental health, 10(5), 225-
234. 
 
Rumberg, B., Baars, A., Fiebach, J., Ladd, M. E., Forsting, M., Senf, W., & Gizewski, E. 
R. (2010). Cycle and gender-specific cerebral activation during a verb generation task 
using fMRI: comparison of women in different cycle phases, under oral contraception, 








Class-Wide Email Announcement 
 
Study on Sex, Hormones, and Emotion 
 
You are invited to participate in a psychology study looking at individual differences with 
respect to sex, hormones and emotion. We are seeking both Female and Male participants 
to complete a 30-minute screening questionnaire and one lab sessions that will be 60 
minutes in duration. If you wish to complete the screening questionnaire using a hard 
copy, please contact the researchers at nkeir@lakeheadu.ca. If you would like to 
complete the questionnaire online, please click on the link listed below. 
 
Introductory Psychology students will receive a one-half bonus point for completing 
the screening questionnaire and one bonus point for the lab session completed (for up to 
1.5 bonus points). Participants that do not qualify for bonus marks will be provided 
with $2 for their participation in the laboratory portion of this study. This $2 can be 
used to cover parking expenses at Lakehead University or can be kept for personal 
use. Additionally, all participants in the laboratory portion of this study will be 
entered into a draw to win one of two $50 gift certificates to a local restaurant 
and/or a bookstore chain.  
 
 
This study has been reviewed and approved by the Lakehead University Research Ethics 
Board. 
 




If you have any questions regarding this study please email Nicole Keir at 
nkeir@lakeheadu.ca. 
 




Nicole Keir, H.B.A.                Dr. Kirsten Oinonen Ph.D., C. Psych 
M.A. Student                                                              Associate Professor 
Department of Psychology    Department of Psychology 
Lakehead University     Lakehead University                                                   
955 Oliver Road     955 Oliver Road                                                          
Thunder Bay, Ontario P7B 5E1   Thunder Bay, Ontario P7B 5E1                                  









General Recruitment Poster 
 
 
If so, researchers in the department of Psychology are looking for YOU to 
participate in a study on SEX, HORMONES, & EMOTIONS! 
 
Participants will complete ONE short screening questionnaire and 
participate in ONE laboratory session where they will complete a variety of 
fun emotional and perceptual tasks. 
 
All participants will receive $2* and will be entered into a draw to win 1 of 
2 $50 gift certificates to a local bookstore or restaurant chain! 
*Participants who qualify for BONUS POINTS towards their psychology 
grade will receive up to 2.0 bonus points rather than the $2 
 
 
For more information and details on how to participate please email: 
nkeir@lakeheadu.ca 
 
This is a GREAT way to contribute to health and hormone research!! 
 









This study has received ethical approval by the Lakehead University  
Research Ethics Board 
 
 
Are YOU currently taking ORAL 
CONTRACEPTIVES (the Birth Control Pill?) OR are 
YOU currently taking NO HORMONES? 






Targeted Recruitment Poster 
 
 
If so, researchers in the department of Psychology are looking for YOU to 
participate in a study on SEX, HORMONES, & EMOTIONS! 
 
Participants will complete ONE short screening questionnaire and 
participate in ONE laboratory session. In the session, participants will 
complete a variety of interesting emotional and perceptual tasks. 
 
All participants will receive $2* and will be entered into a draw to win 1 of 
2 $50 gift certificates to a local bookstore or restaurant chain! 
*Participants who qualify for BONUS POINTS towards their psychology 
grade will receive up to 2.0 bonus points rather than the $2 
 
 
For more information and details on how to participate please email: 
nkeir@lakeheadu.ca 
 
This is a GREAT way to contribute to health and hormone research!! 
 











This study has received ethical approval by the Lakehead University  
ARE YOU currently experiencing CHANGES IN 
YOUR MOOD from Oral Contraceptives (The Birth 
control pill)? 
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Research Ethics Board 
Appendix L 
 
Personal Email Announcements to Non-Lakehead Student Individuals 
 
Study on Hormones and Cognition 
 
You are invited to participate in a psychology study being conducted at Lakehead 
University looking at investigating individual differences with respect to sex, homrones, 
and emotions. We are looking for men and women who are 18 years of age or older, to 
complete a screening questionnaire and ONE lab session. The screening questionnaire 
will take 30 minutes and can be completed using the link below.  
 
Following completion of the screening questionnaire, participants will be contacted via 
email and asked to participate in ONE lab sessions that will take 60 minutes to complete. 
The lab session will involve completing a variety of interesting emotional and perceptual 
tasks and short questionnaires in the Health Hormones and Behaviour Laboratory 
(HHABLAB) in the department of Psychology at Lakehead University. All responses 
will be kept anonymous and confidential.  
 
All participants will be provided with $2 for their participation in the laboratory 
portion of this study. This $2 can be used to cover parking expenses at Lakehead 
University or can be kept for personal use. Additionally, all participants in the 
laboratory portion of this study will be entered into a draw to win one of two $50 
gift certificates to a local restaurant and/or a bookstore chain. 
 
This study has been reviewed and approved by Lakehead University Research Ethics 
Board. 
 
Please follow the link below to participate in the online questionnaire: 
insert link here 
 
If you have any questions regarding this study please email Nicole Keir at 
nkeir@lakeheadu.ca. 
 




Nicole Keir, H.B.A.                 Dr. Kirsten Oinonen Ph.D., C. Psych 
M.A. Student                                                              Associate Professor 
Department of Psychology    Department of Psychology 
Lakehead University     Lakehead University                                                   
955 Oliver Road     955 Oliver Road                                                          
Thunder Bay, Ontario P7B 5E1   Thunder Bay, Ontario P7B 5E1                                  
email: nkeir@lakeheadu.ca    email: koinonen@lakeheadu.ca 




REB Approval Letter 
 
